Note: Descriptions are shown in the official language in which they were submitted.
CA 02339047 2001-02-12
r
.
a
DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTS PART1E DE CETTE DEMANDS OU CE BREVET
COMPREND PLUS D'UN TOME.
CECI EST LE TOME '( DE
NOTE: ~ Pour les tomes additionels, veuillez contacter le Bureau canadien des
brevets
JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATIONIPATENT CONTAINS MORE
THAN ONE VOLUME
THIS IS VOLUME ~ , OF
NOTE: For additional volumes please contact the Canadian Patent Office
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM
This application is a continuation-in-part of the following applications:
(1) provisional application Ser. No. 60/096,622 (GI 6075), filed August
14,1998;
(2) provisional application Ser. No. 60/096,815 (GI 6076), filed August
17,1998;
(3) provisional application Ser. No. 60/099,229 (GI 6077), filed September
4,1998;
(4) provisional application Ser. No. 60/105,368 (GI 6078), filed October
23,1998;
(5} provisional application Ser. No. 60/I15,234 (GI 6079), filed January
8,1999;
(6) provisional application Ser. No. 60/119,931 (GI 6080), filed Febxuary
12,1999;
(7) provisional application Ser. No. 60/120,575 (GI 6081), filed February
18,1999;
(8) provisional application Ser. No. 60/132,020 (GI 6082), filed April
30,1999;
2 0 (9) provisional application Ser. No. 60/XXX,XXX (GI 6083), filed August
11,1999;
all of which are incorporated by reference herein.
FIELD OF THE INVENTION
The present invention provides novel polynucleotides and proteins encoded by
such polynucleotides, along with therapeutic, diagnostic and research
utilities for these
polynucleotides and proteins.
35
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
BACKGROUND OF THE INVENTION
Technology aimed at the discovery of protein factors (including e.g.,
cytokines,
such as lymphokines, interferons, CSFs and interleukins) has matured rapidly
over the
past decade. The now routine hybridization cloning and expression cloning
techniques
clone novel polynucleotides "directly" in the sense that they rely on
information directly
related to the discovered protein (i.e., partial DNA/amino acid sequence of
the protein
in the case of hybridization cloning; activity of the protein in the case of
expression
cloning). More recent "indirect" cloning techniques such as signal sequence
cloning, which
isolates DNA sequences based on the presence of a now well-recognized
secretory leader
sequence motif, as well as various PCR-based or low stringency hybridization
cloning
techniques, have advanced the state of the art by making available large
numbers of
DNA/amino acid sequences for proteins that are known to have biological
activity by
virtue of their secreted nature in the case of leader sequence cloning, or by
virtue of the
cell or tissue source in the case of PCR-based techniques. It is to these
proteins and the
polynucleotides encoding them that the present invention is directed.
SUMMARY OF THE INVENTION
In one embodiment, the present invention provides a composition comprising an
2 0 isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:1;
(b) a polynudeotide comprising the nucleotide sequence of SEQ ID
NO:1 from nucleotide 87 to nucleotide 821;
2 5 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:1 from nucleotide 120 to nucleotide 821;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:1 from nucleotide 1 to nucleotide 1625;
(e) a polynucleotide comprising the nucleotide sequence of the full-
3 0 length protein coding sequence of clone co62_12 deposited under accession
number ATCC 98825;
(f) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone co62_12 deposited under accession number ATCC 98825;
2
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(g) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone co62_12 deposited under accession number
ATCC 98825;
(h) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone co62_12 deposited under accession number ATCC 98825;
(i) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:2;
(j) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:2 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:2;
(k) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(h) above;
(1) a polynucleotide which encodes a species homologue of the protein
of (i) or (j) above ;
(m) a polynudeotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(j); and
(n) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(j) and that has a length that is
at least
25% of the length of SEQ ID NO:1.
2 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
NO:1 from nucleotide 87 to nucleotide 821; the nucleotide sequence of SEQ ID
NO:1 from
nucleotide 120 to nucleotide 821; the nucleotide sequence of SEQ ID NO:1 from
nucleotide 1 to nucleotide 1625; the nucleotide sequence of the full-length
protein coding
sequence of clone co62_12 deposited under accession number ATCC 98825; or the
2 5 nucleotide sequence of a mature protein coding sequence of clone co62_12
deposited
under accession number ATCC 98825. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone co62_12 deposited under accession number ATCC 98825. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
3 0 comprising a fragment of the amino acid sequence of SEQ ID N0:2 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:2, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:2
having
3
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
biological activity, the fragment comprising the amino acid sequence from
amino acid 117
to amino acid 126 of SEQ ID N0:2.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:1.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:1, but excluding the poly(A) tail at the
3' end of SEQ ID N0:1; and
(ab) the nucleotide sequence of the cDNA insert of clone
co62_12 deposited under accession number ATCC 98825;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
2 0 {b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID NO:1, but excluding the poly(A) tail at the
2 5 3' end of SEQ ID N0:1; and
(bb) the nucleotide sequence of the cDNA insert of clone
co62_12 deposited under accession number ATCC 98825;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
3 0 (iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1, and
extending
contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:1 to
4
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
a nucleotide sequence corresponding to the 3' end of SEQ ID NO:1 , but
excluding the
poly(A) tail at the 3' end of SEQ ID NO:1. Also preferably the polynucleotide
isolated
according to the above process comprises a nucleotide sequence corresponding
to the
cDNA sequence of SEQ ID NO:1 from nucleotide 87 to nucleotide 821, and
extending
contiguously from a nucleotide sequence corresponding to the 5' end of said
sequence of
SEQ ID N0:1 from nucleotide 87 to nucleotide 821, to a nucleotide sequence
corresponding to the 3' end of said sequence of SEQ ID N0:1 from nucleotide 87
to
nucleotide 821. Also preferably the polynucleotide isolated according to the
above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:1 from nucleotide 120 to nucleotide 821, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
NO:1 from
nucleotide 120 to nucleotide 821, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:1 from nucleotide 120 to nucleotide 821. Also
preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 1 to
nucleotide
1625, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:1 from nucleotide 1 to nucleotide 1625, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:1 from
nucleotide
1 to nucleotide 1625.
2 0 In other embodiments, the present invention provides a composition
comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:2;
(b) a fragment of the amino acid sequence of SEQ ID N0:2, the
2 5 fragment comprising eight contiguous amino acids of SEQ ID N0:2; and
(c) the amino acid sequence encoded by the cDNA insert of clone
co62_12 deposited under accession number ATCC 98825;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:2. In further preferred
3 0 embodiments, the present invention provides a protein comprising a
fragment of the
amino acid sequence of SEQ ID N0:2 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:2, or a protein comprising a fragment of the amino acid sequence
of SEQ
5
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
ID N0:2 having biological activity, the fragment comprising the amino acid
sequence from
amino acid 117 to amino acid 126 of SEQ ID N0:2.
1n one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:3;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:3 from nucleotide 9 to nucleotide 1013;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:3 from nucleotide 96 to nucleotide 1013;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone 10311 8 deposited under accession
number ATCC 98825;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone 10311 8 deposited under accession number ATCC 98825;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone 10311 8 deposited under accession number
ATCC 98825;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
2 0 insert of clone 10311 8 deposited under accession number ATCC 98825;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:4;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:4 having biological activity, the fragment
2 5 comprising eight contiguous amino acids of SEQ ID N0:4;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
3 0 (1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(i) and that has a length that is
at least
25% of the length of SEQ ID N0:3.
6
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:3 from nucleotide 9 to nucleotide 1013; the nucleotide sequence of SEQ ID
N0:3 from
nucleotide 96 to nucleotide 2013; the nucleotide sequence of the full-length
protein coding
sequence of clone Io311 8 deposited under accession number ATCC 98825; or the
nucleotide sequence of a mature protein coding sequence of clone 10311_8
deposited
under accession number ATCC 98825. In other nreferrPrl Pm~,n~ima"+e +~,o
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone 10311 8 deposited under accession number ATCC 98825. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:4 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:4, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:4
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 162
to amino acid 171 of SEQ ID N0:4.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:3.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
2 0 (a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:3, but excluding the poly(A) tail at the
2 5 3' end of SEQ ID N0:3; and
(ab) the nucleotide sequence of the cDNA insert of clone
10311_8 deposited under accession number ATCC 98825;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
3 0 (iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
7
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:3, but excluding the poly(A) tail at the
3' end of SEQ ID N0:3; and
(bb) the nucleotide sequence of the cDNA insert of clone
10311 8 deposited under accession number ATCC 98825;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying.human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:3, and
extending
contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:3 to
a nucleotide sequence corresponding to the 3' end of SEQ ID N0:3 , but
excluding the
poly(A) tail at the 3' end of SEQ ID N0:3. Also preferably the polynucleotide
isolated
according to the above process comprises a nucleotide sequence corresponding
to the
cDNA sequence of SEQ ID N0:3 from nucleotide 9 to nucleotide 1013, and
extending
contiguously from a nucleotide sequence corresponding to the 5' end of said
sequence of
2 0 SEQ ID N0:3 from nucleotide 9 to nucleotide 1013, to a nucleotide sequence
corresponding to the 3' end of said sequence of SEQ ID N0:3 from nucleotide 9
to
nucleotide 2013. Also preferably the polynucleotide isolated according to the
above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:3 from nucleotide 96 to nucleotide 1013, and extending contiguously from a
2 5 nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:3 from
nucleotide 96 to nucleotide 1013, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:3 from nucleotide 96 to nucleotide 1013.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
3 0 consisting of:
(a) the amino acid sequence of SEQ ID N0:4;
(b) a fragment of the amino acid sequence of SEQ ID N0:4, the
fragment comprising eight contiguous amino acids of SEQ ID N0:4; and
8
CA 02339047 2001-02-12
WO 00/09552 PCT/IJS99/18298
(c) the amino acid sequence encoded by the cDNA insert of clone
10311 8 deposited under accession number ATCC 98825;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:4. In further preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:4 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty} contiguous
amino acids
of SEQ ID N0:4, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:4 having biological activity, the fragment comprising the amino acid
sequence from
amino acid 162 to amino acid 171 of SEQ ID N0:4.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:5;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:5 from nucleotide 352 to nucleotide 825;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone ns197 1 deposited under accession
number ATCC 98825;
2 0 (d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone ns197 1 deposited under accession number ATCC 98825;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone ns197_1 deposited under accession number
ATCC 98825;
2 5 (f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone ns197 1 deposited under accession number ATCC 98825;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:6;
(h) a polynucleotide encoding a protein comprising a fragment of the
3 0 amino acid sequence of SEQ ID NO:6 having biological activity, the
fragment
comprising eight contiguous amino acids of SEQ ID N0:6;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
9
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(j} a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynudeotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
25% of the length of SEQ ID N0:5.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:5 from nucleotide 352 to nucleotide 825; the nucleotide sequence of the
full-length
protein coding sequence of clone ns197 1 deposited under accession number ATCC
98825;
or the nucleotide sequence of a mature protein coding sequence of clone ns197
1
deposited under accession number ATCC 98825. In other preferred embodiments,
the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone ns197 1 deposited under accession number ATCC 98825. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:6 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:6, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:6
having
2 0 biological activity, the fragment comprising the amino acid sequence from
amino acid 74
to amino acid 83 of SEQ ID N0:6.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:5.
Further embodiments of the invention provide isolated polynucleotides produced
2 5 according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
3 0 (aa) SEQ ID N0:5, but excluding the poly(A) tail at the
3' end of SEQ ID N0:5; and
(ab) the nucleotide sequence of the cDNA insert of clone
ns197_1 deposited under accession number ATCC 98825;
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:5, but excluding the poly(A) tail at the
3' end of SEQ ID N0:5; and
(bb) the nucleotide sequence of the cDNA insert of clone
ns197 1 deposited under accession number ATCC 98825;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:5, and
extending
2 0 contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:5 to
a nucleotide sequence corresponding to the 3' end of SEQ ID N0:5 , but
excluding the
poly(A) tail at the 3' end of SEQ ID N0:5. Also preferably the polynucleotide
isolated
according to the above process comprises a nucleotide sequence corresponding
to the
cDNA sequence of SEQ ID N0:5 from nucleotide 352 to nucleotide 825, and
extending
2 5 contiguously from a nucleotide sequence corresponding to the 5' end of
said sequence of
SEQ ID N0:5 from nucleotide 352 to nucleotide 825, to a nucleotide sequence
corresponding to the 3' end of said sequence of SEQ ID N0:5 from nucleotide
352 to
nucleotide 825.
In other embodiments, the present invention provides a composition comprising
3 0 a protein, wherein said protein comprises an amino acid sequence selected
from the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:6;
(b) a fragment of the amino acid sequence of SEQ ID N0:6, the
fragment comprising eight contiguous amino acids of SEQ ID N0:6; and
11
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(c) the amino acid sequence encoded by the cDNA insert of clone
ns197_1 deposited under accession number ATCC 98825;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:6. In further preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:6 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:6, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:6 having biological activity, the fragment comprising the amino acid
sequence from
amino acid 74 to amino acid 83 of SEQ ID N0:6.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:7;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:7 from nucleotide 86 to nucleotide 829;
(c} a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:7 from nucleotide 149 to nucleotide 829;
(d) a polynucleotide comprising the nucleotide sequence of the full-
2 0 length protein coding sequence of clone pj193 5 deposited under accession
number ATCC 98825;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone pj193_5 deposited under accession number ATCC 98825;
(f) a polynucleotide comprising the nucleotide sequence of a mature
2 5 protein coding sequence of clone pj193_5 deposited under accession number
ATCC 98825;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone pj193 5 deposited under accession number ATCC 98825;
(h) a polynucleotide encoding a protein comprising the amino acid
3 0 sequence of SEQ ID N0:8;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:8 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:8;
12
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:7.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:7 from nucleotide 8b to nucleotide 829; the nucleotide sequence of SEQ ID
N0:7 from
nucleotide 149 to nucleotide 829; the nucleotide sequence of the full-length
protein coding
sequence of clone pj193_5 deposited under accession number ATCC 98825; or the
nucleotide sequence of a mature protein coding sequence of clone pj193_5
deposited
under accession number ATCC 98825. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone pj193_5 deposited under accession number ATCC 98825. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:8 having
biological
2 0 activity, the fragment preferably comprising eight (more preferably
twenty, most
preferably thirty) contiguous amino acids of SEQ ID N0:8, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:8
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 119
to amino acid 128 of SEQ ID N0:8.
2 5 Other embodiments provide the gene corresponding to the cDNA sequence of
SEQ
ID N0:7.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
3 0 (i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:7, but excluding the poly(A} tail at the
3' end of SEQ ID N0:7; and
13
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(ab) the nucleotide sequence of the cDNA insert of clone
pj193 5 deposited under accession number ATCC 98825;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:7, but excluding the poly(A) tail at the
3' end of SEQ ID N0:7; and
(bb) the nucleotide sequence of the cDNA insert of clone
pj193_5 deposited under accession number ATCC 98825;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
2 0 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:7, and
extending
contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:7 to
a nucleotide sequence corresponding to the 3' end of SEQ ID N0:7 , but
excluding the
poly(A) tail at the 3' end of SEQ ID N0:7. Also preferably the polynucleotide
isolated
2 5 according to the above process comprises a nucleotide sequence
corresponding to the
cDNA sequence of SEQ ID N0:7 from nucleotide 86 to nucleotide 829, and
extending
contiguously from a nucleotide sequence corresponding to the 5' end of said
sequence of
SEQ ID N0:7 from nucleotide 86 to nucleotide 829, to a nucleotide sequence
corresponding to the 3' end of said sequence of SEQ ID N0:7 from nucleotide 86
to
3 0 nucleotide 829. Also preferably the polynucleotide isolated according to
the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:7 from nucleotide 149 to nucleotide 829, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:7 from
I4
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
nucleotide 149 to nucleotide 829, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:7 from nucleotide 149 to nucleotide 829.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:8;
(b) a fragment of the amino acid sequence of SEQ ID N0:8, the
fragment comprising eight contiguous amino acids of SEQ ID N0:8; and
(c) the amino acid sequence encoded by the cDNA insert of clone
pj193_5 deposited under accession number ATCC 98825;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:8. In further preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:8 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:8, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:8 having biological activity, the fragment comprising the amino acid
sequence from
amino acid 119 to amino acid 128 of SEQ ID N0:8.
In one embodiment, the present invention provides a composition comprising an
2 0 isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:9;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:9 from nucleotide 174 to nucleotide 1292;
2 5 (c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone pj317 2 deposited under accession
number ATCC 98825;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone pj317 2 deposited under accession number ATCC 98825;
3 0 (e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone pj317_2 deposited under accession number
ATCC 98825;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone pj317 2 deposited under accession number ATCC 98825;
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID NO:10;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID NO:10 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID NO:10;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-{h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynudeotides specified in (a)-(h) and that has a length that is
at least
25% of the length of SEQ ID N0:9.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:9 from nucleotide 174 to nucleotide 1292; the nucleotide sequence of the
full-length
protein coding sequence of clone pj317 2 deposited under accession number ATCC
98825;
or the nucleotide sequence of a mature protein coding sequence of clone
pj317_2
deposited under accession number ATCC 98825. In other preferred embodiments,
the
2 0 polynucleotide encodes the full-length or a mature protein encoded by the
cDNA insert
of clone pj317 2 deposited under accession number ATCC 98825. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID NO:10 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
2 5 preferably thirty) contiguous amino acids of SEQ ID N0:10, or a
polynucleotide encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 181
to amino acid 190 of SEQ ID NO:10.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
3 0 ID N0:9.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
16
CA 02339047 2001-02-12
_ WO 00/09552 PCT/US99/18298
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:9, but excluding the poly(A) tail at the
3' end of SEQ ID N0:9; and
(ab) the nucleotide sequence of the cDNA insert of clone
pj317 2 deposited under accession number ATCC 98825;
(ii) hybridizing said probes} to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:9, but excluding the poly(A) tail at the
3' end of SEQ ID N0:9; and
(bb) the nucleotide sequence of the cDNA insert of clone
2 0 pj317 2 deposited under accession number ATCC 98825;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
2 5 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:9, and
extending
contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:9 to
a nucleotide sequence corresponding to the 3' end of SEQ ID N0:9 , but
excluding the
poly(A) tail at the 3' end of SEQ ID N0:9. Also preferably the polynucleotide
isolated
3 0 according to the above process comprises a nucleotide sequence
corresponding to the
cDNA sequence of SEQ ID N0:9 from nucleotide 174 to nucleotide 1292, and
extending
contiguously from a nucleotide sequence corresponding to the 5' end of said
sequence of
SEQ ID N0:9 from nucleotide 174 to nucleotide 1292, to a nucleotide sequence
17
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
corresponding to the 3' end of said sequence of SEQ ID N0:9 from nucleotide
174 to
nucleotide 1292.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a} the amino acid sequence of SEQ ID N0:10;
(b) a fragment of the amino acid sequence of SEQ ID NO:10, the
fragment comprising eight contiguous amino acids of SEQ ID N0:10; and
(c} the amino acid sequence encoded by the cDNA insert of clone
pj317 2 deposited under accession number ATCC 98825;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:10. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID NO:10 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:10, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID NO:10 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 181 to amino acid 190 of SEQ ID NO:20.
In one embodiment, the present invention provides a composition comprising an
2 0 isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:11;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:11 from nucleotide 7 to nucleotide 2517;
2 5 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:11 from nucleotide 904 to nucleotide 2517;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone pt332_1 deposited under accession
number ATCC 98825;
3 0 (e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone pt332_1 deposited under accession number ATCC 98825;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone pt332_1 deposited under accession number
ATCC 98825;
18
CA 02339047 2001-02-12
_ WO 00/09552 PCTNS99/18298
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone pt332_1 deposited under accession number ATCC 98825;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:12;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:12 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:12;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID NO:11.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:11 from nucleotide 7 to nucleotide 2517; the nucleotide sequence of SEQ ID
N0:11
from nucleotide 904 to nucleotide 2517; the nucleotide sequence of the full-
length protein
2 0 coding sequence of clone pt332_1 deposited under accession number ATCC
98825; or the
nucleotide sequence of a mature protein coding sequence of clone pt332_1
deposited
under accession number ATCC 98825. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone pt332_1 deposited under accession number ATCC 98825. In further
preferred
2 5 embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:12 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:12, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:12
having
3 0 biological activity, the fragment comprising the amino acid sequence from
amino acid 413
to amino acid 422 of SEQ ID N0:12.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:11.
19
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID NO:11, but excluding the poly(A) tail at the
3' end of SEQ ID N0:11; and
(ab) the nucleotide sequence of the cDNA insert of clone
pt332_1 deposited under accession number ATCC 98825;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
2 0 (ba) SEQ ID N0:11, but excluding the poly(A) tail at the
3' end of SEQ ID N0:11; and
(bb) the nucleotide sequence of the cDNA insert of clone
pt332_1 deposited under accession number ATCC 98825;
(ii) hybridizing said primers) to human genomic DNA in
2 5 conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:11, and
3 0 extending contiguously from a nucleotide sequence corresponding to the 5'
end of SEQ
ID NO:11 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:11
, but
excluding the poly(A) tail at the 3' end of SEQ ID NO:11. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:11 from nucleotide 7 to
nucleotide
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/t8298
2517, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID NO:11 from nucleotide 7 to nucleotide 2517, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:11 from
nucleotide
7 to nucleotide 2517. Also preferably the polynucleotide isolated according to
the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
NO:11 from nucleotide 904 to nucleotide 2517, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:11 from
nucleotide 904 to nucleotide 2517, to a nucleotide sequence corresponding to
the 3' end
of said sequence of SEQ ID N0:11 from nucleotide 904 to nucleotide 2517.
In other embodiments, the present. invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:12;
(b) a fragment of the amino acid sequence of SEQ ID N0:12, the
fragment comprising eight contiguous amino acids of SEQ ID N0:12; and
(c) the amino acid sequence encoded by the cDNA insert of clone
pt332_1 deposited under accession number ATCC 98825;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:12. In further
preferred
2 0 embodiments, the present invention provides a protein comprising a
fragment of the
amino acid sequence of SEQ ID N0:12 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:12, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:12 having biological activity, the fragment comprising the amino acid
sequence
2 5 from amino acid 413 to amino acid 422 of SEQ ID N0:12.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:13;
3 0 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:13 from nucleotide 18 to nucleotide 257;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone qc297 15 deposited under accession
number ATCC 98825;
21
CA 02339047 2001-02-12
- WO 00/09552 PCT/US99/18298
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone qc297 15 deposited under accession number ATCC 98825;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone qc297 15 deposited under accession number
ATCC 98825;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone qc297 15 deposited under accession number ATCC 98825;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:14;
(h) a polynudeotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:14 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:14;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
2 0 one of the polynucleotides specified in (a)-(h) and that has a length that
is at least
25% of the length of SEQ ID N0:13.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:13 from nucleotide 18 to nucleotide 257; the nucleotide sequence of the
full-length
protein coding sequence of clone qc297 15 deposited under accession number
ATCC
2 5 98825; or the nucleotide sequence of a mature protein coding sequence of
clone qc297 15
deposited under accession number ATCC 98825. In other preferred embodiments,
the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone qc297 15 deposited under accession number ATCC 98825. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
3 0 comprising a fragment of the amino acid sequence of SEQ ID N0:14 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:14, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:14
having
22
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
biological activity, the fragment comprising the amino acid sequence from
amino acid 35
to amino acid 44 of SEQ ID N0:14.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:13.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:13, but excluding the poly(A) tail at the
3' end of SEQ ID N0:13; and
(ab) the nucleotide sequence of the cDNA insert of clone
qc297 15 deposited under accession number ATCC 98825;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
2 0 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:13, but excluding the poly(A) tail at the
2 5 3' end of SEQ ID N0:13; and
(bb) the nucleotide sequence of the cDNA insert of clone
qc297 15 deposited under accession number ATCC 98825;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
3 0 (iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:13, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
23
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
ID N0:13 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:13
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:13. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:13 from nucleotide 18 to
nucleotide
257, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:13 from nucleotide 18 to nucleotide 257, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:13 from
nucleotide
18 to nucleotide 257.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:14;
(b) a fragment of the amino acid sequence of SEQ ID N0:14, the
fragment comprising eight contiguous amino acids of SEQ ID N0:14; and
(c) the amino acid sequence encoded by the cDNA insert of clone
qc297_15 deposited under accession number ATCC 98825;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:14. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
2 0 amino acid sequence of SEQ ID N0:14 having biological activity, the
fragment preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:14, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:14 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 35 to amino acid 44 of SEQ ID N0:14.
2 5 In one embodiment, the present invention provides a composition comprising
an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:15;
{b} a polynucleotide comprising the nucleotide sequence of SEQ ID
3 0 N0:15 from nucleotide 21 to nucleotide 2432;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone qg596_12 deposited under accession
number ATCC 98825;
24
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone qg596_12 deposited under accession number ATCC 98825;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone qg596_12 deposited under accession number
ATCC 98825;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone qg596_12 deposited under accession number ATCC 98825;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:16;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:16 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:16;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
{k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
2 0 one of the polynucleotides specified in (ar(h) and that has a length that
is at least
25% of the length of SEQ ID N0:15.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:15 from nucleotide 21 to nucleotide 2432; the nucleotide sequence of the
full-length
protein coding sequence of clone qg596_12 deposited under accession number
ATCC
2 5 98825; or the nucleotide sequence of a mature protein coding sequence of
clone qg596_12
deposited under accession number ATCC 98825. In other preferred embodiments,
the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone qg596_12 deposited under accession number ATCC 98825. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
3 0 comprising a fragment of the amino acid sequence of SEQ ID N0:16 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:16, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:16
having
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
biological activity, the fragment comprising the amino acid sequence from
amino and 397
to amino acid 406 of SEQ ID N0:16.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:15.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:15, but excluding the poly(A) tail at the
3' end of SEQ ID N0:15; and
(ab) the nucleotide sequence of the cDNA insert of clone
qg596_12 deposited under accession number ATCC 98825;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
2 0 (b) a process comprising the steps of:
{i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:15, but excluding the poly(A) tail at the
2 5 3' end of SEQ ID N0:15; and
(bb) the nucleotide sequence of the cDNA insert of clone
qg596_12 deposited under accession number ATCC 98825;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
3 0 (iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:15, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
26
CA 02339047 2001-02-12
WO 00/09552 PCT/I1S99/18298
ID N0:15 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:15
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:15. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:15 from nucleotide 21 to
nucleotide
2432, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:15 from nucleotide 21 to nucleotide 2432, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:15 from
nucleotide
21 to nucleotide 2432.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a} the amino acid sequence of SEQ ID N0:16;
(b) a fragment of the amino acid sequence of SEQ ID N0:16, the
fragment comprising eight contiguous amino acids of SEQ ID NO:I6; and
(c) the amino acid sequence encoded by the cDNA insert of clone
qg596_12 deposited under accession number ATCC 98825;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:16. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
2 0 amino acid sequence of SEQ ID NO:I6 having biological activity, the
fragment preferably
comprising eight (more preferably twenty, most preferably tlvrty) contiguous
amino acids
of SEQ ID N0:16, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:16 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 397 to amino acid 406 of SEQ ID N0:16.
2 5 In one embodiment, the present invention provides a composition comprising
an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:17;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
3 0 N0:17 from nucleotide 339 to nucleotide 2105;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:17 from nucleotide 501 to nucleotide 2105;
27
CA 02339047 2001-02-12
- WO 00/09552 PCT/US99/18298
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone rb649_3 deposited under accession
number ATCC 98825;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone rb649_3 deposited under accession number ATCC 98825;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone rbb49_3 deposited under accession number
ATCC 98825;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone rb649_3 deposited.under accession number ATCC 98825;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:18;
(i} a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID NO:18 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:18;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
2 0 (1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(i) and that has a length that is
at least
25% of the length of SEQ ID N0:17.
2 5 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:17 from nucleotide 339 to nucleotide 2105; the nucleotide sequence of SEQ
ID N0:17
from nucleotide 501 to nucleotide 2105; the nucleotide sequence of the full-
length protein
coding sequence of clone rb649_3 deposited under accession number ATCC 98825;
or the
nucleotide sequence of a mature protein coding sequence of clone rb649_3
deposited
3 0 under accession number ATCC 98825. In other nrPfPrrP~ a",~""~;.,.,o"E~
.~,..
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone rb649_3 deposited under accession number ATCC 98825. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:18 having
biological
28
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:18, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:18
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 289
to amino acid 298 of SEQ ID N0:18.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:17.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:17, but excluding the poly(A) tail at the
3' end of SEQ ID N0:17; and
(ab) the nucleotide sequence of the cDNA insert of clone
rbti49 3 deposited under accession number ATCC 98825;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
2 0 (iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
2 5 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:17, but excluding the poly(A) tail at the
3' end of SEQ ID N0:17; and
(bb) the nucleotide sequence of the cDNA insert of clone
3 0 rb649_3 deposited under accession number ATCC 98825;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
29
CA 02339047 2001-02-12
_ WO 00/09552 PCT/US99/18298
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:17, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:17 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:17
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:17. Also preferably the
polynudeotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:17 from nucleotide 339 to
nucleotide
2105, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:17 from nucleotide 339 to nucleotide 2105, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:17 from
nucleotide
339 to nucleotide 2105. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:17 from nucleotide 501 to nucleotide 2105, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:17 from
nucleotide 501 to nucleotide 2105, to a nucleotide sequence corresponding to
the 3' end
of said sequence of SEQ ID N0:17 from nucleotide 501 to nucleotide 2105.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
2 0 (a) the amino acid sequence of SEQ ID N0:18;
(b) a fragment of the amino acid sequence of SEQ ID N0:18, the
fragment comprising eight contiguous amino acids of SEQ ID NO:18; and
(c) the amino arid sequence encoded by the cDNA insert of clone
rb649_3 deposited under accession number ATCC 98825;
2 5 the protein being substantially free from other mammalian proteins.
Preferably such
protein comprises the amino acid sequence of SEQ ID N0:18. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:18 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
3 0 of SEQ ID N0:18, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:18 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 289 to amino acid 298 of SEQ ID N0:18.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:19;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:19 from nucleotide 509 to nucleotide 2467;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone ca106_19x deposited under accession
number ATCC 98835;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone ca106_19x deposited under accession number ATCC 98835;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone ca106_19x deposited under accession number
ATCC 98835;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone ca106_19x deposited under accession number ATCC 98835;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:20;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:20 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:20;
2 0 (i} a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
2 5 one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(h) and that has a length that is
at least
25% of the length of SEQ ID N0:19.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
3 0 N0:19 from nucleotide 509 to nucleotide 2467; the nucleotide sequence of
the full-length
protein coding sequence of clone ca106_19x deposited under accession number
ATCC
98835; or the nucleotide sequence of a mature protein coding sequence of clone
ca106_19x
deposited under accession number ATCC 98835. In other preferred embodiments,
the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
31
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
of clone ca106_19x deposited under accession number ATCC 98835. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:20 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:20, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:20
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 321
to amino acid 330 of SEQ ID N0:20.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:19.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:19, but excluding the poly(A) tail at the
3' end of SEQ ID N0:19; and
(ab} the nucleotide sequence of the cDNA insert of clone
2 0 ca106_19x deposited under accession number ATCC 98835;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
2 5 and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
3 0 (ba) SEQ ID N0:19, but excluding the poly(A) tail at the
3' end of SEQ ID N0:19; and
(bb) the nucleotide sequence of the cDNA insert of clone
ca106_19x deposited under accession number ATCC 98835;
32
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:19, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:19 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:19
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:19. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:19 from nucleotide 509 to
nucleotide
2467, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:19 from nucleotide 509 to nucleotide 2467, to a
nucleoside
sequence corresponding to the 3' end of said sequence of SEQ ID N0:19 from
nucleotide
509 to nucleotide 2467.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:20;
2 0 (b) a fragment of the amino acld sequence of SEQ ID N0:20, the
fragment comprising eight contiguous amino acids of SEQ ID N0:20; and
(c) the amino acid sequence encoded by the cDNA insert of clone
ca106_19x deposited under accession number ATCC 98835;
the protein being substantially free from other mammalian proteins. Preferably
such
2 5 protein comprises the amino acid sequence of SEQ ID N0:20. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:20 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:20, or a protein comprising a fragment of the amino acid sequence
of SEQ
3 0 ID N0:20 having biological activity, the fragment comprising the amino
acid sequence
from amino acid 321 to amino acid 330 of SEQ ID N0:20.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
33
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:21;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:21 from nucleotide 179 to nucleotide 802;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:21 from nucleotide 242 to nucleotide 802;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone ci52 2 deposited under accession
number
ATCC 98835;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone ci52_2 deposited under accession number ATCC 98835;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone ci52 2 deposited under accession number ATCC
98835;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone ci52 2 deposited under accession number ATCC 98835;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:22;
(i) a polynucleotide encoding a protein comprising a fragment of the
2 0 amino acid sequence of SEQ ID N0:22 having biological activity, the
fragment
comprising eight contiguous amino acids of SEQ ID N0:22;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
2 5 of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
3 0 25% of the length of SEQ ID N0:21.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:21 from nucleotide 179 to nucleotide 802; the nucleotide sequence of SEQ ID
N0:21
from nucleotide 242 to nucleotide 802; the nucleotide sequence of the full-
length protein
coding sequence of clone ci52 2 deposited under accession number ATCC 98835;
or the
34
CA 02339047 2001-02-12
WO 00/09552 PCTNS99/18298
nucleotide sequence of a mature protein coding sequence of clone ci52_2
deposited under
accession number ATCC 98835. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone ci52 2
deposited under accession number ATCC 98835. In further preferred embodiments;
the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:22 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:22, or a polynucleotide encoding a protein comprising
a
fragment of the amino acid sequence of SEQ ID N0:22 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 99 to amino acid
108 of
SEQ ID N0:22.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:21.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynudeotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
2 0 (aa) SEQ ID N0:21, but excluding the poly(A) tail at the
3' end of SEQ ID N0:21; and
(ab) the nucleotide sequence of the cDNA insert of clone
ci52_2 deposited under accession number ATCC 98835;
(ii) hybridizing said probes) to human genomic DNA in
2 5 conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotldes detected with the
probe(s);
and
(b) a process comprising the steps of:
3 0 (i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:21, but excluding the poly(A) tail at the
3' end of SEQ ID N0:21; and
CA 02339047 2001-02-12
_ WO 00/09552 PCT/US99/18298
(bb) the nucleotide sequence of the cDNA insert of clone
ci52_2 deposited under accession number ATCC 98835;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:21, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:21 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:21
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:21. Also preferably the
polynudeotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:21 from nucleotide 179 to
nucleotide
802, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:21 from nucleotide 179 to nucleotide 802, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:21 from
nucleotide
179 to nucleotide 802. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:21 from nucleotide 242 to nucleotide 802, and extending contiguously from a
2 0 nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:21 from
nucleotide 242 to nucleotide 802, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:21 from nucleotide 242 to nucleotide 802.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
2 5 consisting of:
(a) the amino acid sequence of SEQ ID N0:22;
(b) a fragment of the amino acid sequence of SEQ ID N0:22, the
fragment comprising eight contiguous amino acids of SEQ ID N0:22; and
(c) the amino acid sequence encoded by the cDNA insert of clone
3 0 ci52_2 deposited under accession number ATCC 98835;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:22. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:22 having biological activity, the fragment
preferably
36
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:22, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:22 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 99 to amino acid 108 of SEQ ID N0:22.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:23;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:23 from nucleotide 46 to nucleotide 714;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:23 from nucleotide 538 to nucleotide 714;
(d) a polynucleotide comprising the nucleotide sequence of the full
length protein coding sequence of clone md124_16 deposited under accession
number ATCC 98835;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone md124_16 deposited under accession number ATCC 98835;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone md124_16 deposited under accession number
2 0 ATCC 98835;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone md124_16 deposited under accession number ATCC 98835;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:24;
2 5 (i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ TD N0:24 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:24;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
3 0 (k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a}-(i); and
37
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynudeotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:23.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:23 from nucleotide 46 to nucleotide 714; the nucleotide sequence of SEQ ID
N0:23
from nucleotide 538 to nucleotide 714; the nucleotide sequence of the full-
length protein
coding sequence of clone md124_16 deposited under accession number ATCC 98835;
or
the nucleotide sequence of a mature protein coding sequence of clone md124_16
deposited
under accession number ATCC 98835. In other preferred embodiments, the
polynucleotide encodes the full-length or. a mature protein encoded by the
cDNA insert
of clone md124_16 deposited under accession number ATCC 98835. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:24 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:24, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:24
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 106
to amino acid 115 of SEQ ID N0:24.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID N0:23.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
2 5 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa} SEQ ID N0:23, but excluding the poly(A) tail at the
3' end of SEQ ID N0:23; and
(ab) the nucleotide sequence of the cDNA insert of clone
3 0 md124_16 deposited under accession number ATCC 98835;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
38
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:23, but excluding the poly(A) tail at the
3' end of SEQ ID N0:23; and
{bb) the nucleotide sequence of the cDNA insert of clone
md124_16 deposited under accession number ATCC 98835;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:23, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:23 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:23
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:23. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
2 0 corresponding to the cDNA sequence of SEQ ID N0:23 from nucleotide 46 to
nucleotide
714, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:23 from nucleotide 46 to nucleotide 714, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:23 from
nucleotide
46 to nucleotide 714. Also preferably the polynucleotide isolated according to
the above
2 5 process comprises a nucleotide sequence corresponding to the cDNA sequence
of SEQ ID
N0:23 from nucleotide 538 to nucleotide 714, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:23 from
nucleotide 538 to nucleotide 714, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:23 from nucleotide 538 to nucleotide 714.
3 0 In other embodiments, the present invention provides a composition
comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:24;
39
CA 02339047 2001-02-12
WO 00/09552 PCT/US99I18298
(b) a fragment of the amino acid sequence of SEQ ID N0:24, the
fragment comprising eight contiguous amino acids of SEQ ID N0:24; and
(c) the amino acid sequence encoded by the cDNA insert of clone
md124_16 deposited under accession number ATCC 98835;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:24. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:24 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:24, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:24 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 106 to amino acid 115 of SEQ ID N0:24.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ TI7
N0:25;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:25 from nucleotide 92 to nucleotide 1726;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
2 0 N0:25 from nucleotide 1211 to nucleotide 1726;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone pk366_7 deposited under accession
number ATCC 98835;
(e) a polynucleotide encoding the full-length protein encoded by the
2 5 cDNA insert of clone pk366_7 deposited under accession number ATCC 98835;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone pk366_7 deposited under accession number
ATCC 98835;
{g) a polynucleotide encoding a mature protein encoded by the cDNA
3 0 insert of clone pk366_7 deposited under accession number ATCC 98835;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:26;
CA 02339047 2001-02-12
- WO 00/09552
PCT/US99/18298
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:26 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:26;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:25.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:25 from nucleotide 92 to nucleotide 1726; the nucleotide sequence of SEQ ID
N0:25
from nucleotide 1211 to nucleotide 1726; the nucleotide sequence of the full-
length
protein coding sequence of clone pk366_7 deposited under accession number ATCC
98835; or the nucleotide sequence of a mature protein coding sequence of clone
pk366_7
deposited under accession number ATCC 98835. In other preferred embodiments,
the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
2 0 of clone pk366_7 deposited under accession number ATCC 98835. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:26 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:26, or a polynucleotide
encoding
2 5 a protein comprising a fragment of the amino acid sequence of SEQ ID N0:26
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 267
to amino acid 276 of SEQ ID N0:26.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:25.
3 0 Further embodiments of the invention provide isolated polynucleotides
produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
41
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:25, but excluding the poly(A) tail at the
3' end of SEQ ID N0:25; and
(ab) the nucleotide sequence of the cDNA insert of clone
pk366_7 deposited under accession number ATCC 98835;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:25, but excluding the poly(A) tail at the
3' end of SEQ ID N0:25; and
(bb) the nucleotide sequence of the cDNA insert of clone
2 0 pk366_7 deposited under accession number ATCC 98835;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
2 5 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:25, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:25 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:25
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:25. Also preferably the
3 0 polynucleotide isolated according to the above process comprises a
nucleotide sequence
corresponding to the cDNA sequence of SEQ ID N0:25 from nucleotide 92 to
nucleotide
1726, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:25 from nucleotide 92 to nucleotide 1726, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:25 from
nucleotide
42
CA 02339047 2001-02-12
WO 00/09552 PC1'/US99/18298
92 to nucleotide 1726. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:25 from nucleotide 1211 to nucleotide 1726, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:25 from
nucleotide 1211 to nucleotide 1726, to a nucleotide sequence corresponding to
the 3' end
of said sequence of SEQ ID N0:25 from nucleotide 1211 to nucleotide 1726.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:26;
(b) a fragment of the amino acid sequence of SEQ ID N0:26, the
fragment comprising eight contiguous amino acids of SEQ ID N0:26; and
(c) the amino acid sequence encoded by the cDNA insert of clone
pk366_7 deposited under accession number ATCC 98835;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:26. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:26 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
2 0 of SEQ ID N0:26, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:26 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 267 to amino acid 276 of SEQ ID N0:26.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
2 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:27;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:27 from nucleotide 16 to nucleotide 1788;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
3 0 N0:27 from nucleotide 61 to nucleotide 1788;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone p1741 5 deposited under accession
number ATCC 98835;
43
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone p1741 5 deposited under accession number ATCC 98835;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone p1741 5 deposited under accession number
ATCC 98835;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone p1741 5 deposited under accession number ATCC 98835;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:28;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:28 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:28;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
2 0 one of the polynucleotides specified in (a)-(i} and that has a length that
is at least
25% of the length of SEQ ID N0:27.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:27 from nucleotide 16 to nucleotide 1788; the nucleotide sequence of SEQ ID
N0:27
from nucleotide 61 to nucleotide 1788; the nucleotide sequence of the full-
length protein
2 5 coding sequence of clone p1741 5 deposited under accession number ATCC
98835; or the
nucleotide sequence of a mature protein coding sequence of clone p1741 5
deposited
under accession number ATCC 98835. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone p1741_5 deposited under accession number ATCC 98835. In further
preferred
3 0 embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:28 having
biological
activity, the fragment preferably comprising eight {more preferably twenty,
most
preferably thirty} contiguous amino ands of SEQ ID N0:28, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:28
having
44
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/Z8298
biological activity, the fragment comprising the amino acid sequence from
amino acid 290
to amino acid 299 of SEQ ID N0:28.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:27.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
{i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:27, but excluding the poly(A) tail at the
3' end of SEQ ID N0:27; and
(ab) the nucleotide sequence of the cDNA insert of clone
p1741 5 deposited under accession number ATCC 98835;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
2 0 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:27, but excluding the poly(A) tail at the
2 5 3' end of SEQ ID N0:27; and
(bb) the nucleotide sequence of the cDNA insert of clone
p1741 5 deposited under accession number ATCC 98835;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
3 0 (iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii}.
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:27, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
CA 02339047 2001-02-12
- WO 00/09552 PCT/US99/18298
ID N0:27 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:27
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:27. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:27 from nucleotide 16 to
nucleotide
1788, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:27 from nucleotide 16 to nucleotide 1788, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:27 from
nucleotide
16 to nucleotide 1788. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:27 from nucleotide 61 to nucleotide 1788, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:27 from
nucleotide 61 to nucleotide 1788, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:27 from nucleotide 61 to nucleotide 1788.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:28;
(b) a fragment of the amino acid sequence of SEQ ID N0:28, the
fragment comprising eight contiguous amino acids of SEQ ID N0:28; and
2 0 (c) the amino acid sequence encoded by the cDNA insert of clone
p1741 5 deposited under accession number ATCC 98835;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:28. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
2 5 amino acid sequence of SEQ ID N0:28 having biological activity, the
fragment preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:28, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:28 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 290 to amino acid 299 of SEQ ID N0:28.
3 0 In one embodiment, the present invention provides a composition comprising
an
isolated polynucleotide selected from the group consisting of:
(a} a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:29;
46
CA 02339047 2001-02-12
WO 00/09552 PGT/US99/18298
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:29 from nucleotide 629 to nucleotide 2338;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone pp314_19 deposited under accession
number ATCC 98835;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone pp314_19 deposited under accession number ATCC 98835;
(e) a polynudeotide comprising the nucleotide sequence of a mature
protein coding sequence of clone pp314_19 deposited under accession number
2 0 ATCC 98835;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone pp314_19 deposited under accession number ATCC 98835;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:30;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:30 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:30;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
2 0 (j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
2 5 one of the polynucleotides specified in (a)-(h) and that has a length that
is at least
25% of the length of SEQ ID N0:29.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:29 from nucleotide 629 to nucleotide 2338; the nucleotide sequence of the
full-length
protein coding sequence of clone pp314_19 deposited under accession number
ATCC
3 0 98835; or the nucleotide sequence of a mature protein coding sequence of
clone pp314_19
deposited under accession number ATCC 98835. In other preferred embodiments,
the
polynudeotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone pp314_19 deposited under accession number ATCC 98835. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
47
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
comprising a fragment of the amino acid sequence of SEQ ID N0:30 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:30, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:30
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 280
to amino acid 289 of SEQ ID N0:30.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:29.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:29, but excluding the poly(A) tail at the
3' end of SEQ ID N0:29; and
(ab) the nucleotide sequence of the cDNA insert of clone
pp314_19 deposited under accession number ATCC 98835;
(ii) hybridizing said probes) to human genomic DNA in
2 0 conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
2 5 (i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:29, but excluding the poly(A) tail at the
3' end of SEQ ID N0:29; and
3 0 (bb) the nucleotide sequence of the cDNA insert of clone
pp314_19 deposited under accession number ATCC 98835;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
48
CA 02339047 2001-02-12
WO 00/09552 PCTNS99/18298
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:29, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:29 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:29
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:29. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:29 from nucleotide 629 to
nucleotide
2338, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:29 from nucleotide 629 to nucleotide 2338, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:29 from
nucleotide
629 to nucleotide 2338.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:30;
(b) a fragment of the amino acid sequence of SEQ ID N0:30, the
fragment comprising eight contiguous amino acids of SEQ ID N0:30; and
(c) the amino acid sequence encoded by the cDNA insert of clone
2 0 pp314_19 deposited under accession number ATCC 98835;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:30. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:30 having biological activity, the fragment
preferably
2 5 comprising eight (more preferably twenty, most preferably thirty)
contiguous amino acids
of SEQ ID N0:30, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:30 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 280 to amino acid 289 of SEQ ID N0:30.
In one embodiment, the present invention provides a composition comprising an
3 0 isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:31;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:31 from nucleotide 158 to nucleotide 1102;
49
CA 02339047 2001-02-12
_ WO 00/09552 PCT/US99/18298
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone pv35_1 deposited under accession
number ATCC 98835;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone pv35_1 deposited under accession number ATCC 98835;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone pv35_1 deposited under accession number
ATCC 98835;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone pv35_1 deposited under accession number ATCC 98835;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:32;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:32 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:32;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
2 0 (k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
25% of the length of SEQ ID N0:31.
2 5 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:31 from nucleotide 158 to nucleotide 1102; the nucleotide sequence of the
full-length
protein coding sequence of clone pv35_1 deposited under accession number ATCC
98835;
or the nucleotide sequence of a mature protein coding sequence of clone pv35_1
deposited
under accession number ATCC 98835. In other nrPfPrrPrl am~,na;".,o.,~~ ~~...
3 0 polynucleotide encodes the full-length or a mature protein encoded by the
cDNA insert
of clone pv35_1 deposited under accession number ATCC 98835. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:32 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
preferably thirty) contiguous amino acids of SEQ ID N0:32, or a polynudeotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:32
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 152
to amino acid 161 of SEQ ID N0:32.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:31.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:31, but excluding the poly(A) tail at the
3' end of SEQ ID N0:31; and
(ab) the nucleotide sequence of the cDNA insert of clone
pv35_1 deposited under accession number ATCC 98835;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
2 0 probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
2 5 the group consisting of:
(ba) SEQ ID N0:31, but excluding the poly(A) tail at the
3' end of SEQ ID N0:31; and
(bb) the nucleotide sequence of the cDNA insert of clone
pv35_1 deposited under accession number ATCC 98835;
3 0 (ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
51
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:31, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:31 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:31
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:31. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:31 from nucleotide 158 to
nucleotide
1102, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:31 from nucleotide 158 to nucleotide 1102, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:31 from
nucleotide
158 to nucleotide 1102.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:32;
(b) a fragment of the amino acid sequence of SEQ ID N0:32, the
fragment comprising eight contiguous amino acids of SEQ ID N0:32; and
(c) the amino acid sequence encoded by the cDNA insert of clone
pv35_1 deposited under accession number ATCC 98835;
2 0 the protein being substantially free from other mammalian proteins.
Preferably such
protein comprises the amino acid sequence of SEQ ID N0:32. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:32 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino atids
2 5 of SEQ ID N0:32, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:32 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 152 to amino acid 161 of SEQ ID N0:32.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
3 0 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:33;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:33 from nucleotide 413 to nucleotide 733;
52
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone pw337_6 deposited under accession
number ATCC 98835;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone pw337 6 deposited under accession number ATCC 98835;
{e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone pw337_6 deposited under accession number
ATCC 98835;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone pw337_6 deposited under accession number ATCC 98835;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:34;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:34 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:34;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h} above ;
2 0 (k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a}-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~{h) and that has a length that is
at least
25% of the length of SEQ ID N0:33.
2 5 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:33 from nucleotide 413 to nucleotide 733; the nucleotide sequence of the
full-length
protein coding sequence of clone pw337_6 deposited under accession number ATCC
98835; or the nucleotide sequence of a mature protein coding sequence of clone
pw337 6
deposited under accession number ATCC 98835. In other preferred embodiments,
the
3 0 polynucleotide encodes the full-length or a mature protein encoded by the
cDNA insert
of clone pw337 6 deposited under accession number ATCC 98835. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:34 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
53
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
preferably thirty) contiguous amino acids of SEQ ID N0:34, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:34
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 48
to amino acid 57 of SEQ ID N0:34.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:33.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:33, but excluding the poly(A) tail at the
3' end of SEQ ID N0:33; and
(ab) the nucleotide sequence of the cDNA insert of clone
pw337_6 deposited under accession number ATCC 98835;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
2 0 probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
2 5 the group consisting of:
(ba) SEQ ID N0:33, but excluding the poly(A) tail at the
3' end of SEQ ID N0:33; and
(bb) the nucleotide sequence of the cDNA insert of clone
pw337_6 deposited under accession number ATCC 98835;
3 0 (ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
{iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
54
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:33, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:33 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:33
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:33. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:33 from nucleotide 413 to
nucleotide
733, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:33 from nucleotide 413 to nucleotide 733, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:33 from
nucleotide
413 to nucleotide 733.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:34;
(b) a fragment of the amino acid sequence of SEQ ID N0:34, the
fragment comprising eight contiguous amino acids of SEQ ID N0:34; and
(c) the amino acid sequence encoded by the cDNA insert of clone
pw337_6 deposited under accession number ATCC 98835;
2 0 the protein being substantially free from other mammalian proteins.
Preferably such
protein comprises the amino acid sequence of SEQ ID N0:34. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:34 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
2 5 of SEQ ID N0:34, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:34 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 48 to amino acid 57 of SEQ ID N0:34.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
3 0 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:35;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:35 from nucleotide 678 to nucleotide 938;
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone rd6lU_1 deposited under accession
number ATCC 98835;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone rd610_1 deposited under accession number ATCC 98835;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone rd610_1 deposited under accession number
ATCC 98835;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone rd610_1 deposited under accession number ATCC 98835;
(g} a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:36;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:36 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:36;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
2 0 (k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a}-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
25% of the length of SEQ ID N0:35.
2 5 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:35 from nucleotide 678 to nucleotide 938; the nucleotide sequence of the
full-length
protein coding sequence of clone rd610_1 deposited under accession number ATCC
98835;
or the nucleotide sequence of a mature protein coding sequence of clone
rd610_1
deposited under accession number ATCC 98835. In other preferred embodiments,
the
3 0 polynucleotide encodes the full-length or a mature protein encoded by the
cDNA insert
of clone rd610_1 deposited under accession number ATCC 98835. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:36 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
56
CA 02339047 2001-02-12
_ WO 00/09552 PCTNS99/18298
preferably thirty) contiguous amino acids of SEQ ID N0:36, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:36
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 38
to amino acid 47 of SEQ ID NO:36.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:35.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
{i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:35, but excluding the poly(A) tail at the
3' end of SEQ ID N0:35; and
25 (ab) the nucleotide sequence of the cDNA insert of clone
rd610_1 deposited under accession number ATCC 98835;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
2 0 probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
2 5 the group consisting of:
(ba) SEQ ID N0:35, but excluding the poly(A) tail at the
3' end of SEQ ID N0:35; and
(bb) the nucleotide sequence of the cDNA insert of clone
rd610_1 deposited under accession number ATCC 98835;
3 0 (ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
57
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:35, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:35 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:35
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:35. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:35 from nucleotide 678 to
nucleotide
938, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:35 from nucleotide 678 to nucleotide 938, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:35 from
nucleotide
678 to nucleotide 938.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:36;
(b) a fragment of the amino acid sequence of SEQ ID N0:36, the
fragment comprising eight contiguous amino acids of SEQ ID N0:36; and
(c) the amino acid sequence encoded by the cDNA insert of clone
rd610_1 deposited under accession number ATCC 98835;
2 0 the protein being substantially free from other mammalian proteins.
Preferably such
protein comprises the amino acid sequence of SEQ ID N0:36. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:36 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
2 5 of SEQ ID N0:36, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:36 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 38 to amino acid 47 of SEQ ID N0:36.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
3 0 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:37;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:37 from nucleotide 75 to nucleotide 494;
58
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:37 from nucleotide 447 to nucleotide 494;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone rd810 6 deposited under accession
number ATCC 98835;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone rd810_6 deposited under accession number ATCC 98835;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone rd810_6 deposited under accession number
ATCC 98835;
(g} a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone rd810_6 deposited under accession number ATCC 98835;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:38;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:38 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:38;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
2 0 (k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
2 5 one of the polynucleotides specified in (a)-(i) and that has a length that
is at least
25% of the length of SEQ ID N0:37.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:37 from nucleotide 75 to nucleotide 494; the nucleotide sequence of SEQ ID
N0:37
from nucleotide 447 to nucleotide 494; the nucleotide sequence of the full-
length protein
3 0 coding sequence of clone rd810_6 deposited under accession number ATCC
98835; or the
nucleotide sequence of a mature protein coding sequence of clone rd810_6
deposited
under accession number ATCC 98835. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone rd810_6 deposited under accession number ATCC 98835. In further
preferred
59
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:38 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:38, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:38
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 65
to amino acid 74 of SEQ ID N0:38.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:37.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID NO:37, but excluding the poly(A) tail at the
3' end of SEQ ID N0:37; and
(ab) the nucleotide sequence of the cDNA insert of clone
rd810_6 deposited under accession number ATCC 98835;
2 0 (ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
2 5 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:37, but excluding the poly(A) tail at the
3 0 3' end of SEQ ID N0:37; and
(bb) the nucleotide sequence of the cDNA insert of clone
rd810_6 deposited under accession number ATCC 98835;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleoHde products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:37, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:37 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:37
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:37. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:37 from nucleotide 75 to
nucleotide
494, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:37 from nucleotide 75 to nucleotide 494, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:37 from
nucleotide
75 to nucleotide 494. Also preferably the polynucleotide isolated according to
the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:37 from nucleotide 447 to nucleotide 494, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:37 from
nucleotide 447 to nucleotide 494, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:37 from nucleotide 447 to nucleotide 494.
In other embodiments, the present invention provides a composition comprising
2 0 a protein, wherein said protein comprises an amino acid sequence selected
from the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:38;
(b) a fragment of the amino acid sequence of SEQ ID N0:38, the
fragment comprising eight contiguous amino acids of SEQ ID N0:38; and
2 5 {c) the amino acid sequence encoded by the cDNA insert of clone
rd810_6 deposited under accession number ATCC 98835;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:38. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
3 0 amino acid sequence of SEQ ID N0:38 having biological activity, the
fragment preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:38, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:38 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 65 to amino acid 74 of SEQ ID N0:38.
61
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:39;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:39 from nucleotide 181 to nucleotide 1080;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone cf85_1 deposited under accession
number
ATCC 98850;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone cf85_1 deposited under accession number ATCC 98850;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone cf85 1 deposited under accession number ATCC
98850;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone cf85_1 deposited under accession number ATCC 98850;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:40;
(h) a polynucleotide encoding a protein comprising a fragment of the
2 0 amino acid sequence of SEQ ID N0:40 having biological activity, the
fragment
comprising eight contiguous amino acids of SEQ ID N0:40;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
2 5 of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a}-(h) and that has a length that is
at least
3 0 25% of the length of SEQ ID N0:39.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:39 from nucleotide 181 to nucleotide 1080; the nucleotide sequence of the
full-length
protein coding sequence of clone cf85_1 deposited under accession number ATCC
98850;
or the nucleotide sequence of a mature protein coding sequence of clone cf85_1
deposited
62
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
under accession number ATCC 98850. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone cf85_I deposited under accession number ATCC 98850. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:40 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:40, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:40
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 145
to amino acid 154 of SEQ ID N0:40.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:39.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:39, but excluding the poly(A) tail at the
2 0 3' end of SEQ ID N0:39; and
(ab) the nucleotide sequence of the cDNA insert of clone
cf85_1 deposited under accession number ATCC 98850;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
2 5 (iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
3 0 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:39, but excluding the poly(A) tail at the
3' end of SEQ ID N0:39; and
63
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(bb) the nucleotide sequence of the cDNA insert of clone
cf85_1 deposited under accession number ATCC 98850;
(ii) hybridizing said primers) to human genonuc DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:39, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:39 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:39
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:39. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:39 from nucleotide 181 to
nucleotide
1080, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:39 from nucleotide 181 to nucleotide 1080, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:39 from
nucleotide
181 to nucleotide 1080.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
2 0 consisting of:
(a) the amino acid sequence of SEQ ID N0:40;
(b) a fragment of the amino acid sequence of SEQ ID N0:40, the
fragment comprising eight contiguous amino acids of SEQ ID N0:40; and
(c) the amino acid sequence encoded by the cDNA insert of clone
2 5 cf85_1 deposited under accession number ATCC 98850;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:40. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:40 having biological activity, the fragment
preferably
3 0 comprising eight (more preferably twenty, most preferably thirty)
contiguous amino acids
of SEQ ID N0:40, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:40 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 145 to amino acid 154 of SEQ ID N0:40.
64
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleoride comprising the nucleotide sequence of SEQ ID
N0:41;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:41 from nucleotide 161 to nucleotide 1348;
(c) a polynucleoHde comprising the nucleotide sequence of SEQ ID
N0:41 from nucleotide 599 to nucleotide 1348;
(d) a polynucleotide comprising the nucleotide sequence of the full
length protein coding sequence.of clone dd504_18 deposited under accession
number ATCC 98850;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone dd504_18 deposited under accession number ATCC 98850;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone dd504_18 deposited under accession number
ATCC 98850;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone dd504_18 deposited under accession number ATCC 98850;
(h) a polynucleotide encoding a protein comprising the amino acid
2 0 sequence of SEQ ID N0:42;
(i} a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:42 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:42;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
2 5 (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
3 0 (m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a Length that is
at least
25% of the length of SEQ ID N0:41.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:41 from nucleotide 161 to nucleotide 1348; the nucleotide sequence of SEQ
ID N0:41
CA 02339047 2001-02-12
WO 00/09552 PC'T/US99/18298
from nucleotide 599 to nucleotide 1348; the nucleotide sequence of the full-
length protein
coding sequence of clone dd504_18 deposited under accession number ATCC 98850;
or
the nucleotide sequence of a mature protein coding sequence of clone dd504_18
deposited
under accession number ATCC 98850. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone dd504_18 deposited under accession number ATCC 98850. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:42 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:42, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:42
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 193
to amino acid 202 of SEQ ID N0:42.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:41.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
2 0 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:41, but excluding the poly(A) tail at the
3' end of SEQ ID N0:41; and
(ab) the nucleotide sequence of the cDNA insert of clone
2 5 dd504_18 deposited under accession number ATCC 98850;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
3 0 and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
66
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(ba) SEQ ID N0:41, but excluding the poly(A) tail at the
3' end of SEQ ID N0:41; and
(bb) the nucleotide sequence of the cDNA insert of clone
dd504_18 deposited under accession number ATCC 98850;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to . the cDNA sequence of SEQ ID N0:41, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:41 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:41
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:41. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:41 from nucleotide 161 to
nucleotide
1348, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:41 from nucleotide 161 to nucleotide 1348, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:41 from
nucleotide
161 to nucleotide 1348. Also preferably the polynucleotide isolated according
to the above
2 0 process comprises a nucleotide sequence corresponding to the cDNA sequence
of SEQ ID
N0:41 from nucleotide 599 to nucleotide 1348, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:41 from
nucleotide 599 to nucleotide 1348, to a nucleotide sequence corresponding to
the 3' end
of said sequence of SEQ ID N0:41 from nucleotide 599 to nucleotide 1348.
2 5 In other embodiments, the present invention provides a composition
comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:42;
(b) a fragment of the amino acid sequence of SEQ ID N0:42, the
3 0 fragment comprising eight contiguous amino acids of SEQ ID N0:42; and
(c) the amino acid sequence encoded by the cDNA insert of clone
dd504_18 deposited under accession number ATCC 98850;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:42. In further
preferred
67
CA 02339047 2001-02-12
_ WO 00/09552 PCT/US99/18298
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:42 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino ands
of SEQ ID N0:42, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:42 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 193 to amino acid 202 of SEQ ID N0:42.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:43;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:43 from nucleotide 70 to nucleotide 1386;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone np26_3 deposited under accession
number ATCC 98850;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone np26 3 deposited under accession number ATCC 98850;
(e) a polynucleotide comprising the .nucleotide sequence of a mature
protein coding sequence of clone np26_3 deposited under accession number
2 0 ATCC 98850;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone np26_3 deposited under accession number ATCC 98850;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:44;
2 5 (h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:44 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:44;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
3 0 (j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
68
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(h) and that has a length that is
at least
25% of the length of SEQ ID N0:43.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:43 from nucleotide 70 to nucleotide 1386; the nucleotide sequence of the
full-length
protein coding sequence of clone np26_3 deposited under accession number ATCC
98850;
or the nucleotide sequence of a mature protein coding sequence of clone np26 3
deposited
under accession number ATCC 98850. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone np26_3 deposited under accession number ATCC 98850. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:44 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:44, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:44
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 214
to amino acid 223 of SEQ ID N0:44.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:43.
2 0 Further embodiments of the invention provide isolated polynucleotides
produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
2 5 consisting of:
(aa) SEQ ID N0:43, but excluding the poly(A) tail at the
3' end of SEQ ID N0:43; and
(ab) the nucleotide sequence of the cDNA insert of done
np26_3 deposited under accession number ATCC 98850;
3 0 (ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
69
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(b) a process comprising the steps of:
(i} preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:43, but excluding the poly(A) tail at the
3' end of SEQ ID N0:43; and
(bb) the nucleotide sequence of the cDNA insert of clone
np26_3 deposited under accession number ATCC 98850;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isalated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:43, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:43 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:43
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:43. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:43 from nucleotide 70 to
nucleotide
2 0 1386, and extending contiguously from a nucleotide sequence corresponding
to the 5' end
of said sequence of SEQ ID N0:43 from nucleotide 70 to nucleotide 1386, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:43 from
nucleotide
70 to nucleotide 1386.
In other embodiments, the present invention provides a composition comprising
2 5 a protein, wherein said protein comprises an amino acid sequence selected
from the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:44;
(b) a fragment of the amino acid sequence of SEQ ID N0:44, the
fragment comprising eight contiguous amino acids of SEQ ID N0:44; and
3 0 (c) the amino acid sequence encoded by the cDNA insert of clone
np26_3 deposited under accession number ATCC 98850;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:44. 1n further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
CA 02339047 2001-02-12
WO 00/09552 PCTNS99/18298
amino acid sequence of SEQ ID N0:44 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:44, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:44 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 214 to amino acid 223 of SEQ ID N0:44.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:45;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:45 from nucleotide 60 to nucleotide 3515;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone pm412_12 deposited under accession
number ATCC 98850;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone pm412_12 deposited under accession number ATCC 98850;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone pm412_12 deposited under accession number
ATCC 98850;
2 0 (f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone pm412_12 deposited under accession number ATCC 98850;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:46;
(h) a polynucleotide encoding a protein comprising a fragment of the
2 5 amino acid sequence of SEQ ID N0:46 having biological activity, the
fragment
comprising eight contiguous amino acids of SEQ ID N0:46;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
3 0 of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
71
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
25% of the length of SEQ ID N0:45.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:45 from nucleotide 60 to nucleotide 3515; the nucleotide sequence of the
full-length
protein coding sequence of clone pm412_12 deposited under accession number
ATCC
98850; or the nucleotide sequence of a mature protein coding sequence of clone
pm412_12
deposited under accession number ATCC 98850. In other preferred embodiments,
the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone pm412_12 deposited under acces$ion number ATCC 98850. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:46 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:46, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:46
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 571
to amino acid 580 of SEQ ID N0:46.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:45.
2 0 Further embodiments of the invention provide isolated polynucleotides
produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
2 5 consisting of:
(aa) SEQ ID N0:45, but excluding the poly(A) tail at the
3' end of SEQ ID N0:45; and
(ab) the nucleotide sequence of the cDNA insert of clone
pm412_12 deposited under accession number ATCC 98850;
3 0 (ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probes};
and
72
CA 02339047 2001-02-12
WO 00/09552 PCT/CJS99/18298
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
{ba) SEQ ID N0:45, but excluding the poly(A) tail at the
3' end of SEQ ID N0:45; and
(bb) the nucleotide sequence of the cDNA insert of clone
pm412_12 deposited under accession number ATCC 98850;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:45, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:4S to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:45
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:45. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:45 from nucleotide 60 to
nucleotide
2 0 3515, and extending contiguously from a nucleotide sequence corresponding
to the 5' end
of said sequence of SEQ ID N0:45 from nucleotide 60 to nucleotide 3515, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:45 from
nucleotide
60 to nucleotide 3515.
In other embodiments, the present invention provides a composition comprising
2 5 a protein, wherein said protein comprises an amino acid sequence selected
from the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:46;
(b) a fragment of the amino acid sequence of SEQ ID N0:46, the
fragment comprising eight contiguous amino acids of SEQ ID N0:46; and
3 0 (c) the amino acid sequence encoded by the cDNA insert of clone
pm412_12 deposited under accession number ATCC 98850;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:46. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
73
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
amino acid sequence of SEQ ID N0:46 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:46, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:46 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 571 to amino acid 580 of SEQ ID N0:46.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:47;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:47 from nucleotide 1490 to nucleotide 1780;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:47 from nucleotide 1556 to nucleotide 1780;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone pm421 3 deposited under accession
number ATCC 98850;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone pm421 3 deposited under accession number ATCC 98850;
(f) a polynucleotide comprising the nucleotide sequence of a mature
2 0 protein coding sequence of clone pm421 3 deposited under accession number
ATCC 98850;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone pm421 3 deposited under accession number ATCC 98850;
(h) a polynucleotide encoding a protein comprising the amino acid
2 5 sequence of SEQ ID N0:48;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:48 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:48;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
3 0 (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to arty
one of the polynucleotides specified in (a)-(i); and
74
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:47.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:47 from nucleotide 1490 to nucleotide 1780; the nucleotide sequence of SEQ
ID N0:47
from nucleotide 1556 to nucleotide 1780; the nucleotide sequence of the full-
length
protein coding sequence of clone pm421 3 deposited under accession number ATCC
98850; or the nucleotide sequence of a mature protein coding sequence of clone
pm421_3
deposited under accession number ATCC 98850. In other preferred embodiments,
the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone pm421 3 deposited under accession number ATCC 98850. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:48 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
2 5 preferably thirty) contiguous amino ands of SEQ ID N0:48, or a
polynucleotide encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:48
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 43
to amino acid 52 of SEQ ID N0:48.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID N0:47.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
2 5 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:47, but excluding the poly(A) tail at the
3' end of SEQ ID N0:47; and
(ab) the nucleotide sequence of the cDNA insert of clone
3 0 pm421_3 deposited under accession number ATCC 98850;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:47, but excluding the poly{A) tail at the
3' end of SEQ ID N0:47; and
(bb) the nucleotide sequence of the cDNA insert of clone
pm421 3 deposited under accession number ATCC 98850;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
{iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:47, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:47 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:47
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:47. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
2 0 corresponding to the cDNA sequence of SEQ ID N0:47 from nucleotide 1490 to
nucleotide
1780, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:47 from nucleotide 1490 to nucleotide 1780, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:47 from
nucleotide
1490 to nucleotide 1780. Also preferably the polynucleotide isolated according
to the
2 5 above process comprises a nucleotide sequence corresponding to the cDNA
sequence of
SEQ ID N0:47 from nucleotide 1556 to nucleotide 1780, and extending
contiguously from
a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:47 from
nucleotide 1556 to nucleotide 1780, to a nucleotide sequence corresponding to
the 3' end
of said sequence of SEQ ID N0:47 from nucleotide 1556 to nucleotide 1780.
3 0 In other embodiments, the present invention provides a composition
comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:48;
76
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(b) a fragment of the amino acid sequence of SEQ ID N0:48, the
fragment comprising eight contiguous amino acids of SEQ ID N0:48; and
(c) the amino acid sequence encoded by the cDNA insert of clone
pm421 3 deposited under accession number ATCC 98850;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ 1D N0:48. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:48 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:48, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:48 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 43 to amino acid 52 of SEQ ID N0:48.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:49;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:49 from nucleotide 64 to nucleotide 486;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
2 0 N0:49 from nucleotide 217 to nucleotide 486;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone pv6_1 deposited under accession number
ATCC 98850;
(e) a polynucleotide encoding the full-length protein encoded by the
2 5 cDNA insert of clone pv6_1 deposited under accession number ATCC 98850;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone pv6_1 deposited under accession number ATCC
98850;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
3 0 insert of clone pv6_1 deposited under accession number ATCC 98850;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:50;
77
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:50 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:50;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynudeotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (ar(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:49.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:49 from nucleotide 64 to nucleotide 486; the nucleotide sequence of SEQ ID
N0:49
from nucleotide 217 to nucleotide 486; the nucleotide sequence of the full-
length protein
coding sequence of clone pv6_1 deposited under accession number ATCC 98850; or
the
nucleotide sequence of a mature protein coding sequence of clone pv6_1
deposited under
accession number ATCC 98850. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone pv6_1
2 0 deposited under accession number ATCC 98850. In further preferred
embodiments, the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID, N0:50 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:50, or a polynucleotide encoding a protein comprising
a
2 5 fragment of the amino acid sequence of SEQ ID N0:50 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 65 to amino acid
74 of SEQ
ID N0:50.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:49.
3 0 Further embodiments of the invention provide isolated polynucleotides
produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
78
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
{aa) SEQ ID N0:49, but excluding the poly(A) tail at the
3' end of SEQ ID N0:49; and
(ab) the nucleotide sequence of the cDNA insert of clone
pv6_1 deposited under accession number ATCC 98850;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
{iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:49, but excluding the poly(A) tail at the
3' end of SEQ ID NO:49; and
(bb) the nucleotide sequence of the cDNA insert of clone
2 0 pv6_1 deposited under accession number ATCC 98850;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
2 5 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:49, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:49 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:49
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:49. Also preferably the
3 0 polynucleotide isolated according to the above process comprises a
nucleotide sequence
corresponding to the cDNA sequence of SEQ ID N0:49 from nucleotide 64 to
nucleotide
486, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:49 from nucleotide 64 to nucleotide 486, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:49 from
nucleotide
79
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
64 to nucleotide 486. Also preferably the polynucleotide isolated according to
the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:49 from nucleotide 217 to nucleotide 486, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:49 from
nucleotide 217 to nucleotide 486, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:49 from nucleotide 217 to nucleotide 486.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:50;
(b) a fragment of the amino acid sequence of SEQ ID N0:50, the
fragment comprising eight contiguous amino acids of SEQ ID N0:50; and
(c) the amino acid sequence encoded by the cDNA insert of clone
pv6_1 deposited under accession number ATCC 98850;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:50. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:50 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
2 0 of SEQ ID N0:50, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:50 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 65 to amino acid 74 of SEQ ID N0:50.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
2 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:51;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:51 from nucleotide 379 to nucleotide 3783;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
3 0 N0:51 from nucleotide 460 to nucleotide 3783;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:51 from nucleotide 1983 to nucleotide 3938;
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(e) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone qsl4 3 deposited under accession
number
ATCC 98850;
(f) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone qsl4 3 deposited under accession number ATCC 98850;
(g) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone qsl4 3 deposited under accession number ATCC
98850;
(h) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone qsl4 3 deposited under accession number ATCC 98850;
(i) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:52;
(j) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:52 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:52;
(k) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(h) above;
(1) a polynucleotide which encodes a species homologue of the protein
of (i) or (j) above ;
2 0 (m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(j); and
(n) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(j) and that has a length that is
at least
25% of the length of SEQ ID N0:51.
2 5 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:51 from nucleotide 379 to nucleotide 3783; the nucleotide sequence of SEQ
ID N0:51
from nucleotide 460 to nucleotide 3783; the nucleotide sequence of SEQ ID
N0:51 from
nucleotide 1983 to nucleotide 3938; the nucleotide sequence of the full-length
protein
coding sequence of clone qsl4_3 deposited under accession number ATCC 98850;
or the
3 0 nucleotide sequence of a mature protein coding sequence of clone qsl4 3
deposited under
accession number ATCC 98850. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone qsl4 3
deposited under accession number ATCC 98850. In yet other preferred
embodiments,
the present invention provides a polynucleotide encoding a protein comprising
the amino
81
CA 02339047 2001-02-12
_ WO 00/09552 PCT/US99/18298
acid sequence of SEQ ID N0:52 from amino acid 536 to amino acid 1135. In
further
preferred embodiments, the present invention provides a polynucleotide
encoding a
protein comprising a fragment of the amino acid sequence of SEQ ID N0:52
having
biological activity, the fragment preferably comprising eight (more preferably
twenty,
most preferably thirty) contiguous amino acids of SEQ ID N0:52, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:52
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 562 to amino acid 571 of SEQ ID NO:52.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:51.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:51, but excluding the poly(A) tail at the
3' end of SEQ ID N0:51; and
(ab) the nucleotide sequence of the cDNA insert of clone
2 0 qsl4 3 deposited under accession number ATCC 98850;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
2 5 and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
3 0 (ba) SEQ ID N0:51, but excluding the poly(A) tail at the
3' end of SEQ ID N0:51; and
(bb) the nucleotide sequence of the cDNA insert of clone
qsl4 3 deposited under accession number ATCC 98850;
82
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b}(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:51, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:51 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:51,
but
excluding the poly(A) tail at the 3' end of SEQ ID N0:51. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:51 from nucleotide 379 to
nucleotide
3783, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:51 from nucleotide 379 to nucleotide 3783, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:51 from
nucleotide
379 to nucleotide 3783. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:51 from nucleotide 460 to nucleotide 3783, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:51 from
nucleotide 460 to nucleotide 3783, to a nucleotide sequence corresponding to
the 3' end
2 0 of said sequence of SEQ ID N0:51 from nucleotide 460 to nucleotide 3783.
Also preferably
the polynucleotide isolated according to the above process comprises a
nucleotide
sequence corresponding to the cDNA sequence of SEQ ID N0:51 from nucleotide
1983 to
nucleotide 3938, and extending contiguously from a nucleotide sequence
corresponding
to the 5' end of said sequence of SEQ ID N0:51 from nucleotide 1983 to
nucleotide 3938,
2 5 to a nucleotide sequence corresponding to the 3' end of said sequence of
SEQ ID N0:51
from nucleotide 1983 to nucleotide 3938.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
3 0 (a} the amino acid sequence of SEQ ID N0:52;
(b) the amino acid sequence of SEQ ID N0:52 from amino acid 536 to
amino acid 1135;
(c) a fragment of the amino acid sequence of SEQ ID N0:52, the
fragment comprising eight contiguous amino acids of SEQ ID N0:52; and
83
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(d) the amino acid sequence encoded by the cDNA insert of clone
qsl4_3 deposited under accession number ATCC 98850;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID NO:52 or the amino acid
sequence
of SEQ ID N0:52 from amino acid 536 to amino acid 1135. In further preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino and sequence of SEQ ID N0:52 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:52, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:52 having biological activity, the, fragment comprising the amino acid
sequence
from amino acid 562 to amino acid 571 of SEQ ID N0:52.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:53;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:53 from nucleotide 1 to nucleotide 843;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:53 from nucleotide 469 to nucleotide 843;
2 0 (d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone qy338 9 deposited under accession
number ATCC 98850;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone qy338 9 deposited under accession number ATCC 98850;
2 5 (f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone qy338_9 deposited under accession number
ATCC 98850;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone qy338_9 deposited under accession number ATCC 98850;
3 0 (h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:54;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:54 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:54;
84
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:53.
Preferably, such polynucleotide, comprises the nucleotide sequence of SEQ ID
N0:53 from nucleotide 1 to nucleotide 843; the nucleotide sequence of SEQ ID
N0:53 from
nucleotide 469 to nucleotide 843; the nucleotide sequence of the full-length
protein coding
sequence of clone qy338_9 deposited under accession number ATCC 98850; or the
nucleotide sequence of a mature protein coding sequence of clone qy338 9
deposited
under accession number ATCC 98850. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone qy338_9 deposited under accession number ATCC 98850. In further
preferred
embodiments, the present invention provides a polynucieotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:54 having
biological
2 0 activity, the fragment preferably comprising eight (more preferably
twenty, most
preferably thirty) contiguous amino atids of SEQ ID N0:54, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:54
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 135
to amino acid 144 of SEQ ID N0:54.
2 5 Other embodiments provide the gene corresponding to the cDNA sequence of
SEQ
ID N0:53.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
3 0 (i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:53, but excluding the poly(A) tail at the
3' end of SEQ ID N0:53; and
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(ab) the nucleotide sequence of the cDNA insert of clone
qy338 9 deposited under accession number ATCC 98850;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:53, but excluding the poly(A) tail at the
3' end of SEQ ID N0:53; and
(bb) the nucleotide sequence of the cDNA insert of clone
qy338 9 deposited under accession number ATCC 98850;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
2 0 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:53, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:53 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:53
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:53. Also preferably the
2 5 polynucleotide isolated according to the above process comprises a
nucleotide sequence
corresponding to the cDNA sequence of SEQ ID N0:53 from nucleotide 1 to
nucleotide
843, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:53 from nucleotide 1 to nucleotide 843, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:53 from
nucleotide
3 0 1 to nucleotide 843. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:53 from nucleotide 469 to nucleotide 843, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:53 from
86
CA 02339047 2001-02-12
WO 00109552 PCT/US99/18298
nucleotide 469 to nucleotide 843, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:53 from nucleotide 469 to nucleotide 843.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:54;
(b) a fragment of the amino acid sequence of SEQ ID N0:54, the
fragment comprising eight contiguous amino acids of SEQ ID N0:54; and
(c) the amino acid sequence encoded by the cDNA insert of clone
qy338_9 deposited under accession number ATCC 98850;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:54. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:54 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:54, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:54 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 135 to amino acid 144 of SEQ ID N0:54.
In one embodiment, the present invention provides a composition comprising an
2 0 isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:55;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:55 from nucleotide 283 to nucleotide 906;
2 5 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:55 from nucleotide 325 to nucleotide 906;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone rc58_1 deposited under accession
number
ATCC 98850;
3 0 (e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone rc58_1 deposited under accession number ATCC 98850;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone rc58_1 deposited under accession number ATCC
98850;
87
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone rc58_1 deposited under accession number ATCC 98850;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:56;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:56 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:56;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynudeotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(i) and that has a length that is
at least
25% of the length of SEQ ID N0:55.
Preferably, such polynudeotide comprises the nucleotide sequence of SEQ ID
N0:55 from nucleotide 283 to nucleotide 906; the nucleotide sequence of SEQ ID
N0:55
from nucleotide 325 to nucleotide 906; the nucleotide sequence of the full-
length protein
2 0 coding sequence of clone rc58_1 deposited under accession number ATCC
98850; or the
nucleotide sequence of a mature protein coding sequence of clone rc58_1
deposited under
accession number ATCC 98850. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone rc58_1
deposited under accession number ATCC 98850. In further preferred embodiments,
the
2 5 present invention provides a polynucleotide encoding a protein comprising
a fragment
of the amino acid sequence of SEQ ID N0:56 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:56, or a polynucleotide encoding a protein comprising
a
fragment of the amino acid sequence of SEQ ID N0:56 having biological
activity, the
3 0 fragment comprising the amino acid sequence from amino acid 99 to amino
acid 108 of
SEQ ID N0:56.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:55.
88
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more palynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:55, but excluding the poly(A) tail at the
3' end of SEQ ID N0:55; and
(ab) the nucleotide sequence of the cDNA insert of clone
rc58_1 deposited under accession number ATCC 98850;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
2 0 (ba) SEQ ID N0:55, but excluding the poly(A) tail at the
3' end of SEQ ID N0:55; and
(bb) the nucleotide sequence of the cDNA insert of clone
rc58_1 deposited under accession number ATCC 98850;
(ii) hybridizing said primers) to human genomic DNA in
2 5 conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleatide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:55, and
3 0 extending contiguously from a nucleotide sequence corresponding to the 5'
end of SEQ
ID N0:55 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:55
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:55. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:55 from nucleotide 283 to
nucleotide
89
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
906, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:55 from nucleotide 283 to nucleotide 906, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:55 from
nucleotide
283 to nucleotide 906. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:55 from nucleotide 325 to nucleotide 906, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:55 from
nucleotide 325 to nucleotide 906, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:55 from nucleotide 325 to nucleotide 906.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:56;
(b) a fragment of the amino acid sequence of SEQ ID N0:56, the
fragment comprising eight contiguous amino acids of SEQ ID N0:56; and
(c) the amino acid sequence encoded by the cDNA insert of clone
rc58_1 deposited under accession number ATCC 98850;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:56. In further
preferred
2 0 embodiments, the present invention provides a protein comprising a
fragment of the
amino acid sequence of SEQ ID N0:56 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:56, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:56 having biological activity, the fragment comprising the amino acid
sequence
2 5 from amino acid 99 to amino acid 108 of SEQ ID N0:56.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:57;
3 0 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:57 from nucleotide 56 to nucleotide 973;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone rd232 5 deposited under accession
number ATCC 98850;
CA 02339047 2001-02-12
WO 00/09552 PCTNS99/18298
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone rd232_5 deposited under accession number ATCC 98850;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone rd232 5 deposited under accession number
ATCC 98850;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone rd232 5 deposited under accession number ATCC 98850;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:58;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:58 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:58;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k} a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
2 0 one of the polynucleotides specified in (a~(h) and that has a length that
is at least
25% of the length of SEQ ID N0:57.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:57 from nucleotide 56 to nucleotide 973; the nucleotide sequence of the
full-length
protein coding sequence of clone rd232_5 deposited under accession number ATCC
98850;
2 5 or the nucleotide sequence of a mature protein coding sequence of clone
rd232_5
deposited under accession number ATCC 98850. In other preferred embodiments,
the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone rd232_5 deposited under accession number ATCC 98850. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
3 0 comprising a fragment of the amino acid sequence of SEQ ID N0:58 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:58, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:58
having
91
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
biological activity, the fragment comprising the amino acid sequence from
amino and 148
to amino acid 157 of SEQ ID N0:58.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:57.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:57, but excluding the poly(A) tail at the
3' end of SEQ ID N0:57; and
(ab) the nucleotide sequence of the cDNA insert of clone
rd232_5 deposited under accession number ATCC 98850;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
2 0 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:57, but excluding the poly(A) tail at the
2 5 3' end of SEQ ID N0:57; and
(bb) the nucleotide sequence of the cDNA insert of clone
rd232_5 deposited under accession number ATCC 98850;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
3 0 (iii) amplifying human DNA sequences; and
(iv} isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:57, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
92
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
ID N0:57 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:57
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:57. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:57 from nucleotide 56 to
nucleotide
973, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:57 from nucleotide 56 to nucleotide 973, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:57 from
nucleotide
56 to nucleotide 973.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:58;
(b) a fragment of the amino acid sequence of SEQ ID N0:58, the
fragment comprising eight contiguous amino acids of SEQ ID N0:58; and
(c) the amino acid sequence encoded by the cDNA insert of clone
rd232_5 deposited under accession number ATCC 98850;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:58. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
2 0 amino acid sequence of SEQ ID NOSE having biological activity, the
fragment preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:58, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:58 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 148 to amino acid 157 of SEQ ID N0:58.
2 5 In one embodiment, the present invention provides a composition comprising
an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:59;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
3 0 N0:59 from nucleotide 893 to nucleotide 2596;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone ck213_12 deposited under accession
number ATCC 98918;
93
CA 02339047 2001-02-12
_ WO 00/09552 PCT/US99/18298
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone ck213_12 deposited under accession number ATCC 98918;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone ck213_12 deposited under accession number
ATCC 98918;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone ck223 12 deposited under accession number ATCC 98918;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:60;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:60 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:60;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
2 0 one of the polynucleotides specified in (a~(h) and that has a length that
is at least
25% of the length of SEQ ID N0:59.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:59 from nucleotide 893 to nucleotide 2596; the nucleotide sequence of the
full-length
protein coding sequence of clone ck213_12 deposited under accession number
ATCC
2 5 98918; or the nucleotide sequence of a mature protein coding sequence of
clone ck213_12
deposited under accession number ATCC 98918. In other preferred embodiments,
the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone ck213_12 deposited under accession number ATCC 98918. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
3 0 comprising a fragment of the amino acid sequence of SEQ ID N0:60 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:60, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:60
having
94
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
biological activity, the fragment comprising the amino acid sequence from
amino acid 279
to amino acid 288 of SEQ ID N0:60.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:59.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:59, but excluding the poly(A) tail at the
3' end of SEQ ID N0:59; and
(ab) the nucleotide sequence of the cDNA insert of clone
ck213_12 deposited under accession number ATCC 98918;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii} isolating the DNA polynucleotides detected with the
probe(s);
and
2 0 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:59, but excluding the poly(A) tail at the
2 5 3' end of SEQ ID N0:59; and
(bb) the nucleotide sequence of the cDNA insert of clone
ck213_12 deposited under accession number ATCC 98918;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
3 0 (iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:59, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
CA 02339047 2001-02-12
WO 00/09552 PC'TNS99/18298
ID N0:59 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:59
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:59. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:59 from nucleotide 893 to
nucleotide
2596, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:59 from nucleotide 893 to nucleotide 2596, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:59 from
nucleotide
893 to nucleotide 2596.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:60;
(b) a fragment of the amino acid sequence of SEQ ID N0:60, the
fragment comprising eight contiguous amino acids of SEQ ID N0:60; and
(c) the amino acid sequence encoded by the cDNA insert of done
ck213_12 deposited under accession number ATCC 98918;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:60. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
2 0 amino acid sequence of SEQ ID N0:60 having biological activity, the
fragment preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:60, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:60 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 279 to amino acid 288 of SEQ ID N0:60.
2 5 In one embodiment, the present invention provides a composition comprising
an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:61;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
3 0 N0:61 from nucleotide 29 to nucleotide 1750;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone pg195_1 deposited under accession
number ATCC 98918;
96
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone pg195_1 deposited under accession number ATCC 98918;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone pg195_1 deposited under accession number
ATCC 98918;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone pg195 1 deposited under accession number ATCC 98918;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:62;
(h) a polynudeotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:62 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:62;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
2 0 one of the polynucleotides specified in (a)-(h) and that has a length that
is at least
25% of the length of SEQ ID N0:61.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:61 from nucleotide 29 to nucleotide 1750; the nucleotide sequence of the
full-length
protein coding sequence of clone pg195 1 deposited under accession number ATCC
2 5 98918; or the nucleotide sequence of a mature protein coding sequence of
clone pg195_1
deposited under accession number ATCC 98918. In other preferred embodiments,
the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone pg195_1 deposited under accession number ATCC 98918. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
3 0 comprising a fragment of the amino acid sequence of SEQ ID N0:62 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:62, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:62
having
97
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
biological activity, the fragment comprising the amino acid sequence from
amino acid 282
to amino acid 291 of SEQ ID N0:62.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:61.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:61, but excluding the poly(A) tail at the
3' end of SEQ ID N0:61; and
(ab) the nucleotide sequence of the cDNA insert of clone
pg195_1 deposited under accession number ATCC 98918;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
2 0 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:61, but excluding the poly(A) tail at the
2 5 3' end of SEQ ID N0:61; and
(bb) the nucleotide sequence of the cDNA insert of clone
pg195_1 deposited under accession number ATCC 98918;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
3 0 (iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:61, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
98
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
ID N0:61 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:61
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:61. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:61 from nucleotide 29 to
nucleotide
1750, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:61 from nucleotide 29 to nucleotide 1750, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:61 from
nucleotide
29 to nucleotide 1750.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:62;
(b) a fragment of the amino acid sequence of SEQ ID N0:62, the
fragment comprising eight contiguous amino acids of SEQ ID N0:62; and
(c) the amino acid sequence encoded by the cDNA insert of clone
pg195_1 deposited under accession number ATCC 98918;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:62. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
2 0 amino acid sequence of SEQ ID N0:62 having biological activity, the
fragment preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:62, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:62 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 282 to amino acid 291 of SEQ ID N0:62.
2 5 In one embodiment, the present invention provides a composition comprising
an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:63;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
3 0 N0:63 from nucleotide 1147 to nucleotide 1440;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:63 from nucleotide 1234 to nucleotide 1440;
99
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone pw460_5 deposited under accession
number ATCC 98918;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone pw460_5 deposited under accession number ATCC 98918;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone pw460_5 deposited under accession number
ATCC 98918;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone pw460 5 deposited under accession number ATCC 98918;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:64;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:64 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:64;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
2 0 (1} a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:63.
2 5 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:63 from nucleotide 1147 to nucleotide 1440; the nucleotide sequence of SEQ
ID N0:63
from nucleotide 1234 to nucleotide 1440; the nucleotide sequence of the full-
length
protein coding sequence of clone pw460_5 deposited under accession number ATCC
98918; or the nucleotide sequence of a mature protein coding sequence of clone
pw460_5
3 0 deposited under accession number ATCC 98918. In other preferred
embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone pw460_5 deposited under accession number ATCC 98918. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:64 having
biological
100
CA 02339047 2001-02-12
- WO 00/09552 PCTNS99/18298
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:64, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:64
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 44
to amino acid 53 of SEQ ID N0:64.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:63.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:63, but excluding the poly(A} tail at the
3' end of SEQ ID N0:63; and
(ab) the nucleotide sequence of the cDNA insert of clone
pw460_5 deposited under accession number ATCC 98918;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
2 0 (iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
2 5 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:63, but excluding the poly(A) tail at the
3' end of SEQ ID N0:63; and
(bb) the nucleotide sequence of the cDNA insert of clone
3 0 pw460_5 deposited under accession number ATCC 98918;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step {b)(iii).
101
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:63, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:63 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:63
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:63. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:63 from nucleotide 1147 to
nucleotide
1440, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:63 from nucleotide 1147 to nucleotide 1440, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:63 from
nucleotide
1147 to nucleotide 1440. Also preferably the polynucleotide isolated according
to the
above process comprises a nucleotide sequence corresponding to the cDNA
sequence of
SEQ ID N0:63 from nucleotide 1234 to nucleotide 1440, and extending
contiguously from
a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:63 from
nucleotide 1234 to nucleotide 1440, to a nucleotide sequence corresponding to
the 3' end
of said sequence of SEQ ID N0:63 from nucleotide 1234 to nucleotide 1440.
1n other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
2 0 (a) the amino acid sequence of SEQ ID N0:64;
(b) a fragment of the amino acid sequence of SEQ ID N0:64, the
fragment comprising eight contiguous amino acids of SEQ ID N0:64; and
(c) the amino acid sequence encoded by the cDNA insert of clone
pw460 5 deposited under accession number ATCC 98918;
2 5 the protein being substantially free from other mammalian proteins.
Preferably such
protein comprises the amino acid sequence of SEQ ID N0:64. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino and sequence of SEQ ID N0:64 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
3 0 of SEQ ID N0:64, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:64 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 44 to amino acid 53 of SEQ ID N0:64.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
102
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:65;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:65 from nucleotide 46 to nucleotide 1356;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:65 from nucleotide 127 to nucleotide 1356;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone qa136_1 deposited under accession
number ATCC 98918;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone qa136_1 deposited under accession number ATCC 98918;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone qa136_1 deposited under accession number
ATCC 98918;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone qa136_1 deposited under accession number ATCC 98918;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:66;
(i) a polynucleotide encoding a protein comprising a fragment of the
2 0 amino acid sequence of SEQ ID N0:66 having biological activity, the
fragment
comprising eight contiguous amino acids of SEQ ID N0:66;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
2 5 of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
3 0 25% of the length of SEQ ID N0:65.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:65 from nucleotide 46 to nucleotide 1356; the nucleotide sequence of SEQ ID
N0:65
from nucleotide 127 to nucleotide 1356; the nucleotide sequence of the full-
length protein
coding sequence of clone qa136_1 deposited under accession number ATCC 98918;
or the
103
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
nucleotide sequence of a mature protein coding sequence of clone qa136_1
deposited
under accession number ATCC 98918. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone qa136_1 deposited under accession number AT CC 98918. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:66 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:66, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:66
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 213
to amino acid 222 of SEQ ID N0:66.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:65.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
2 0 (aa) SEQ ID N0:65; and
(ab) the nucleotide sequence of the cDNA insert of clone
qa136_1 deposited under accession number ATCC 98918;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
2 5 (iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
3 0 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:65; and
(bb) the nucleotide sequence of the cDNA insert of clone
qa136_1 deposited under accession number ATCC 98918;
104
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:65, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:65 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:65
. Also
preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:65 from
nucleotide 46 to nucleotide 1356, and extending contiguously from a nucleotide
sequence
corresponding to the 5' end of said sequence of SEQ ID N0:65 from nucleotide
46 to
nucleotide 1356, to a nucleotide sequence corresponding to the 3' end of said
sequence of
SEQ ID N0:65 from nucleotide 46 to nucleotide 1356. Also preferably the
polynucleotide
isolated according to the above process comprises a nucleotide sequence
corresponding
to the cDNA sequence of SEQ ID N0:65 from nucleotide 127 to nucleotide 1356,
and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of said
sequence of SEQ ID N0:65 from nucleotide 127 to nucleotide 1356, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:65 from
nucleotide
2 0 127 to nucleotide 1356.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino and sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:66;
2 5 (b) a fragment of the amino acid sequence of SEQ ID N0:66, the
fragment comprising eight contiguous amino acids of SEQ ID N0:66; and
(c) the amino acid sequence encoded by the cDNA insert of clone
qa136_1 deposited under accession number ATCC 98918;
the protein being substantially free from other mammalian proteins. Preferably
such
3 0 protein comprises the amino acid sequence of SEQ ID N0:66. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:66 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino ands
of SEQ ID N0:66, or a protein comprising a fragment of the amino acid sequence
of SEQ
105
CA 02339047 2001-02-12
WO 00/09552 PCT1US99/18298
ID N0:66 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 213 to amino acid 222 of SEQ ID N0:66.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:67;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:67 from nucleotide 206 to nucleotide 1624;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:67 from nucleotide 542 to nucleotide 1624;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone qy1261 2 deposited under accession
number ATCC 98918;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone qy1261 2 deposited under accession number ATCC 98918;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone qy1261 2 deposited under accession number
ATCC 98918;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
2 0 insert of clone qy1261 2 deposited under accession number ATCC 98918;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:68;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:68 having biological activity, the fragment
2 5 comprising eight contiguous amino acids of SEQ ID N0:68;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k} a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
3 0 (1} a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a}-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:67.
106
CA 02339047 2001-02-12
WO 00/09552 PC1'/US99/18298
Preferably, such poiynucleotide comprises the nucleotide sequence of SEQ ID
NCr67 from nucleotide 206 to nucleotide 1624; the nucleotide sequence of SEQ
ID N0:67
from nucleotide 542 to nucleotide 1624; the nucleotide sequence of the full-
length protein
coding sequence of clone qy1261 2 deposited under accession number ATCC 98918;
or
the nucleotide sequence of a mature protein coding sequence of clone qy1261 2
deposited
under accession number ATCC 98918. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone qy1261_2 deposited under accession number ATCC 98918. In further
preferred
embodiments, the present invention provides a poiynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:68 having
biological
activity, the fragment preferably comprising eight {more preferably twenty,
most
preferably thirty) contiguous amino ands of SEQ ID NO:68, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:68
having
biological activity, the fragment comprising the amino acid sequence from
amino and 231
to amino acid 240 of SEQ ID N0:68.
C?ther embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:67.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
2 0 (a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:67, but excluding the poly(A) tail at the
2 5 3' end of SEQ ID N0:67; and
(ab) the nucleotide sequence of the cDNA insert of clone
qy1261 2 deposited under accession number ATCC 98918;
(ii) hybridizing said probes} to human genomic DNA in
conditions at least as stringent as 4X SSC: at 50 degrees C; and
3 0 (iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
107
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:67, bu.t excluding the poly(A) tail at the
3' end of SEQ ID N0:67; and
(bb) the nucleotide sequence of the cDNA insert of clone
qy1261_2 deposited under accession number ATCC 98918;
(ii) hybridizing said primer{s) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:67, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:67 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:67
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:67. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:67 from nucleotide 206 to
nucleotide
1624, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
2 0 of said sequence of SEQ ID N0:67 from nucleotide 206 to nucleotide 1624,
to a nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:67 from
nucleotide
206 to nucleotide 1624. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:67 from nucleotide 542 to nucleotide 1624, and extending contiguously from
a
2 5 nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:67 from
nucleotide 542 to nucleotide 1624, to a nucleotide sequence corresponding to
the 3' end
of said sequence of SEQ ID N0:67 from nucleotide 542 to nucleotide 1624.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
3 0 consisting of:
(a) the amino acid sequence of SEQ ID N0:68;
(b) a fragment of the amino acid sequence of SEQ ID N0:68, the
fragment comprising eight contiguous amino acids of SEQ ID N0:68; and
108
CA 02339047 2001-02-12
WO 00/09552 PCT/LJS99/18298
(c) the amino acid sequence encoded by the cDNA insert of clone
qy1261 2 deposited under accession number ATCC 98918;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:68. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:68 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:68, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:68 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 231 to amino acid 240 of SEQ ID N0:68.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynudeotide comprising the nucleotide sequence of SEQ ID
N0:69;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:69 from nucleotide 1359 to nucleotide 1817;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone rd432 4 deposited under accession
number ATCC 98918;
2 0 (d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone rd432 4 deposited under accession number ATCC 98918;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone rd432_4 deposited under accession number
ATCC 98918;
2 5 (f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone rd432 4 deposited under accession number ATCC 98918;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:70;
(h) a polynucleotide encoding a protein comprising a fragment of the
3 0 amino acid sequence of SEQ ID N0:70 having biological activity, the
fragment
comprising eight contiguous amino acids of SEQ ID N0:70;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
109
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
25% of the length of SEQ ID N0:69.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:69 from nucleotide 1359 to nucleotide 1817; the nucleotide sequence of the
full-length
protein coding sequence of clone rd432 4 deposited under accession number ATCC
98918;
or the nucleotide sequence of a mature protein coding sequence of clone rd432
4
deposited under accession number ATCC 98918. In other preferred embodiments,
the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone rd432_4 deposited under accession number A TCC 98918. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:70 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably tlvrty) contiguous amino acids of SEQ ID N0:70, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:70
having
2 0 biological activity, the fragment comprising the amino acid sequence from
amino acid 71
to amino acid 80 of SEQ ID N0:70.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:69.
Further embodiments of the invention provide isolated polynucleotides produced
2 5 according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
3 0 (aa) SEQ ID N0:69, but excluding the poly(A) tail at the
3' end of SEQ ID N0:69; and
(ab) the nucleotide sequence of the cDNA insert of clone
rd432 4 deposited under accession number ATCC 98918;
110
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:69, but excluding the poly(A) tail at the
3' end of SEQ ID NO:69; and
(bb) the nucleotide sequence of the cDNA insert of clone
rd432 4 deposited under accession number ATCC 98918;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:69, and
2 0 extending contiguously from a nucleotide sequence corresponding to the 5'
end of SEQ
ID N0:69 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:69
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:69. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:69 from nucleotide 1359 to
nucleotide
2 5 1817, and extending contiguously from a nucleotide sequence corresponding
to the 5' end
of said sequence of SEQ ID N0:69 from nucleotide 1359 to nucleotide 1817, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:69 from
nucleotide
1359 to nucleotide 1817.
In other embodiments, the present invention provides a composition comprising
3 0 a protein, wherein said protein comprises an amino acid sequence selected
from the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:70;
(b} a fragment of the amino acid sequence of SEQ ID N0:70, the
fragment comprising eight contiguous amino acids of SEQ ID N0:70; and
111
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(c) the amino acid sequence encoded by the cDNA insert of clone
rd432_4 deposited under accession number ATCC 98918;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:70. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino and sequence of SEQ ID N0:70 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:70, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:70 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 71 to amino acid 80 of SEQ ID N0:70.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:71;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:71 from nucleotide 884 to nucleotide 1195;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:71 from nucleotide 947 to nucleotide 1195;
(d) a polynucleotide comprising the nucleotide sequence of the full-
2 0 length protein coding sequence of clone rb789_14 deposited under accession
number ATCC 207004;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone rb789_14 deposited under accession number ATCC 207004;
(f) a polynucleotide comprising the nucleotide sequence of a mature
2 5 protein coding sequence of clone rb789_14 deposited under accession number
ATCC 207004;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone rb789_14 deposited under accession number ATCC 207004;
(h) a polynucleotide encoding a protein comprising the amino acid
3 0 sequence of SEQ ID N0:72;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:72 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:72;
112
CA 02339047 2001-02-12
WO 00/09552 PCTNS99/18298
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a}-(i}; and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:71.
Preferably, such polynudeotide .comprises the nucleotide sequence of SEQ ID
N0:71 from nucleotide 884 to nucleotide 1195; the nucleotide sequence of SEQ
ID N0:71
from nucleotide 947 to nucleotide 1195; the nucleotide sequence of the full-
length protein
coding sequence of clone rb789_14 deposited under accession number ATCC
207004; or
the nucleotide sequence of a mature protein coding sequence of clone rb789_14
deposited
under accession number ATCC 207004. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone rb789_14 deposited under accession number ATCC 207004. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:72 having
biological
2 0 activity, the fragment preferably comprising eight (more preferably
twenty, most
preferably thirty) contiguous amino acids of SEQ ID N0:72, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:72
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 47
to amino acid 56 of SEQ ID N0:72.
2 5 Other embodiments provide the gene corresponding to the cDNA sequence of
SEQ
ID N0:71.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
3 0 (i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:71, but excluding the poly(A) tail at the
3' end of SEQ ID N0:71; and
113
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(ab) the nucleotide sequence of the cDNA insert of clone
rb789_14 deposited under accession number ATCC 207004;
(ii) hybridizing said probes} to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:71, but excluding the poly(A) tail at the
3' end of SEQ ID N0:71; and
(bb) the nucleotide sequence of the cDNA insert of clone
rb789_14 deposited under accession number ATCC 207004;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
2 0 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:71, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:71 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:71
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:71. Also preferably the
2 5 polynucleotide isolated according to the above process comprises a
nucleotide sequence
corresponding to the cDNA sequence of SEQ ID N0:71 from nucleotide 884 to
nucleotide
1195, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:71 from nucleotide 884 to nucleotide 1195, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:71 from
nucleotide
3 0 884 to nucleotide 1195. Also preferably the polynucleotide isolated
according to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:71 from nucleotide 947 to nucleotide 1195, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:71 from
114
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
nucleotide 947 to nucleotide 1195, to a nucleotide sequence corresponding to
the 3' end
of said sequence of SEQ ID N0:71 from nucleotide 947 to nucleotide 1195.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:72;
(b) a fragment of the amino acid sequence of SEQ ID N0:72, the
fragment comprising eight contiguous amino acids of SEQ ID N0:72; and
(c) the amino acid sequence encoded by the cDNA insert of clone
rb789_14 deposited under accession number ATCC 207004;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:72. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:72 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:72, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:72 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 47 to amino acid 56 of SEQ ID N0:72.
In one embodiment, the present invention provides a composition comprising an
2 0 isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:73;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:73 from nucleotide 69 to nucleotide 374;
2 5 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:73 from nucleotide 186 to nucleotide 374;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yd137_1 deposited under accession
number ATCC 207004;
3 0 (e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yd137_1 deposited under accession number ATCC 207004;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yd137_1 deposited under accession number
ATCC 207004;
115
CA 02339047 2001-02-12
WO 00/09552 PCTNS99/18298
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yd137_1 deposited under accession number ATCC 207004;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:74;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:74 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:74;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
{k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1} a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(i) and that has a length that is
at least
25% of the length of SEQ ID N0:73.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:73 from nucleotide 69 to nucleotide 374; the nucleotide sequence of SEQ ID
N0:73
from nucleotide 186 to nucleotide 374; the nucleotide sequence of the full-
length protein
2 0 coding sequence of clone yd137_1 deposited under accession number ATCC
207004; or
the nucleotide sequence of a mature protein coding sequence of clone yd137_1
deposited
under accession number ATCC 207004. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone yd137_1 deposited under accession number ATCC 207004. In further
preferred
2 5 embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:74 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:74, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:74
having
3 0 biological activity, the fragment comprising the amino acid sequence from
amino acid 46
to amino acid 55 of SEQ ID N0:74.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:73.
116
CA 02339047 2001-02-12
WO 00/09552 PCTlUS99/18298
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:73, but excluding the poly(A) tail at the
3' end of SEQ ID N0:73; and
(ab) the nucleotide sequence of the cDNA insert of clone
yd137_1 deposited under accession number ATCC 207004;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
2 0 (ba) SEQ ID N0:73, but excluding the poly(A) tail at the
3' end of SEQ ID N0:73; and
(bb) the nucleotide sequence of the cDNA insert of clone
yd137_1 deposited under accession number ATCC 207004;
(ii) hybridizing said primers) to human genomic DNA in
2 5 conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:73, and
3 0 extending contiguously from a nucleotide sequence corresponding to the 5'
end of SEQ
ID N0:73 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:73
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:73. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:73 from nucleotide 69 to
nucleotide
117
CA 02339047 2001-02-12
WO 00/09552 PC'T/US99/18298
374, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:73 from nucleotide 69 to nucleotide 374, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:73 from
nucleotide
69 to nucleotide 374. Also preferably the polynucleotide isolated according to
the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:73 from nucleotide 186 to nucleotide 374, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:73 from
nucleotide 186 to nucleotide 374, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:73 from nucleotide 186 to nucleotide 374.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:74;
(b) a fragment of the amino acid sequence of SEQ ID N0:74, the
fragment comprising eight contiguous amino acids of SEQ ID N0:74; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yd137_1 deposited under accession number ATCC 207004;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:74. In further
preferred
2 0 embodiments, the present invention provides a protein comprising a
fragment of the
amino acid sequence of SEQ ID N0:74 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:74, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:74 having biological activity, the fragment comprising the amino acid
sequence
2 5 from amino acid 46 to amino acid 55 of SEQ ID N0:74.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:75;
3 0 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:75 from nucleotide 8 to nucleotide 343;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:75 from nucleotide 50 to nucleotide 343;
118
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yd218_1 deposited under accession
number ATCC 207004;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yd218_1 deposited under accession number ATCC 207004;
(f} a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yd218_1 deposited under accession number
ATCC 207004;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yd218_1 deposited under accession number ATCC 207004;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:76;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:76 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:76;
(j} a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
2 0 (1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:75.
2 5 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:75 from nucleotide 8 to nucleotide 343; the nucleotide sequence of SEQ ID
N0:75 from
nucleotide 50 to nucleotide 343; the nucleotide sequence of the full-length
protein coding
sequence of clone yd218_1 deposited under accession number ATCC 207004; or the
nucleotide sequence of a mature protein coding sequence of clone yd218_1
deposited
3 0 under accession number ATCC 207004. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone yd218_1 deposited under accession number ATCC 207004. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:76 having
biological
119
CA 02339047 2001-02-12
WO 00/09552 PG"T/US99/18298
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:76, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:76
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 51
to amino acid 60 of SEQ ID N0:76.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:75.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:75, but excluding the poly(A) tail at the
3' end of SEQ ID N0:75; and
(ab) the nucleotide sequence of the cDNA insert of clone
yd218_1 deposited under accession number ATCC 207004;
(ii} hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
2 0 (iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b} a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
2 5 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:75, but excluding the poly(A) tail at the
3' end of SEQ ID N0:75; and
(bb) the nucleotide sequence of the cDNA insert of clone
3 0 yd218_1 deposited under accession number ATCC 207004;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
120
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
Preferably the polynucleodde isolated according to the above process comprises
a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:75, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:75 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:75
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:75. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:75 from nucleotide 8 to
nucleotide
343, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:75 from nucleotide 8 to nucleotide 343, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:75 from
nucleotide
8 to nucleotide 343. Also preferably the polynucleotide isolated according to
the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:75 from nucleotide 50 to nucleotide 343, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:75 from
nucleotide 50 to nucleotide 343, to a nucleotide sequence corresponding to the
3' end of
said sequence of SEQ ID N0:75 from nucleotide 50 to nucleotide 343.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
2 0 (a) the amino acid sequence of SEQ ID N0:76;
(b) a fragment of the amino acid sequence of SEQ ID N0:76, the
fragment comprising eight contiguous amino acids of SEQ ID N0:76; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yd218_1 deposited under accession number A'TCC 207004;
2 5 the protein being substantially free from other mammalian proteins.
Preferably such
protein comprises the amino acid sequence of SEQ ID N0:76. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino aad sequence of SEQ ID N0:76 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino ands
3 0 of SEQ ID N0:76, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:76 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 51 to amino acid 60 of SEQ ID N0:76.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
121
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:77;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:77 from nucleotide 84 to nucleotide 1679;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yel l_1 deposited under accession
number
ATCC 207004;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yell 1 deposited under accession number ATCC 207004;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yel l 1 deposited under accession number ATCC
207004;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yell 1 deposited under accession number ATCC 207004;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:78;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:78 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:78;
2 0 (i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
2 5 one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
25% of the length of SEQ ID N0:77.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
3 0 N0:77 from nucleotide 84 to nucleotide 1679; the nucleotide sequence of
the full-length
protein coding sequence of clone yell 1 deposited under accession number ATCC
207004; or the nucleotide sequence of a mature protein coding sequence of
clone yell_1
deposited under accession number ATCC 207004. In other preferred embodiments,
the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
122
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
of clone yell 1 deposited under accession number ATCC 207004. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:78 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:78, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:78
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 261
to amino acid 270 of SEQ ID N0:78.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:77.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:77, but excluding the poly(A) tail at the
3' end of SEQ ID N0:77; and
(ab) the nucleotide sequence of the cDNA insert of clone
2 0 yel l 1 deposited under accession number ATCC 207004;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
2 5 and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
3 0 (ba) SEQ ID N0:77, but excluding the poly(A) tail at the
3' end of SEQ ID N0:77; and
(bb) the nucleotide sequence of the cDNA insert of clone
yell 1 deposited under accession number ATCC 207004;
123
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:77, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:77 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:77
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:77. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:77 from nucleotide 84 to
nucleotide
1679, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:77 from nucleotide 84 to nucleotide 1679, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:77 from
nucleotide
84 to nucleotide 1679.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:78;
2 0 (b) a fragment of the amino acid sequence of SEQ ID N0:78, the
fragment comprising eight contiguous amino acids of SEQ ID N0:78; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yell_1 deposited under accession number ATCC 207004;
the protein being substantially free from other mammalian proteins. Preferably
such
2 5 protein comprises the amino acid sequence of SEQ ID N0:78. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:78 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:78, or a protein comprising a fragment of the amino acid sequence
of SEQ
3 0 ID N0:78 having biological activity, the fragment comprising the amino
acid sequence
from amino acid 261 to amino acid 270 of SEQ ID N0:78.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
124
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:79;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:79 from nucleotide 72 to nucleotide 1646;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:79 from nucleotide 180 to nucleotide 1646;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone ye72_1 deposited under accession
number
ATCC 207004;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone ye72_1 deposited under accession number ATCC 207004;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone ye72_1 deposited under accession number ATCC
207004;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone ye72_1 depasited under accession number ATCC 207004;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:80;
(i) a polynucleotide encoding a protein comprising a fragment of the
2 0 amino acid sequence of SEQ ID N0:80 having biological activity, the
fragment
comprising eight contiguous amino acids of SEQ ID NO:80;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
2 5 of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
3 0 25% of the length of SEQ ID N0:79.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:79 from nucleotide 72 to nucleotide 1646; the nucleotide sequence of SEQ ID
N0:79
from nucleotide 180 to nucleotide 1646; the nucleotide sequence of the full-
length protein
coding sequence of clone ye72_1 deposited under accession number ATCC 207004;
or the
125
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
nucleotide sequence of a mature protein coding sequence of clone ye72_1
deposited under
accession number ATCC 207004. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone ye72_1
deposited under accession number ATCC 207004. In further preferred
embodiments, the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:80 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:80, or a polynucleotide encoding a protein comprising
a
fragment of the amino acid sequence of SEQ ID N0:80 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 257 to amino acid
266 of
SEQ ID N0:80.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:79.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
2 0 (aa) SEQ ID N0:79, but excluding the poly(A} tail at the
3' end of SEQ ID N0:79; and
(ab) the nucleotide sequence of the cDNA insert of clone
ye72_1 deposited under accession number ATCC 207004;
(ii) hybridizing said probes) to human genomic DNA in
2 5 conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
3 0 (i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:79, but excluding the poly(A) tail at the
3' end of SEQ ID N0:79; and
126
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(bb) the nucleotide sequence of the cDNA insert of clone
ye72_1 deposited under accession number ATCC 207004;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:79, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:79 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:79
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:79. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:79 from nucleotide 72 to
nucleotide
1646, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:79 from nucleotide 72 to nucleotide 1646, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:79 from
nucleotide
72 to nucleotide 1646. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:79 from nucleotide 180 to nucleotide 1646, and extending contiguously from
a
2 0 nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:79 from
nucleotide 180 to nucleotide 1646, to a nucleotide sequence corresponding to
the 3' end
of said sequence of SEQ ID N0:79 from nucleotide 180 to nucleotide 1646.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino and sequence selected from
the group
2 5 consisting of:
(a) the amino acid sequence of SEQ ID N0:80;
(b) a fragment of the amino acid sequence of SEQ ID N0:80, the
fragment comprising eight contiguous amino acids of SEQ ID N0:80; and
(c) the amino acid sequence encoded by the cDNA insert of clone
3 0 ye72_1 deposited under accession number ATCC 207004;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:80. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:80 having biological activity, the fragment
preferably
127
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:80, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:80 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 257 to amino acid 266 of SEQ ID N0:80.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:81;
(b} a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:81 from nucleotide 954 to nucleotide 2423;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:81 from nucleotide 1224 to nucleotide 2423;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone ye78_1 deposited under accession
number
ATCC 207004;
(e) a polynucleatide encoding the full-length protein encoded by the
cDNA insert of clone ye78_1 deposited under accession number ATCC 207004;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone ye78_1 deposited under accession number ATCC
2 0 207004;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone ye78_1 deposited under accession number ATCC 207004;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:82;
2 5 (i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:82 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:82;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
3 0 (k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
128
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:81.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:81 from nucleotide 954 to nucleotide 2423; the nucleotide sequence of SEQ
ID N0:81
from nucleotide 1224 to nucleotide 2423; the nucleotide sequence of the full-
length
protein coding sequence of clone ye78_1 deposited under accession number ATCC
207004; or the nucleotide sequence of a mature protein coding sequence of
clone ye78_1
deposited under accession number ATCC 207004. In other preferred embodiments,
the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone ye78_1 deposited under accession number ATCC 207004. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:82 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino ands of SEQ ID N0:82, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:82
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 240
to amino acid 249 of SEQ ID N0:82.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID N0:81.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
2 5 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:81, but excluding the poly(A) tail at the
3' end of SEQ ID N0:81; and
(ab) the nucleotide sequence of the cDNA insert of clone
3 0 ye78_1 deposited under accession number ATCC 207004;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
129
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:81, but excluding the poly(A) tail at the
3' end of SEQ ID N0:81; and
(bb) the nucleotide sequence of the cDNA insert of clone
ye78_1 deposited under accession number ATCC 207004;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:81, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:81 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:81
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:81. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
2 0 corresponding to the cDNA sequence of SEQ ID N0:81 from nucleotide 954 to
nucleotide
2423, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:81 from nucleotide 954 to nucleotide 2423, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:81 from
nucleotide
954 to nucleotide 2423. Also preferably the polynucleotide isolated according
to the above
2 5 process comprises a nucleotide sequence corresponding to the cDNA sequence
of SEQ ID
N0:81 from nucleotide 1224 to nucleotide 2423, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:81 from
nucleotide 1224 to nucleotide 2423, to a nucleotide sequence corresponding to
the 3' end
of said sequence of SEQ ID N0:81 from nucleotide 1224 to nucleotide 2423.
3 0 In other embodiments, the present invention provides a composition
comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:82;
130
CA 02339047 2001-02-12
WO 00/09552 PCTNS99/18298
(b) a fragment of the amino acid sequence of SEQ ID N0:82, the
fragment comprising eight contiguous amino acids of SEQ ID N0:82; and
(c) the amino acid sequence encoded by the cDNA insert of clone
ye78_1 deposited under accession number ATCC 207004;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:82. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:82 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:82, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:82 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 240 to amino acid 249 of SEQ ID N0:82.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ iD
N0:83;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:83 from nucleotide 176 to nucleotide 1321;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
2 0 N0:83 from nucleotide 233 to nucleotide 1321;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone ye90_1 deposited under accession
number
ATCC 207004;
(e) a polynucleotide encoding the full-length protein encoded by the
2 5 cDNA insert of clone ye90_1 deposited under accession number ATCC 207004;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone ye90 1 deposited under accession number ATCC
207004;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
3 0 insert of clone ye90_1 deposited under accession number ATCC 207004;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:84;
131
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:84 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:84;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a}-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:83.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:83 from nucleotide 176 to nucleotide 1321; the nucleotide sequence of SEQ
ID N0:83
from nucleotide 233 to nucleotide 1321; the nucleotide sequence of the full-
length protein
coding sequence of clone ye90_1 deposited under accession number ATCC 207004;
or the
nucleotide sequence of a mature protein coding sequence of clone ye90_1
deposited under
accession number ATCC 207004. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone ye90_1
2 0 deposited under accession number ATCC 207004. In further preferred
embodiments, the
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:84 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:84, or a polynucleotide encoding a protein comprising
a
2 5 fragment of the amino acid sequence of SEQ ID N0:84 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 186 to amino acid
195 of
SEQ ID N0:84.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:83.
3 0 Further embodiments of the invention provide isolated polynucleotides
produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
132
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:83, but excluding the poly(A) tail at the
3' end of SEQ ID N0:83; and
(ab) the nucleotide sequence of the cDNA insert of clone
ye90_1 deposited under accession number ATCC 207004;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating .the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or mare polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:83, but excluding the poly(A) tail at the
3' end of SEQ ID N0:83; and
(bb) the nucleotide sequence of the cDNA insert of clone
2 0 ye90_1 deposited under accession number ATCC 207004;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
2 5 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:83, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:83 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:83
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:83. Also preferably the
3 0 polynucleotide isolated according to the above process comprises a
nucleotide sequence
corresponding to the cDNA sequence of SEQ ID N0:83 from nucleotide 176 to
nucleotide
1321, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:83 from nucleotide 176 to nucleotide 1321, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:83 from
nucleotide
133
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
176 to nucleotide 1321. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:83 from nucleotide 233 to nucleotide 1321, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:83 from
nucleotide 233 to nucleotide 1321, to a nucleotide sequence corresponding to
the 3' end
of said sequence of SEQ ID N0:83 from nucleotide 233 to nucleotide 1321.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:84;
(b) a fragment of the amino acid sequence of SEQ ID N0:84, the
fragment comprising eight contiguous amino acids of SEQ ID N0:84; and
(c) the amino acid sequence encoded by the cDNA insert of clone
ye90_1 deposited under accession number ATCC 207004;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:84. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:84 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
2 0 of SEQ ID N0:84, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:84 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 186 to amino acid 195 of SEQ ID N0:84.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
2 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:85;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:85 from nucleotide 105 to nucleotide 605;
(c) a polynucleotide comprising the nucleotide sequence of the full-
3 0 length protein coding sequence of clone yi62_1 deposited under accession
number
ATCC 207004;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yi62_1 deposited under accession number ATCC 207004;
134
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yi62_1 deposited under accession number ATCC
207004;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yi62_1 deposited under accession number ATCC 207004;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:86;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:86 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:86;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
25% of the length of SEQ ID N0:85.
2 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:85 from nucleotide 105 to nucleotide 605; the nucleotide sequence of the
full-length
protein coding sequence of clone yi62_1 deposited under accession number ATCC
207004;
or the nucleotide sequence of a mature protein coding sequence of clone yi62_1
deposited
under accession number ATCC 207004. In other preferred embodiments, the
2 5 polynucleotide encodes the full-length or a mature protein encoded by the
cDNA insert
of clone yi62_1 deposited under accession number ATCC 207004. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:86 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
3 0 preferably thirty) contiguous amino acids of SEQ ID N0:86, or a
polynucleotide encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:86
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 78
to amino acid 87 of SEQ ID N0:86.
135
CA 02339047 2001-02-12
WO 00/09552 PCTNS99/18298
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:85.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:85, but excluding the poly(A) tail at the
3' end of SEQ ID N0:85; and
(ab) the nucleotide sequence of the cDNA insert of clone
yi62_1 deposited under accession number ATCC 207004;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
2 0 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:85, but excluding the poly(A) tail at the
3' end of SEQ ID N0:85; and
(bb) the nucleotide sequence of the cDNA insert of clone
2 5 yi62_1 deposited under accession number ATCC 207004;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii} amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
3 0 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:85, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:85 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:85
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:85. Also preferably the
136
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:85 from nucleotide 105 to
nucleotide
605, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:85 from nucleotide 105 to nucleotide 605, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:85 from
nucleotide
105 to nucleotide 605.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:86;
(b) a fragment of the amino acid sequence of SEQ ID N0:86, the
fragment comprising eight contiguous amino acids of SEQ ID N0:86; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yi62_1 deposited under accession number ATCC 207004;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:86. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:86 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
2 0 of SEQ ID N0:86, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:86 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 78 to amino acid 87 of SEQ ID N0:86.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
2 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:87;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:87 from nucleotide 223 to nucleotide 798;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
3 0 N0:87 from nucleotide 430 to nucleotide 798;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yk78_1 deposited under accession
number
ATCC 207004;
137
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yk78_1 deposited under accession number ATCC 207004;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yk78_1 deposited under accession number ATCC
207004;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yk78_1 deposited under accession number ATCC 207004;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:88;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:88 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:88;
(j) a polynucleatide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
2 0 one of the polynucleotides specified in (a)-(i) and that has a length that
is at least
25% of the length of SEQ ID N0:87.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:87 from nucleotide 223 to nucleotide 798; the nucleotide sequence of SEQ ID
N0:87
from nucleotide 430 to nucleotide 798; the nucleotide sequence of the full-
length protein
2 5 coding sequence of clone yk78_1 deposited under accession number ATCC
207004; or the
nucleotide sequence of a mature protein coding sequence of clone yk78_1
deposited under
accession number ATCC 207004. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone yk78_1
deposited under accession number ATCC 207004. In further preferred
embodiments, the
3 0 present invention provides a polynucleotide encoding a protein comprising
a fragment
of the amino acid sequence of SEQ ID N0:88 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:88, or a polynucleotide encoding a protein comprising
a
fragment of the amino acid sequence of SEQ ID N0:88 having biological
activity, the
138
CA 02339047 2001-02-12
WO 00/09552 PCTNS99/18298
fragment comprising the amino acid sequence from amino acid 91 to amino acid
100 of
SEQ ID N0:88.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:87.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:87, but excluding the poly(A) tail at the
3' end of SEQ ID N0:87; and
(ab) the nucleotide sequence of the cDNA insert of clone
yk78_1 deposited under accession number ATCC 207004;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
2 0 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba} SEQ ID N0:87, but excluding the poly(A) tail at the
2 5 3' end of SEQ ID N0:87; and
(bb) the nucleotide sequence of the cDNA insert of clone
yk78_1 deposited under accession number ATCC 207004;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
3 0 (iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:87, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
139
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
ID N0:87 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:87
, but
excluding the poly(A} tail at the 3' end of SEQ ID N0:87. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:87 from nucleoside 223 to
nucleotide
798, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:87 from nucleotide 223 to nucleotide 798, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:87 from
nucleotide
223 to nucleotide 798. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:87 from nucleotide 430 to nucleotide 798, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:87 from
nucleotide 430 to nucleotide 798, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:87 from nucleotide 430 to nucleotide 798.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:88;
(b) a fragment of the amino acid sequence of SEQ ID N0:88, the
fragment comprising eight contiguous amino acids of SEQ ID N0:88; and
2 0 (c) the amino acid sequence encoded by the cDNA insert of clone
yk78_1 deposited under accession number ATCC 207004;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:88. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
2 5 amino acid sequence of SEQ ID N0:88 having biological activity, the
fragment preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:88, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:88 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 91 to amino acid 100 of SEQ ID N0:88.
3 0 In one embodiment, the present invention provides a composition comprising
an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:89;
140
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:89 from nucleotide 211 to nucleotide 942;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:89 from nucleotide 298 to nucleotide 942;
(d} a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone yk251 1 deposited under accession
number ATCC 207004;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone yk251_1 deposited under accession number ATCC 207004;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone yk251 1 deposited under accession number
ATCC 207004;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yk251 1 deposited under accession number ATCC 207004;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:90;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:90 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:90;
2 0 (j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of {h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
2 5 one of the polynucleotides specified in (a)-(i); and
{m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:89.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
3 0 N0:89 from nucleotide 211 to nucleotide 942; the nucleotide sequence of
SEQ ID N0:89
from nucleotide 298 to nucleotide 942; the nucleotide sequence of the full-
length protein
coding sequence of clone yk251 1 deposited under accession number ATCC 207004;
or
the nucleotide sequence of a mature protein coding sequence of clone yk251 1
deposited
under accession number ATCC 207004. In other preferred embodiments, the
141
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone y1c251 1 deposited under accession number ATCC 207004. In further
»rPfP,~,~P~
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:90 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID NO:90, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:90
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 117
to amino acid 126 of SEQ ID N0:90.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:89.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:89, but excluding the poly(A) tail at the
3' end of SEQ ID N0:89; and
2 0 (ab) the nucleotide sequence of the cDNA insert of clone
yk251 1 deposited under accession number ATCC 207004;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
2 5 probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
3 0 the group consisting of:
(ba) SEQ ID N0:89, but excluding the poly(A) taff at the
3' end of SEQ ID N0:89; and
(bb) the nucleotide sequence of the cDNA insert of clone
yk251 1 deposited under accession number ATCC 207004;
142
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:89, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:89 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:89
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:89. Also preferably the
polynucleotide isolated according to the. above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:89 from nucleotide 211 to
nucleotide
942, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:89 from nucleotide 211 to nucleotide 942, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:89 from
nucleotide
211 to nucleotide 942. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:89 from nucleotide 298 to nucleotide 942, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said. sequence of SEQ ID
N0:89 from
nucleotide 298 to nucleotide 942, to a nucleotide sequence corresponding to
the 3' end of
2 0 said sequence of SEQ ID N0:89 from nucleotide 298 to nucleotide 942.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:90;
2 5 (b) a fragment of the amino acid sequence of SEQ ID N0:90, the
fragment comprising eight contiguous amino acids of SEQ ID N0:90; and
(c) the amino acid sequence encoded by the cDNA insert of clone
yk251 1 deposited under accession number ATCC 207004;
the protein being substantially free from other mammalian proteins. Preferably
such
3 0 protein comprises the amino acid sequence of SEQ ID N0:90. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:90 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:90, or a protein comprising a fragment of the amino acid sequence
of SEQ
143
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
ID N0:90 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 117 to amino acid 126 of SEQ ID N0:90.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
S (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:91;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:91 from nucleotide 149 to nucleotide 784;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone ytl4_1 deposited under accession
number
ATCC 207004;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone ytl4_1 deposited under accession number ATCC 207004;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone ytl4_1 deposited under accession number ATCC
207004;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone ytl4_1 deposited under accession number ATCC 207004;
(g) a polynucleotide encoding a protein comprising the amino acid
2 0 sequence of SEQ ID N0:92;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:92 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:92;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
2 5 (a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
3 0 (1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
25% of the length of SEQ ID N0:91.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:91 from nucleotide 149 to nucleotide 784; the nucleotide sequence of the
full-length
144
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
protein coding sequence of clone ytl4_1 deposited under accession number ATCC
207004;
or the nucleotide sequence of a mature protein coding sequence of clone ytl4_1
deposited
under accession number ATCC 207004. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone ytl4_1 deposited under accession number ATCC 207004. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:92 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:92, or a polynucleotide
encoding
a protein comprising a fragment of the, amino acid sequence of SEQ ID N0:92
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 101
to amino acid 110 of SEQ ID N0:92.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:91.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
2 0 consisting of:
(aa) SEQ ID N0:91, but excluding the poly(A) tail at the
3' end of SEQ ID N0:91; and
(ab) the nucleotide sequence of the cDNA insert of clone
ytl4_1 deposited under accession number ATCC 207004;
2 5 (ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
3 0 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
145
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(ba) SEQ ID N0:91, but excluding the poly(A) tail at the
3' end of SEQ ID N0:91; and
(bb) the nucleotide sequence of the cDNA insert of clone
ytl4_1 deposited under accession number ATCC 207004;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii}.
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:91, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:91 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:91
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:91. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:91 from nucleotide 149 to
nucleotide
784, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:91 from nucleotide 149 to nucleotide 784, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:91 from
nucleotide
149 to nucleotide 784.
2 0 In other embodiments, the present invention provides a composition
comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:92;
(b) a fragment of the amino acid sequence of SEQ ID N0:92, the
2 5 fragment comprising eight contiguous amino acids of SEQ ID N0:92; and
(c) the amino acid sequence encoded by the cDNA insert of clone
ytl4_1 deposited under accession number ATCC 207004;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:92. In further
preferred
3 0 embodiments, the present invention provides a protein comprising a
fragment of the
amino acid sequence of SEQ ID N0:92 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:92, or a protein comprising a fragment of the amino acid sequence
of SEQ
146
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
ID N0:92 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 101 to amino acid 110 of SEQ ID N0:92.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:93;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:93 from nucleotide 89 to nucleotide 1441;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone bf157_16 deposited under accession
number ATCC 207088;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone bf157 16 deposited under accession number ATCC 207088;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of done bf157_16 deposited under accession number
ATCC 207088;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone bf157_16 deposited under accession number ATCC 207088;
(g) a polynucleotide encoding a protein comprising the amino acid
2 0 sequence of SEQ ID N0:94;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:94 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:94;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
2 5 (a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
3 0 (1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(h) and that has a length that is
at least
25% of the length of SEQ ID N0:93.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:93 from nucleotide 89 to nucleotide 1441; the nucleotide sequence of the
full-length
147
CA 02339047 2001-02-12
WO 00!09552 PCTNS99/18298
protein coding sequence of clone bf157_16 deposited under accession number
ATCC
207088; or the nucleotide sequence of a mature protein coding sequence of
clone bf157 16
deposited under accession number ATCC 207088. In other preferred embodiments,
the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone bf157_16 deposited under accession number ATCC 207088. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:94 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:94, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:94
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 220
to amino acid 229 of SEQ ID N0:94.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:93.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
2 0 consisting of:
(aa) SEQ ID N0:93, but excluding the poly(A) tail at the
3' end of SEQ ID N0:93; and
(ab) the nucleotide sequence of the cDNA insert of clone
bf157_16 deposited under accession number ATCC 207088;
2 5 (ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
3 0 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
148
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(ba) SEQ ID N0:93, but excluding the poly(A) tail at the
3' end of SEQ ID N0:93; and
(bb) the nucleotide sequence of the cDNA insert of clone
bf157_16 deposited under accession number ATCC 207088;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to. the cDNA sequence of SEQ ID N0:93, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:93 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:93
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:93. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:93 from nucleotide 89 to
nucleotide
1441, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:93 from nucleotide 89 to nucleotide 1441, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:93 from
nucleotide
89 to nucleotide 1441.
2 0 In other embodiments, the present invention provides a composition
comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting af:
(a) the amino acid sequence of SEQ ID N0:94;
(b) a fragment of the amino acid sequence of SEQ ID N0:94, the
2 5 fragment comprising eight contiguous amino acids of SEQ ID N0:94; and
(c) the amino acid sequence encoded by the cDNA insert of clone
bf157_16 deposited under accession number ATCC 207088;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:94. In further
preferred
3 0 embodiments, the present invention provides a protein comprising a
fragment of the
amino acid sequence of SEQ ID N0:94 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:94, or a protein comprising a fragment of the amino acid sequence
of SEQ
149
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
ID N0:94 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 220 to amino acid 229 of SEQ ID N0:94.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:95;
(h) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:95 from nucleotide 219 to nucleotide 629;
(c} a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone bk343_2 deposited under accession
number ATCC 207088;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone bk343_2 deposited under accession number ATCC 207088;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone bk343 2 deposited under accession number
ATCC 207088;
(f} a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone bk343 2 deposited under accession number ATCC 207088;
{g) a polynucleotide encoding a protein comprising the amino acid
2 0 sequence of SEQ ID N0:96;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:96 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:96;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
2 5 (a)-{f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
3 0 (1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
25% of the length of SEQ ID N0:95.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:95 from nucleotide 2I9 to nucleotide 629; the nucleotide sequence of the
full-length
150
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
protein coding sequence of clone bk343_2 deposited under accession number ATCC
207088; or the nucleotide sequence of a mature protein coding sequence of
clone bk343 2
deposited under accession number ATCC 207088. In other preferred embodiments,
the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone bk343_2 deposited under accession number AT'CC 207088. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:96 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:96, or a polynucleotide
encoding
a protein comprising a fragment of the.amino acid sequence of SEQ ID N0:96
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 63
to amino acid 72 of SEQ ID N0:96.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:95.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
2 0 consisting of:
(aa) SEQ ID N0:95, but excluding the poly(A) tail at the
3' end of SEQ ID N0:95; and
(ab) the nucleotide sequence of the cDNA insert of clone
bk343 2 deposited under accession number ATCC 207088;
2 5 (ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
3 0 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
151
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(ba) SEQ ID N0:95, but excluding the poly(A) tail at the
3' end of SEQ ID N0:95; and
(bb) the nucleotide sequence of the cDNA insert of clone
bk343_2 deposited under accession number ATCC 207088;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:95, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:95 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:95
, but
excluding the poly(A) tail at the 3' end of SEQ TD N0:95. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:95 from nucleotide 219 to
nucleotide
629, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:95 from nucleotide 219 to nucleotide 629, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:95 from
nucleotide
219 to nucleotide 629.
2 0 In other embodiments, the present invention provides a composition
comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:96;
(b) a fragment of the amino acid sequence of SEQ ID N0:96, the
fragment comprising eight contiguous amino acids of SEQ ID N0:96; and
(c) the amino acid sequence encoded by the cDNA insert of clone
bk343 2 deposited under accession number ATCC 207088;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:96. In further
preferred
3 0 embodiments, the present invention provides a protein comprising a
fragment of the
amino acid sequence of SEQ ID N0:96 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:96, or a protein comprising a fragment of the amino acid sequence
of SEQ
152
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
ID N0:96 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 63 to amino acid 72 of SEQ ID N0:96.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:97;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:97 from nucleotide 556 to nucleotide 951;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:97 from nucleotide 868 to nucleotide 951;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:97 from nucleotide 9 to nucleotide 1295;
(e} a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone cd205 2 deposited under accession
number ATCC 207088;
(f) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone cd205 2 deposited under accession number ATCC 207088;
(g) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone cd205 2 deposited under accession number
2 0 ATCC 207088;
(h) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone cd205_2 deposited under accession number ATCC 207088;
(i) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:98;
2 5 (j) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:98 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:98;
(k) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(h) above;
3 0 (1) a polynucleotide which encodes a species homologue of the protein
of (i) or (j) above ;
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(j); and
153
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(n) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(j) and that has a length that is
at least
25% of the length of SEQ ID N0:97.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:97 from nucleotide 556 to nucleotide 951; the nucleotide sequence of SEQ ID
N0:97
from nucleotide 868 to nucleotide 951; the nucleotide sequence of SEQ ID N0:97
from
nucleotide 9 to nucleotide 1295; the nucleotide sequence of the full-length
protein coding
sequence of clone cd205 2 deposited under accession number ATCC 207088; or the
nucleotide sequence of a mature protein coding sequence of clone cd205 2
deposited
under accession number ATCC 207088. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone cd205 2 deposited under accession number ATCC 207088. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:98 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:98, or a polynucleotide
encoding
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:98
having
biological activity, the fragment comprising the amino acid sequence from
amino acid 61
to amino acid 70 of SEQ ID N0:98.
2 0 Other embodiments provide the gene corresponding to the cDNA sequence of
SEQ
ID N0:97.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
2 5 (i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:97, but excluding the poly(A) tail at the
3' end of SEQ ID N0:97; and
3 0 {ab) the nucleotide sequence of the cDNA insert of clone
cd205_2 deposited under accession number ATCC 207088;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
154
CA 02339047 2001-02-12
WO 00/09552 PCTNS99/18298
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:97, but excluding the poly(A) tail at the
3' end of SEQ ID N0:97; and
(bb) the nucleotide sequence of the cDNA insert of clone
cd205 2 deposited under accession number ATCC 207088;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:97, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:97 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:97
, but
2 0 excluding the poly(A) tail at the 3' end of SEQ ID N0:97. Also preferably
the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:97 from nucleotide 556 to
nucleotide
951, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:97 from nucleotide 556 to nucleotide 951, to a
nucleotide
2 5 sequence corresponding to the 3' end of said sequence of SEQ ID N0:97 from
nucleotide
556 to nucleotide 951. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:97 from nucleotide 868 to nucleotide 951, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:97 from
3 0 nucleotide 868 to nucleotide 951, to a nucleotide sequence corresponding
to the 3' end of
said sequence of SEQ ID N0:97 from nucleotide 868 to nucleotide 951. Also
preferably
the polynucleotide isolated according to the above process comprises a
nucleotide
sequence corresponding to the cDNA sequence of SEQ ID N0:97 from nucleotide 9
to
nucleotide 1295, and extending contiguously from a nucleotide sequence
corresponding
155
CA 02339047 2001-02-12
WO 00/89552 PCTNS99/18298
to the 5' end of said sequence of SEQ ID N0:97 from nucleotide 9 to nucleotide
1295, to
a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID
N0:97 from
nucleotide 9 to nucleotide 1295.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:98;
(b) a fragment of the amino acid sequence of SEQ ID N0:98, the
fragment comprising eight contiguous amino acids of SEQ ID N0:98; and
(c) the amino acid sequence encoded by the cDNA insert of clone
cd205 2 deposited under accession number ATCC 207088;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:98. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:98 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:98, or a protein comprising a fragment of the amino acid sequence
of SEQ
ID N0:98 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 61 to amino acid 70 of SEQ ID N0:98.
2 0 In one embodiment, the present invention provides a composition comprising
an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:99;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
2 5 N0:99 from nucleotide 216 to nucleotide 443;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:99 from nucleotide 306 to nucleotide 443;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone cw1292_8 deposited under accession
3 0 number ATCC 207088;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone cw1292_8 deposited under accession number ATCC 207088;
156
CA 02339047 2001-02-12
WO 00/09552 PCTNS99/18298
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone cw1292_8 deposited under accession number
ATCC 207088;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone cw1292_8 deposited under accession number ATCC 207088;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:100;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID NO:100 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID NO:100;
(j} a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(I) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:99.
2 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:99 from nucleotide 216 to nucleotide 443; the nucleotide sequence of SEQ ID
N0:99
from nucleotide 306 to nucleotide 443; the nucleotide sequence of the full-
length protein
coding sequence of clone cw1292_8 deposited under accession number ATCC
207088; or
the nucleotide sequence of a mature protein coding sequence of clone cw1292_8
deposited
2 5 under accession number ATCC 207088. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone cw1292_8 deposited under accession number ATCC 207088. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:100 having
biological
3 0 activity, the fragment preferably comprising eight (more preferably
twenty, most
preferably thirty) contiguous amino acids of SEQ ID NO:200, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:100
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 33 to amino acid 42 of SEQ ID N0:100.
157
CA 02339047 2001-02-12
WO 00/09552 PCTNS99/18298
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:99.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:99, but excluding the poly{A) tail at the
3' end of SEQ ID N0:99; and
(ab) the nucleotide sequence of the cDNA insert of done
cw1292_8 deposited under accession number ATCC 207088;
(ii} hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
2 0 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:99, but excluding the poly(A) tail at the
3' end of SEQ ID N0:99; and
(bb) the nucleotide sequence of the cDNA insert of clone
2 5 cw1292_8 deposited under accession number ATCC 207088;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
3 0 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:99, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:99 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:99
, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:99. Also preferably the
158
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:99 from nucleotide 216 to
nucleotide
443, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:99 from nucleotide 216 to nucleotide 443, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:99 from
nucleotide
216 to nucleotide 443. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:99 from nucleotide 306 to nucleotide 443, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:99 from
nucleotide 306 to nucleotide 443, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:99 from nucleotide 306 to nucleotide 443.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID NO:100;
(b) a fragment of the amino acid sequence of SEQ ID NO:100, the
fragment comprising eight contiguous amino acids of SEQ ID NO:100; and
(c) the amino acid sequence encoded by the cDNA insert of clone
cw1292_8 deposited under accession number ATCC 207088;
2 0 the protein being substantially free from other mammalian proteins.
Preferably such
protein comprises the amino acid sequence of SEQ ID NO:100. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:100 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino ands
2 5 of SEQ ID NO:100, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID NO:100 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 33 to amino acid 42 of SEQ ID N0:100.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
3 0 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:101;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:101 from nucleotide 2136 to nucleotide 2447;
159
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone cw1475 2 deposited under accession
number ATCC 207088;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone cw1475 2 deposited under accession number ATCC 207088;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone cw1475 2 deposited under accession number
ATCC 207088;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone cw1475_2 deposited under accession number ATCC 207088;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:102;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:102 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:102;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
2 0 (k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that.hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
25% of the length of SEQ ID N0:101.
2 5 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
NO:101 from nucleotide 2136 to nucleotide 2447; the nucleotide sequence of the
full-
length protein coding sequence of clone cw1475 2 deposited under accession
number
ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of
clone
cw1475_2 deposited under accession number ATCC 207088. In other preferred
3 0 embodiments, the polynucleotide encodes the full-length or a mature
protein encoded by
the cDNA insert of clone cw1475 2 deposited under accession number ATCC
207088.
In further preferred embodiments, the present invention provides a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:102
having biological activity, the fragment preferably comprising eight (more
preferably
160
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/I8298
twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:102, or a
polynucleotide encoding a protein comprising a fragment of the amino acid
sequence of
SEQ ID N0:102 having biological activity, the fragment comprising the amino
acid
sequence from amino acid 47 to amino acid 56 of SEQ ID N0:102.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:101.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:101, but excluding the poly(A) tail at the
3' end of SEQ ID N0:101; and
(ab) the nucleotide sequence of the cDNA insert of clone
cw1475_2 deposited under accession number ATCC 207088;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
2 0 probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
2 5 the group consisting of:
(ba) SEQ ID NO:101, but excluding the poly(A) tail at the
3' end of SEQ ID NO:101; and
(bb) the nucleotide sequence of the cDNA insert of clone
cw1475 2 deposited under accession number ATCC 207088;
3 0 (ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
161
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:101, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:101 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:101, but
excluding the poly(A) tail at the 3' end of SEQ ID NO:101. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:101 from nucleotide 2136 to
nucleotide 2447, and extending contiguously from a nucleotide sequence
corresponding
to the 5' end of said sequence of SEQ ID N0:101 from nucleotide 2136 to
nucleotide 2447,
to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ
ID N0:101
from nucleotide 2136 to nucleotide 2447.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:102;
(b) a fragment of the amino acid sequence of SEQ ID N0:102, the
fragment comprising eight contiguous amino acids of SEQ ID N0:102; and
(c) the amino acid sequence encoded by the cDNA insert of clone
cw1475_2 deposited under accession number ATCC 207088;
2 0 the protein being substantially free from other mammalian proteins.
Preferably such
protein comprises the amino acid sequence of SEQ ID N0:102. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:102 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
2 5 of SEQ ID N0:102, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:102 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 47 to amino acid 56 of SEQ ID N0:102.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
3 0 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:103;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:103 from nucleotide 310 to nucleotide 954;
162
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone dd428 4 deposited under accession
number ATCC 207088;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone dd428_4 deposited under accession number ATCC 207088;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone dd428_4 deposited under accession number
ATCC 207088;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone dd428 4 deposited under accession number ATCC 207088;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:104;
(h) a polynudeotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:104 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:104;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
2 0 (k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynudeotides specified in (a~(h) and that has a length that is at
least
25% of the length of SEQ ID N0:103.
2 5 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:103 from nucleotide 310 to nucleotide 954; the nucleotide sequence of the
full-length
protein coding sequence of clone dd428_4 deposited under accession number ATCC
207088; or the nucleotide sequence of a mature protein coding sequence of
clone dd428 4
deposited under accession number ATCC 207088. In other preferred embodiments,
the
3 0 polynucleotide encodes the full-length or a mature protein encoded by the
cDNA insert
of clone dd428 4 deposited under accession number ATCC 207088. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:104 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
163
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
preferably thirty) contiguous amino acids of SEQ ID N0:104, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:104
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 102 to amino acid 111 of SEQ ID N0:104.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:103.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:103, but excluding the poly(A) tail at the
3' end of SEQ ID N0:103; and
(ab) the nucleotide sequence of the cDNA insert of clone
dd428 4 deposited under accession number ATCC 207088;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
2 0 probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
2 5 the group consisting of:
(ba) SEQ ID N0:103, but excluding the poly(A) tail at the
3' end of SEQ ID N0:103; and
(bb) the nucleotide sequence of the cDNA insert of clone
dd428 4 deposited under accession number ATCC 207088;
3 0 (ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b}(iii).
164
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:103, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:103 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:103 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:103. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:103 from nucleotide 310 to
nucleotide
954, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:103 from nucleotide 310 to nucleotide 954, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:103 from
nucleotide
310 to nucleotide 954.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
I5 (a) the amino acid sequence of SEQ ID N0:104;
(b) a fragment of the amino acid sequence of SEQ ID N0:104, the
fragment comprising eight contiguous amino acids of SEQ ID N0:104; and
(c) the amino acid sequence encoded by the cDNA insert of clone
dd428_4 deposited under accession number ATCC 207088;
2 0 the protein being substantially free from other mammalian proteins.
Preferably such
protein comprises the amino acid sequence of SEQ ID N0:104. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:104 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
2 5 of SEQ ID N0:104, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:104 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 102 to amino acid 111 of SEQ ID N0:1.04.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
3 0 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:105;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:105 from nucleotide 1698 to nucleotide 1895;
165
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone dh1073_12 deposited under accession
number ATCC 207088;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone dh1073_12 deposited under accession number ATCC 207088;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone dh1073_12 deposited under accession number
ATCC 207088;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone dh1073_12 deposited under accession number ATCC 207088;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:106;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:106 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:106;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
2 0 (k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
25% of the length of SEQ ID N0:105.
2 5 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:105 from nucleotide 1698 to nucleotide 1895; the nucleotide sequence of the
full-
length protein coding sequence of clone dh1073_12 deposited under accession
number
ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of
clone
dh1073_12 deposited under accession number ATCC 207088. In other preferred
3 0 embodiments, the polynucleotide encodes the full-length or a mature
protein encoded by
the cDNA insert of clone dh1073_I2 deposited under accession number ATCC
207088.
In further preferred embodiments, the present invention provides a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:106
having biological activity, the fragment preferably comprising eight (more
preferably
166
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:106, or a
polynucleotide encoding a protein comprising a fragment of the amino acid
sequence of
SEQ ID N0:106 having biological activity, the fragment comprising the amino
acid
sequence from amino acid 28 to amino acid 37 of SEQ ID N0:106.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:105.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps af:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:105, but excluding the poly(A) tail at the
3' end of SEQ ID N0:105; and
(ab) the nucleotide sequence of the cDNA insert of clone
dh1073_12 deposited under accession number ATCC 207088;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
2 0 probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
2 5 the group consisting of:
(ba) SEQ ID N0:105, but excluding the poly(A) tail at the
3' end of SEQ ID N0:105; and
(bb) the nucleotide sequence of the cDNA insert of clone
dh1073_12 deposited under accession number ATCC 207088;
3 0 (ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
167
CA 02339047 2001-02-12
- WO 00/09552 PCT/US99/18298
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:105, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:105 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:105 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:105. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:105 from nucleotide 1698 to
nucleotide 1895, and extending contiguously from a nucleotide sequence
corresponding
to the 5' end of said sequence of SEQ ID N0:105 from nucleotide 1698 to
nucleotide 1895,
to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ
ID N0:105
from nucleotide 1698 to nucleotide 1895.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:106;
{b) a fragment of the amino acid sequence of SEQ ID N0:106, the
fragment comprising eight contiguous amino acids of SEQ ID N0:106; and
(c) the amino acid sequence encoded by the cDNA insert of clone
dh1073_12 deposited under accession number ATCC 207088;
2 0 the protein being substantially free from other mammalian proteins.
Preferably such
protein comprises the amino acid sequence of SEQ ID N0:106. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:106 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
2 5 of SEQ ID N0:106, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:106 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 28 to amino acid 37 of SEQ ID N0:106.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
3 0 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:107;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:107 from nucleotide 423 to nucleotide 791;
168
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/I8298
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone dw78_1 deposited under accession
number ATCC 207088;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone dw78_1 deposited under accession number ATCC 207088;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone dw78_1 deposited under accession number
ATCC 207088;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone dw78_1 deposited under accession number ATCC 207088;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:108;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:108 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:108;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
2 0 (k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specifiied in (a)-(h) and that has a length that is
at least
25% of the length of SEQ ID N0:107.
2 5 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:107 from nucleotide 423 to nucleotide 791; the nucleotide sequence of the
full-length
protein coding sequence of clone dw78 1 deposited under accession number ATCC
207088; or the nucleotide sequence of a mature protein coding sequence of
clone dw78_1
deposited under accession number ATCC 207088. In other preferred embodiments,
the
3 0 polynucleotide encodes the full-length or a mature protein encoded by the
cDNA insert
of done dw78_1 deposited under accession number ATCC 207088. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:108 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
169
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
preferably thirty) contiguous amino acids of SEQ ID NO:I08, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:108
having biological acfivity, the fragment comprising the amino acid sequence
from amino
acid 56 to amino acid 65 of SEQ ID N0:108.
S Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:107.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:107, but excluding the poly(A) tail at the
3' end of SEQ ID N0:107; and
(ab) the nucleotide sequence of the cDNA insert of clone
dw78_1 deposited under accession number ATCC 207088;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
2 0 probe(s);
and
(b} a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
2 5 the group consisting of:
(ba) SEQ ID N0:107, but excluding the poly(A) tail at the
3' end of SEQ ID N0:107; and
(bb) the nucleotide sequence of the cDNA insert of clone
dw78_1 deposited under accession number ATCC 207088;
3 0 (ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
170
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:107, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:107 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:107 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:107. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:107 from nucleotide 423 to
nucleotide
791, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:107 from nucleotide 423 to nucleotide 791, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:107 from
nucleotide
423 to nucleotide 791.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:108;
(b) a fragment of the amino acid sequence of SEQ ID N0:108, the
fragment comprising eight contiguous amino acids of SEQ ID N0:108; and
(c) the amino acid sequence encoded by the cDNA insert of clone
dw78_1 deposited under accession number ATC:C 207088;
2 0 the protein being substantially free from other mammalian proteins.
Preferably such
protein comprises the amino acid sequence of SEQ ID N0:108. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:108 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
2 5 of SEQ ID N0:108, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:108 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 56 to amino acid 65 of SEQ ID N0:108.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
3 0 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:109;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:109 from nucleotide 96 to nucleotide 944;
171
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone fh116_ll deposited under accession
number ATCC 207088;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of done fh116_11 deposited under accession number ATCC 207088;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone fh116_11 deposited under accession number
ATCC 207088;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone fh116_ll deposited under accession number ATCC 207088;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID NO:110;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:110 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:110;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
2 0 (k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
25% of the length of SEQ ID N0:109.
2 5 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:109 from nucleotide 96 to nucleotide 944; the nucleotide sequence of the
full-length
protein coding sequence of clone fh116_11 deposited under accession number
ATCC
207088; or the nucleotide sequence of a mature protein coding sequence of
clone fh116_11
deposited under accession number ATCC 207088. In other preferred embodiments,
the
3 0 polynucleotide encodes the full-length or a mature protein encoded by the
cDNA insert
of clone fh116_ll deposited under accession number ATCC 207088. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:110 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
172
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
preferably thirty) contiguous amino acids of SEQ ID N0:110, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
NO:110
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 136 to amino acid 145 of SEQ ID NO:110.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:109.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:109, but excluding the poly(A) tail at the
3' end of SEQ ID N0:109; and
(ab) the nucleotide sequence of the cDNA insert of clone
fh116_ll deposited under accession number ATCC 207088;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
2 0 probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
2 5 the group consisting of:
(ba) SEQ ID N0:109, but excluding the poly(A} tail at the
3' end of SEQ ID N0:109; and
(bb) the nucleotide sequence of the cDNA insert of clone
fh116_11 deposited under accession number ATCC 207088;
3 0 (ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
173
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:109, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:109 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:109 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:209. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:109 from nucleotide 96 to
nucleotide
944, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:109 from nucleotide 96 to nucleotide 944, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:109 from
nucleotide
96 to nucleotide 944.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:110;
(b) a fragment of the amino acid sequence of SEQ ID NO:110, the
fragment comprising eight contiguous amino acids of SEQ ID NO:110; and
(c) the amino acid sequence encoded by the cDNA insert of clone
fh116_ll deposited under accession number ATCC 207088;
2 0 the protein being substantially free from other mammalian proteins.
Preferably such
protein comprises the amino acid sequence of SEQ ID NO:110. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID NO:110 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
2 5 of SEQ ID N0:110, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID NO:I10 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 136 to amino acid 145 of SEQ ID N0:110.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
3 0 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:111;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:111 from nucleotide 150 to nucleotide 1610;
174
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone fy356_14 deposited under accession
number ATCC 207088;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone fy356_14 deposited under accession number ATCC 207088;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone fy356_14 deposited under accession number
ATCC 207088;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone fy356_14 deposited under accession number ATCC 207088;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:112;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:112 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:112;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
{j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
2 0 (k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(h) and that has a length that is
at least
25% of the length of SEQ ID N0:111.
2 5 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
NO:111 from nucleotide 150 to nucleotide 1610; the nucleotide sequence of the
full-length
protein coding sequence of clone fy356_14 deposited under accession number
ATCC
207088; or the nucleotide sequence of a mature protein coding sequence of
clone fy356_14
deposited under accession number ATCC 207088. In other preferred embodiments,
the
3 0 polynucleotide encodes the full-length or a mature protein encoded by the
cDNA insert
of clone fy356_14 deposited under accession number ATCC 207088. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:112 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
175
CA 02339047 2001-02-12
- WO 00/09552 PCT/US99/18298
preferably thirty) contiguous amino acids of SEQ TD N0:112, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:112
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 238 to amino acid 247 of SEQ ID N0:112.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID NO:111.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing.one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:111, but excluding the poly(A) tail at the
3' end of SEQ ID N0:111; and
(ab} the nucleotide sequence of the cDNA insert of clone
fy356_14 deposited under accession number ATCC 207088;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
2 0 probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
2 5 the group consisting of:
(ba) SEQ ID NO:111, but excluding the poly(A) tail at the
3' end of SEQ ID N0:111; and
(bb) the nucleotide sequence of the cDNA insert of clone
fy356_14 deposited under accession number ATCC 207088;
3 0 (ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
176
CA 02339047 2001-02-12
WO 08/09552 PCT/US99/18298
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:111, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:111 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:111 , but
excluding the poly(A) tail at the 3' end of SEQ ID NO:111. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:111 from nucleotide 150 to
nucleotide
1610, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:111 from nucleotide 150 to nucleotide 1610, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:111 from
nucleotide
150 to nucleotide 1610.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ aD N0:112;
(b) a fragment of the amino acid sequence of SEQ ID N0:112, the
fragment comprising eight contiguous amino acids of SEQ ID N0:112; and
(c) the amino acid sequence encoded by the cDNA insert of clone
fy356_14 deposited under accession number ATCC 207088;
2 0 the protein being substantially free from other mammalian proteins.
Preferably such
protein comprises the amino acid sequence of SEQ ID N0:112. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:112 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
2 5 of SEQ ID N0:112, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:112 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 238 to amino acid 247 of SEQ ID N0:112.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
3 0 (a) a polynucleotide comprising the nucleoride sequence of SEQ ID
N0:113;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:113 from nucleotide 49 to nucleotide 669;
177
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:113 from nucleotide 112 to nucleotide 669;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone iw66_1 deposited under accession
number
ATCC 207088;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone iw66_1 deposited under accession number ATCC 207088;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone iw66_1 deposited under accession number ATCC
207088;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone iw66_1 deposited under accessian number ATCC 207088;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:114;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:114 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:114;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
2 0 (k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
2 5 one of the polynucleotides specified in (a)-(i) and that has a length that
is at least
25% of the length of SEQ ID N0:113.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:113 from nucleotide 49 to nucleotide 669; the nucleotide sequence of SEQ ID
N0:113
from nucleotide 112 to nucleotide 669; the nucleotide sequence of the full-
length protein
3 0 coding sequence of clone iw66_1 deposited under accession number ATCC
207088; or the
nucleotide sequence of a mature protein coding sequence of clone iw66_1
deposited under
accession number ATCC 207088. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone iw66_1
deposited under accession number ATCC 207088. In further preferred
embodiments, the
178
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
present invention provides a polynucleotide encoding a protein comprising a
fragment
of the amino acid sequence of SEQ ID N0:114 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:114, or a polynucleotide encoding a protein
comprising a
fragment of the amino acid sequence of SEQ ID N0:114 having biological
activity, the
fragment comprising the amino acid sequence from amino acid 98 to amino acid
107 of
SEQ ID N0:114.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:113.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:113, but excluding the poly(A) tail at the
3' end of SEQ ID N0:113; and
(ab) the nucleotide sequence of the cDNA insert of clone
iw66_1 deposited under accession number ATCC 207088;
2 0 (ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC: at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
2 5 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:113, but excluding the poly(A) tail at the
3 0 3' end of SEQ ID N0:113; and
(bb) the nucleotide sequence of the cDNA insert of clone
iw66_1 deposited under accession number ATCC 207088;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
179
CA 02339047 2001-02-12
- WO 00/09552 PCT/ITS99/18298
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:113, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:113 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:113 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:113. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:113 from nucleotide 49 to
nucleotide
669, and extending contiguously from a ,nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:113 from nucleotide 49 to nucleotide 669, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:113 from
nucleotide
49 to nucleotide 669. Also preferably the polynucleotide isolated according to
the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:113 from nucleotide 112 to nucleotide 669, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:113 from
nucleotide 112 to nucleotide 669, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:113 from nucleotide 112 to nucleotide 669.
In other embodiments, the present invention provides a composition comprising
2 0 a protein, wherein said protein comprises an amino acid sequence selected
from the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:114;
(b) a fragment of the amino acid sequence of SEQ ID N0:114, the
fragment comprising eight contiguous amino acids of SEQ ID N0:114; and
2 5 (c) the amino acid sequence encoded by the cDNA insert of clone
iw66_1 deposited under accession number ATCC 207088;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:114. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
3 0 amino acid sequence of SEQ ID N0:114 having biological activity, the
fragment preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:114, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:114 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 98 to amino acid 107 of SEQ ID N0:114.
180
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:115;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:115 from nucleotide 165 to nucleotide 416;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone khl3 4 deposited under accession
number
ATCC 207089;
(d) a polynucleotide.encoding the full-length protein encoded by the
cDNA insert of clone khl3 4 deposited under accession number ATCC 207089;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone khl3 4 deposited under accession number ATCC
207089;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone khl3_4 deposited under accession number ATCC 207089;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:116;
(h) a polynucleotide encoding a protein comprising a fragment of the
2 0 amino acid sequence of SEQ ID N0:116 having biological activity, the
fragment
comprising eight contiguous amino acids of SEQ ID N0:116;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
2 5 of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at Ieast
3 0 25% of the length of SEQ ID N0:115.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:115 from nucleotide 165 to nucleotide 416; the nucleotide sequence of the
full-length
protein coding sequence of clone khl3 4 deposited under accession number ATCC
207089; or the nucleotide sequence of a mature protein coding sequence of
clone khl3 4
181
CA 02339047 2001-02-12
- WO 00/09552 PCT/US99/18298
deposited under accession number ATCC 207089. In other preferred embodiments,
the
polynudeotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone khl3_4 deposited under accession number ATCC 207089. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:116 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ TD N0:116, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
NO:116
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 37 to amino acid 46 of SEQ ID N0:116.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:115.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:115, but excluding the poly(A) tail at the
2 0 3' end of SEQ ID N0:115; and
(ab) the nucleotide sequence of the cDNA insert of clone
khl3_4 deposited under accession number ATCC 207089;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
2 5 (iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
3 0 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:115, but excluding the poly(A) tail at the
3' end of SEQ ID N0:115; and
182
CA 02339047 2001-02-12
WO 00/09552 PCTNS99/18298
(bb) the nucleotide sequence of the cDNA insert of clone
khl3 4 deposited under accession number ATCC 207089;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:115, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:115 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:115 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:115. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:115 from nucleotide 165 to
nucleotide
416, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:115 from nucleotide 165 to nucleotide 416, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:115 from
nucleotide
165 to nucleotide 416.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
2 0 consisting of:
(a) the amino acid sequence of SEQ ID N0:116;
(b) a fragment of the amino acid sequence of SEQ ID N0:116, the
fragment comprising eight contiguous amino acids of SEQ ID N0:116; and
(c) the amino acid sequence encoded by the cDNA insert of clone
2 5 khl3 4 deposited under accession number ATCC 207089;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID NO:lI6. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:116 having biological activity, the fragment
preferably
3 0 comprising eight (more preferably twenty, most preferably thirty)
contiguous amino acids
of SEQ ID N0:116, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:116 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 37 to amino acid 46 of SEQ ID N0:116.
183
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:117;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:117 from nucleotide 204 to nucleotide 602;
{c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone ko258 4 deposited under accession
number ATCC 207089;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone ko258 4 deposited under accession number ATCC 207089;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone ko258 4 deposited under accession number
ATCC 207089;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone ko258 4 deposited under accession number ATCC 207089;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:118;
(h) a polynucleotide encoding a protein comprising a fragment of the
2 0 amino acid sequence of SEQ ID N0:118 having biological activity, the
fragment
comprising eight contiguous amino acids of SEQ ID NO:118;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
2 5 of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (ar(h) and that has a length that is
at least
3 0 25% of the length of SEQ ID N0:117.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:117 from nucleotide 204 to nucleotide 602; the nucleotide sequence of the
full-length
protein coding sequence of clone ko258_4 deposited under accession number ATCC
207089; or the nucleotide sequence of a mature protein coding sequence of
clone ko258_4
184
CA 02339047 2001-02-12
- WO 00/09552 PCT/US99/18298
deposited under accession number ATCC 207089. In other preferred embodiments,
the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone ko258 4 deposited under accession number ATCC 207089. In further
nrPfPnP~t
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:118 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:118, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:118
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 61 to amino acid 70 of SEQ ID N0:118.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:117.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:127, but excluding the poly(A) tail at the
2 0 3' end of SEQ ID N0:117; and
(ab) the nucleotide sequence of the cDNA insert of clone
ko258 4 deposited under accession number ATCC 207089;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
2 5 (iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
3 0 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:117, but excluding the poly(A) tail at the
3' end of SEQ ID N0:117; and
185
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(bb) the nucleotide sequence of the cDNA insert of clone
ko258 4 deposited under accession number ATCC 207089;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv} isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:117, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:117 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:117 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:117. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:117 from nucleotide 204 to
nucleotide
602, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:117 from nucleotide 204 to nucleotide 602, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID NO:lI7 from
nucleotide
204 to nucleotide 602.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected fram
the group
2 0 consisting of:
(a) the amino acid sequence of SEQ ID N0:118;
(b) a fragment of the amino acid sequence of SEQ II7 N0:118, the
fragment comprising eight contiguous amino acids of SEQ ID N0:118; and
(c} the amino acid sequence encoded by the cDNA insert of clone
2 5 ko258_4 deposited under accession number ATCC 207089;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:118. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:118 having biological activity, the fragment
preferably
3 0 comprising eight (more preferably twenty, most preferably thirty)
contiguous amino acids
of SEQ ID N0:118, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:118 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 61 to amino acid 70 of SEQ ID N0:118.
186
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:119;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:119 from nucleotide 434 to nucleotide 739;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone kvl0_8 deposited under accession
number
ATCC 207089;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone kvl0_8 deposited under accession number ATCC 207089;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone kvl0_8 deposited under accession number ATCC
207089;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone kvl0_8 deposited under accession number ATCC 207089;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:120;
(h) a polynucleotide encoding a protein comprising a fragment of the
2 0 amino acid sequence of SEQ ID N0:120 having biological activity, the
fragment
comprising eight contiguous amino acids of SEQ ID N0:120;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
2 5 of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
3 0 25% of the length of SEQ ID N0:119.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:119 from nucleotide 434 to nucleotide 739; the nucleotide sequence of the
full-length
protein coding sequence of clone kvl0 8 deposited under accession number ATCC
207089; or the nucleotide sequence of a mature protein coding sequence of
clone kvl0_8
187
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
deposited under accession number ATCC 207089. In other preferred embodiments,
the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone kvl0_8 deposited under accession number ATCC 207089. In further
nreferred~
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:120 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:120, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:120
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 46 to amino acid 55 of SEQ ID N0:120.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:119.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:119, but excluding the poly(A) tail at the
2 0 3' end of SEQ ID N0:119; and
(ab) the nucleotide sequence of the cDNA insert of clone
kvl0 8 deposited under accession number ATCC 207089;
(ii) hybridizing said probe{s) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
2 5 (iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
3 0 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:119, but excluding the poly(A) tail at the
3' end of SEQ ID N0:119; and
188
CA 02339047 2001-02-12
- WO 00/09552 PCT/US99/18298
(bb) the nucleotide sequence of the cDNA insert of clone
kvl0_8 deposited under accession number ATCC 207089;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii}.
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:119, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:119 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:119 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:119. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:119 from nucleotide 434 to
nucleotide
739, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:119 from nucleotide 434 to nucleotide 739, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:119 from
nucleotide
434 to nucleotide 739.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
2 0 consisting of: .
(a) the amino acid sequence of SEQ ID N0:120;
(b) a fragment of the amino acid sequence of SEQ ID N0:120, the
fragment comprising eight contiguous amino acids of SEQ ID N0:120; and
(c) the amino acid sequence encoded by the cDNA insert of clone
kvl0 8 deposited under accession number ATCC 207089;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:120. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:120 having biological activity, the fragment
preferably
3 0 comprising eight (more preferably twenty, most preferably thirty)
contiguous amino acids
of SEQ ID N0:120, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:120 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 46 to amino acid 55 of SEQ ID N0:120.
189
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
in one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:121;
(b) a polynucleatide comprising the nucleotide sequence of SEQ ID
N0:121 from nucleotide 149 to nucleotide 310;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone LL89_3 deposited under accession
number ATCC 207089;
(d) a polynucleotide encoding the full-Length protein encoded by the
cDNA insert of clone LL89 3 deposited under accession number ATCC 207089;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone LL89_3 deposited under accession number
ATCC 207089;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone LL89_3 deposited under accession number ATCC 207089;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:122;
(h) a polynucleotide encoding a protein comprising a fragment of the
2 0 amino acid sequence of SEQ ID N0:122 having biological activity, the
fragment
comprising eight contiguous amino acids of SEQ ID N0:122;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
2 5 of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
3 0 25% of the length of SEQ ID N0:121.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:121 from nucleotide 149 to nucleotide 310; the nucleotide sequence of the
full-length
protein coding sequence of clone LL89 3 deposited under accession number ATCC
207089; or the nucleotide sequence of a mature protein coding sequence of
clone LL89_3
190
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
deposited under accession number ATCC 207089. In other preferred embodiments,
the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone LL89_3 deposited under accession number ATCC 207089. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:122 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty} contiguous amino acids of SEQ ID N0:122, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:122
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 22 to amino acid 31 of SEQ ID N0:122.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:121.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:121, but excluding the poly(A) tail at the
2 0 3' end of SEQ ID N0:121; and
(ab) the nucleotide sequence of the cDNA insert of clone
LL89_3 deposited under accession number ATCC 207089;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
2 5 (iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
3 0 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:121, but excluding the poly(A) tail at the
3' end of SEQ ID N0:121; and
191
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(bb) the nucleotide sequence of the cDNA insert of clone
LL89_3 deposited under accession number ATCC 207089;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:121, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:121 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:121, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:121. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:121 from nucleotide 149 to
nucleotide
310, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:121 from nucleotide 149 to nucleotide 310, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:121 from
nucleotide
149 to nucleotide 310.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
2 0 consisting of:
(a) the amino acid sequence of SEQ ID N0:122;
(b) a fragment of the amino acid sequence of SEQ ID N0:122, the
fragment comprising eight contiguous amino acids of SEQ ID N0:122; and
(c) the amino acid sequence encoded by the cDNA insert of clone
2 5 LL89 3 deposited under accession number ATCC 207089;
the protein being substantially free from other mammalian proteins. Preferably
such .
protein comprises the amino acid sequence of SEQ ID N0:122. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:122 having biological activity, the fragment
preferably
3 0 comprising eight (more preferably twenty, most preferably thirty)
contiguous amino acids
of SEQ ID N0:122, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:122 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 22 to amino acid 31 of SEQ ID N0:122.
192
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:123;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:123 from nucleotide 22 to nucleotide 288;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone mc300_1 deposited under accession
number ATCC 207089;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone mc300_1 deposited under accession number ATCC 207089;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone mc300_1 deposited under accession number
ATCC 207089;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone mc300_1 deposited under accession number ATCC 207089;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:124;
(h) a polynucleotide encoding a protein comprising a fragment of the
2 0 amino acid sequence of SEQ ID N0:124 having biological activity, the
fragment
comprising eight contiguous amino acids of SEQ ID N0:124;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
2 5 of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-{h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
3 0 25% of the length of SEQ ID N0:123.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:123 from nucleotide 22 to nucleotide 288; the nucleotide sequence of the
full-length
protein coding sequence of clone mc300_1 deposited under accession number ATCC
207089; or the nucleotide sequence of a mature protein coding sequence of
clone mc300_1
193
CA 02339047 2001-02-12
- WO 00/09552 PCT/US99/18298
deposited under accession number ATCC 207089. In other preferred embodiments,
the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone mc300_1 deposited under accession number ATCC 207089. In further
nrPfP~P~
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:124 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:124, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:124
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 39 to amino acid 48 of SEQ ID N0:124.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:123.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:123, but excluding the poly(A) tail at the
2 0 3' end of SEQ ID N0:123; and
(ab) the nucleotide sequence of the cDNA insert of clone
mc300_1 deposited under accession number ATCC 207089;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
2 5 (iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
3 0 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:123, but excluding the poly(A) tail at the
3' end of SEQ ID N0:123; and
194
CA 02339047 2001-02-12
- WO 00/09552 PCT/US99/18298
(bb) the nucleotide sequence of the cDNA insert of clone
mc300_1 deposited under accession number ATCC 207089;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:123, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:123 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:123 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:123. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:123 from nucleotide 22 to
nucleotide
288, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:123 from nucleotide 22 to nucleotide 288, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:123 from
nucleotide
22 to nucleotide 288.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
2 0 consisting of:
(a) the amino acid sequence of SEQ ID N0:124;
(b) a fragment of the amino acid sequence of SEQ ID N0:124, the
fragment comprising eight contiguous amino acids of SEQ ID N0:124; and
(c) the amino acid sequence encoded by the cDNA insert of clone
2 5 mc300_1 deposited under accession number ATCC 207089;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:124. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:124 having biological activity, the fragment
preferably
3 0 comprising eight (more preferably twenty, most preferably thirty)
contiguous amino acids
of SEQ ID N0:124, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:124 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 39 to amino acid 48 of SEQ ID N0:124.
195
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:125;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:125 from nucleotide 200 to nucleotide 2449;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone m1227_1 deposited under accession
number ATCC 207089;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone m1227 1 deposited under accession number ATCC 207089;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone m1227_1 deposited under accession number
ATCC 207089;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone m1227_1 deposited under accession number ATCC 207089;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:126;
(h) a polynucleotide encoding a protein comprising a fragment of the
2 0 amino acid sequence of SEQ ID N0:126 having biological activity, the
fragment
comprising eight contiguous amino acids of SEQ ID N0:126;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
2 5 of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
3 0 25% of the length of SEQ ID NO:I25.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:125 from nucleotide 200 to nucleotide 2449; the nucleotide sequence of the
full-length
protein coding sequence of clone mI227_1 deposited under accession number ATCC
207089; or the nucleotide sequence of a mature protein coding sequence of
clone m1227_1
196
CA 02339047 2001-02-12
WO 00/09552 PCTNS99/18298
deposited under accession number ATCC 207089. In other preferred embodiments,
the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone m1227 1 deposited under accession number ATCC 207089. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:126 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:126, or a polynucleodde
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:126
having biological activity, the fragment comprising the amino acid sequence
from amino
I 0 acid 370 to amino acid 379 of SEQ ID N0:126.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:125.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:125, but excluding the poly(A) tail at the
2 0 3' end of SEQ ID N0:125; and
(ab) the nucleotide sequence of the cDNA insert of clone
m1227 1 deposited under accession number ATCC 207089;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
2 5 (iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
3 0 hybridize in 6X SSC at 65 degrees C to a nueleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:125, but excluding the poly(A) tail at the
3' end of SEQ ID N0:125; and
197
CA 02339047 2001-02-12
- WO 00/09552 PCT/US99/18298
(bb) the nucleotide sequence of the cDNA insert of clone
m1227 1 deposited under accession number ATCC 207089;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleatide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:125, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:125 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:125 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:125. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:125 from nucleotide 200 to
nucleotide
2449, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:125 from nucleotide 200 to nucleotide 2449, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:125 from
nucleotide
200 to nucleotide 2449.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
2 0 consisting of:
(a) the amino acid sequence of SEQ ID N0:126;
(b) a fragment of the amino acid sequence of SEQ ID N0:126, the
fragment comprising eight contiguous amino acids of SEQ ID N0:126; and
(c) the amino acid sequence encoded by the cDNA insert of clone
2 5 m1227_1 deposited under accession number ATCC 207089;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:126. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:126 having biological activity, the fragment
preferably
3 0 comprising eight (more preferably twenty, most preferably thirty)
contiguous amino acids
of SEQ ID N0:126, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:126 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 370 to amino acid 379 of SEQ ID N0:126.
198
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:127;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:127 from nucleotide 82 to nucleotide 1980;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone mm367_6 deposited under accession
number ATCC 207089;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone mm367 6 deposited under accession number ATCC 207089;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone mm367_6 deposited under accession number
ATCC 207089;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone mm367 6 deposited under accession number ATCC 207089;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:128;
(h) a polynucleotide encoding a pratein comprising a fragment of the
2 0 amino acid sequence of SEQ ID N0:128 having biological activity, the
fragment
comprising eight contiguous amino acids of SEQ 1D N0:128;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
2 5 of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
3 0 25% of the length of SEQ ID N0:127.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:127 from nucleotide 82 to nucleotide 1980; the nucleotide sequence of the
full-length
protein coding sequence of clone mm367_6 deposited under accession number ATCC
207089; or the nucleotide sequence of a mature protein coding sequence of
clone mm367_6
199
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
deposited under accession number ATCC 207089. In other preferred embodiments,
the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone mm367_6 deposited under accession number ATCC 207089. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:128 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty} contiguous amino acids of SEQ 1:D N0:128, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:128
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 311 to amino acid 320 of SEQ ID N0:128.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:127.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:127, but excluding the poly(A) tail at the
2 0 3' end of SEQ ID N0:127; and
(ab) the nucleotide sequence of the cDNA insert of clone
mm367_6 deposited under accession number ATCC 207089;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
2 5 (iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
3 0 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:127, but excluding the poly(A) tail at the
3' end of SEQ ID N0:127; and
200
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(bb) the nucleotide sequence of the cDNA insert of clone
mm367_6 deposited under accession number ATCC 207089;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv} isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:127, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:127 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:127 , but
excluding the poly(A) tail at the 3' end of SEQ IL7 N0:127. Also preferably
the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:12? from nucleotide 82 to
nucleotide
1980, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:127 from nucleotide 82 to nucleotide 1980, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:127 from
nucleotide
82 to nucleotide 1980.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
2 0 consisting of:
(a) the amino acid sequence of SEQ ID N0:128;
(b} a fragment of the amino acid sequence of SEQ ID N0:128, the
fragment comprising eight contiguous amino acids of SEQ ID N0:128; and
(c) the amino acid sequence encoded by the cDNA insert of clone
2 5 mm367_6 deposited under accession number ATCC 207089;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:128. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:128 having biological activity, the fragment
preferably
3 0 comprising eight (more preferably twenty, most preferably thirty)
contiguous amino acids
of SEQ ID N0:128, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:128 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 311 to amino acid 320 of SEQ ID N0:128.
201
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:129;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:129 from nucleotide 125 to nucleotide 856;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone mt124_3 deposited under accession
number ATCC 207089;
(d) a polynucleotide.encoding the full-length protein encoded by the
cDNA insert of clone mt124_3 deposited under accession number ATCC 207089;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone mt124 3 deposited under accession number
ATCC 207089;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone mt124_3 deposited under accession number ATCC 207089;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:130;
(h) a polynucleotide encoding a protein comprising a fragment of the
2 0 amino acid sequence of SEQ ID N0:130 having biological activity, the
fragment
comprising eight contiguous amino acids of SEQ ID N0:130;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a}-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
2 5 of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
3 0 25% of the length of SEQ ID N0:129.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:129 from nucleotide 125 to nucleotide 856; the nucleotide sequence of the
full-length
protein coding sequence of clone mt124 3 deposited under accession number ATCC
207089; or the nucleotide sequence of a mature protein coding sequence of
clone mt124_3
202
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
deposited under accession number ATCC 207089. In other preferred embodiments,
the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone mt124_3 deposited under accession number ATCC 207089. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:130 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:130, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:130
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 117 to amino acid 126 of SEQ ID N0:130.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:129.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps af:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:129, but excluding the poly(A) tail at the
2 0 3' end of SEQ ID N0:129; and
(ab) the nucleotide sequence of the cDNA insert of clone
mt124_3 deposited under accession number ATCC 207089;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
2 5 (iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
3 0 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:129, but excluding the poly(A) tail at the
3' end of SEQ ID N0:129; and
203
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(bb) the nucleotide sequence of the cDNA insert of clone
mt124 3 deposited under accession number ATCC 207089;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv} isolating the polynucleotide products of step (b}(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:129, and
extending contiguously from a nucleotide sequence carresponding to the 5' end
of SEQ
ID N0:129 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:129 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:129. Also preferably the
polynudeotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:129 from nucleotide 125 to
nucleotide
856, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:129 from nucleotide 125 to nucleotide 856, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:129 from
nucleotide
125 to nucleotide 856.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
2 0 consisting of:
(a) the amino acid sequence of SEQ ID N0:130;
(b) a fragment of the amino acid sequence of SEQ ID N0:130, the
fragment comprising eight contiguous amino acids of SEQ ID N0:130; and
(c) the amino acid sequence encoded by the cDNA insert of clone
2 5 mt124 3 deposited under accession number ATCC 207089;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:130. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:130 having biological activity, the fragment
preferably
3 0 comprising eight (more preferably twenty, most preferably thirty)
contiguous amino acids
of SEQ ID N0:130, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:130 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 117 to amino acid 126 of SEQ ID N0:130.
204
CA 02339047 2001-02-12
WO 00/09552 PCTlUS99/18298
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:131;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:131 from nucleotide 856 to nucleotide 2940;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:131 from nucleotide 901 to nucleotide 2940;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone nf56 3 deposited under accession
number
ATCC 207089;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone nf56_3 deposited under accession number ATCC 207089;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone nf56_3 deposited under accession number ATCC
207089;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone nf56_3 deposited under accession number ATCC 207089;
(h) a polynucleotide encoding a protein comprising the amino acid
2 0 sequence of SEQ ID N0:132;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:132 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:132;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
2 5 (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
3 0 (m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:131.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:131 from nucleotide 856 to nucleotide 2940; the nucleotide sequence of SEQ
ID
205
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
N0:131 from nucleotide 901 to nucleotide 2940; the nucleotide sequence of the
full-length
protein coding sequence of clone nf56_3 deposited under accession number ATCC
207089;
or the nucleotide sequence of a mature protein coding sequence of clone nf56 3
deposited
under accession number ATCC 207089. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone nf56_3 deposited under accession number ATCC 207089. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:132 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:132, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:132
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 342 to amino acid 351 of SEQ ID N0:132.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:131.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a} a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
2 0 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:131, but excluding the poly(A} tail at the
3' end of SEQ ID N0:131; and
(ab) the nucleotide sequence of the cDNA insert of clone
2 5 nf56_3 deposited under accession number ATCC 207089;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
3 0 and
(b} a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
206
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(ba) SEQ ID N0:131, but excluding the poly(A) tail at the
3' end of SEQ ID N0:13I; and
(bb) the nucleotide sequence of the cDNA insert of clone
nf56_3 deposited under accession number ATCC 207089;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to . the cDNA sequence of SEQ ID N0:131, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:131 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:131 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:131. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:131 from nucleotide 856 to
nucleotide
2940, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:131 from nucleotide 856 to nucleotide 2940, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:131 from
nucleotide
856 to nucleotide 2940. Also preferably the polynucleotide isolated according
to the above
2 0 process comprises a nucleotide sequence corresponding to the eDNA sequence
of SEQ ID
N0:131 from nucleotide 901 to nucleotide 2940, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:131 from
nucleotide 901 to nucleotide 2940, to a nucleotide sequence corresponding to
the 3' end
of said sequence of SEQ ID N0:131 from nucleotide 901 to nucleotide 2940.
2 5 In other embodiments, the present invention provides a composition
comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:132;
(b) a fragment of the amino acid sequence of SEQ ID N0:132, the
3 0 fragment comprising eight contiguous amino acids of SEQ ID N0:132; and
(c) the amino acid sequence encoded by the cDNA insert of clone
nf56_3 deposited under accession number ATCC 207089;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:132. In further
preferred
207
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:132 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:132, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:132 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 342 to amino acid 351 of SEQ ID N0:132.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:133;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:133 from nucleotide 122 to nucleotide 448;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:133 from nucleotide 167 to nucleotide 448;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone qy442_2 deposited under accession
number ATCC 207089;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone qy442 2 deposited under accession number ATCC 207089;
2 0 (f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone qy442._2 deposited under accession number
ATCC 207089;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone qy442_2 deposited under accession number ATCC 207089;
2 5 (h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:134;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:134 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:134;
3 0 (j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
208
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (ar(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynudeotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:133.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:133 from nucleotide 122 to nucleotide 448; the nucleotide sequence of SEQ
ID N0:133
from nucleotide 167 to nucleotide 448; the nucleotide sequence of the full-
length protein
coding sequence of clone qy442_2 deposited under accession number ATCC 207089;
or
the nucleotide sequence of a mature protein coding sequence of clone qy442_2
deposited
under accession number ATCC 207089. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone qy442 2 deposited under accession number ATCC 207089. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:134 having
biological
activity, the fragment preferably comprising eight {more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:134, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:134
having biological activity, the fragment comprising the amino acid sequence
from amino
2 0 acid 49 to amino acid 58 of SEQ ID N0:134.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:133.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
2 5 (a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:133, but excluding the poly(A) tail at the
3 0 3' end of SEQ ID N0:133; and
(ab) the nucleotide sequence of the cDNA insert of clone
qy442_2 deposited under accession number ATCC 207089;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
209
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:133, but excluding the poly(A) tail at the
3' end of SEQ ID N0:133; and
(bb) the nucleotide sequence of the cDNA insert of clone
qy442_2 deposited under accession number ATCC 207089;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:133, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:133 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:133 , but
2 0 excluding the poly(A) tail at the 3' end of SEQ ID N0:133. Also preferably
the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:133 from nucleotide 122 to
nucleotide
448, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:133 from nucleotide 122 to nucleotide 448, to a
nucleotide
2 5 sequence corresponding to the 3' end of said sequence of SEQ ID N0:133
from nucleotide
122 to nucleotide 448. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:133 from nucleotide 167 to nucleotide 448, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:133 from
3 0 nucleotide I67 to nucleotide 448, to a nucleotide sequence corresponding
to the 3' end of
said sequence of SEQ ID N0:133 from nucleotide 167 to nucleotide 448.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
210
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(a) the amino acid sequence of SEQ ID N0:134;
(b) a fragment of the amino acid sequence of SEQ ID N0:134, the
fragment comprising eight contiguous amino acids of SEQ ID N0:134; and
(c) the amino acid sequence encoded by the cDNA insert of clone
qy442_2 deposited under accession number AT'CC 207089;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:134. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:134 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:134, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:134 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 49 to amino acid 58 of SEQ ID N0:134.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:135;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:135 from nucleotide 28 to nucleotide 777;
2 0 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:135 from nucleotide 73 to nucleotide 777;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone rj214_14 deposited under accession
number ATCC 207089;
2 5 (e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone rj214_14 deposited under accession number ATCC 207089;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone rj214_14 deposited under accession number
ATCC 207089;
3 0 (g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone rj214_14 deposited under accession number ATCC 207089;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:136; w
211
CA 02339047 2001-02-12
WO 00/09552 PCTNS99/18298
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:136 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:136;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:135.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
NO:135 from nucleotide 28 to nucleotide 777; the nucleotide sequence of SEQ ID
N0:135
from nucleotide 73 to nucleotide 777; the nucleotide sequence of the full-
length protein
coding sequence of clone rj214_14 deposited under accession number ATCC
207089; or
the nucleotide sequence of a mature protein coding sequence of clone rj214_14
deposited
under accession number ATCC 207089. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
2 0 of clone rj214_14 deposited under accession number ATCC 207089. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:136 having
biological
activity, the fragment preferably comprising eight {more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:136, or a
polynucleotide
2 5 encoding a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:136
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 120 to amino acid 129 of SEQ ID N0:136.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:135.
3 0 Further embodiments of the invention provide isolated polynucleotides
produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
212
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:135, but excluding the poly(A) tail at the
3' end of SEQ ID N0:135; and
(ab) the nucleotide sequence of the cDNA insert of clone
rj214_14 deposited under accession number ATCC 207089;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps af:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:235, but excluding the poly(A) tail at the
3' end of SEQ ID N0:135; and
(bb) the nucleotide sequence of the cDNA insert of clone
2 0 rj214_14 deposited under accession number ATCC 207089;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
2 5 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:135, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:135 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:135 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:135. Also preferably the
3 0 polynucleotide isolated according to the above process comprises a
nucleotide sequence
corresponding to the cDNA sequence of SEQ ID N0:135 from nucleotide 28 to
nucleotide
777, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:135 from nucleotide 28 to nucleotide 777, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:135 from
nucleotide
213
CA 02339047 2001-02-12
WO 00/09552 PCTNS99/18298
28 to nucleotide 777. Also preferably the polynucleotide isolated according to
the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:135 from nucleotide 73 to nucleotide 777, and extending contiguously from a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:135 from
nucleotide 73 to nucleotide 777, to a nucleotide sequence corresponding to the
3' end of
said sequence of SEQ ID N0:135 from nucleotide 73 to nucleotide 777.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:136;
(b) a fragment of the amino acid sequence of SEQ ID N0:136, the
fragment comprising eight contiguous amino acids of SEQ ID N0:136; and
(c) the amino acid sequence encoded by the cDNA insert of clone
rj214_14 deposited under accession number ATCC 207089;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:136. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:136 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
2 0 of SEQ ID N0:136, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:136 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 120 to amino acid 129 of SEQ ID N0:136.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:137;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:137 from nucleotide 179 to nucleotide 745;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
3 0 N0:137 from nucleotide 233 to nucleotide 745;
(d} a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone rk80_3 deposited under accession
number
ATCC 207089;
214
CA 02339047 2001-02-12
WO 00/09552 PCTNS99118298
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone rk80 3 deposited under accession number ATCC 207089;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone rk80 3 deposited under accession number ATCC
207089;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone rk80 3 deposited under accession number ATCC 207089;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:138;
(i) a polynucleoiide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:138 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:138;
a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h} or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
2 0 one of the polynucleotides specified in (a)-(i) and that has a length that
is at least
25% of the length of SEQ ID N0:137.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:137 from nucleotide 179 to nucleotide 745; the nucleotide sequence of SEQ
ID N0:137
from nucleotide 233 to nucleotide 745; the nucleotide sequence of the full-
length protein
2 5 coding sequence of clone rk80 3 deposited under accession number ATCC
207089; or the
nucleotide sequence of a mature protein coding sequence of clone rk80 3
deposited under
accession number ATCC 207089. In other preferred embodiments, the
polynucleotide
encodes the full-length or a mature protein encoded by the cDNA insert of
clone rk80 3
deposited under accession number ATCC 207089. In further preferred
embodiments, the
3 0 present invention provides a polynucleotide encoding a protein comprising
a fragment
of the amino acid sequence of SEQ ID N0:138 having biological activity, the
fragment
preferably comprising eight (more preferably twenty, most preferably thirty)
contiguous
amino acids of SEQ ID N0:138, or a polynucleotide encoding a protein
comprising a
fragment of the amino acid sequence of SEQ ID N0:138 having biological
activity, the
215
CA 02339047 2001-02-12
- WO 00/09552 PCT/US99/18298
fragment comprising the amino acid sequence from amino acid 89 to amino acid
98 of SEQ
ID N0:138.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:137.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps af:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:137, but excluding the poly(A) tail at the
3' end of SEQ ID N0:137; and
(ab) the nucleotide sequence of the cDNA insert of clone
rk80_3 deposited under accessian number ATCC 207089;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
2 0 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:137, but excluding the poly(A) tail at the
2 5 3' end of SEQ ID N0:137; and
(bb) the nucleotide sequence of the cDNA insert of clone
rk80_3 deposited under accession number ATCC 207089;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC: at 50 degrees C;
3 0 (iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:137, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
216
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
ID N0:137 to a nucleotide sequence corresponding to the 3' end of SEQ ID
NO:I37 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:137. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:137 from nucleotide 179 to
nucleotide
745, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:137 from nucleotide 179 to nucleotide 745, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:137 from
nucleotide
179 to nucleotide 745. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:137 from nucleotide 233 to nucleotide 745, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:137 from
nucleotide 233 to nucleotide 745, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:137 from nucleotide 233 to nucleotide 745.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:138;
(b) a fragment of the amino acid sequence of SEQ ID N0:138, the
fragment comprising eight contiguous amino acids of SEQ ID N0:138; and
2 0 (c) the amino acid sequence encoded by the cDNA insert of clone
rk80 3 deposited under accession number ATCC 207089;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:138. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
2 5 amino acid sequence of SEQ ID N0:138 having biological activity, the
fragment preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:138, or a protein comprising a fragment of the amino and sequence
of SEQ
ID N0:138 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 89 to amino acid 98 of SEQ ID N0:138.
3 0 In one embodiment, the present invention provides a composition comprising
an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:I39;
217
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:139 from nucleotide 1017 to nucleotide 1274;
(c) a polynucleotide comprising the nucleotide sequence of the full
length protein coding sequence of clone au36_42 deposited under accession
number ATCC 207187;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone au36 42 deposited under accession number ATCC 207187;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone au36 42 deposited under accession number
, ATCC 207187;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone au36 42 deposited under accession number ATCC 207187;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:140;
25 (h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:140 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:140;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
2 0 (j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
2 5 one of the polynucleotides specified in (ar(h) and that has a length that
is at least
25% of the length of SEQ ID N0:139.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:139 from nucleotide 1017 to nucleotide 1274; the nucleotide sequence of the
full-
length protein coding sequence of clone au36_42 deposited under accession
number
3 0 ATCC 207187; or the nucleotide sequence of a mature protein coding
sequence of clone
au36_42 deposited under accession number ATCC 207187. In other preferred
embodiments, the polynucleotide encodes the full-length or a mature protein
encoded by
the cDNA insert of clone au36 42 deposited under accession number ATCC 207187.
In
further preferred embodiments, the present invention provides a polynucleotide
encoding
218
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
a protein comprising a fragment of the amino acid sequence of SEQ ID N0:140
having
biological activity, the fragment preferably comprising eight (more preferably
twenty,
most preferably thirty) contiguous amino acids of SEQ ID N0:140, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:140
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 38 to amino acid 47 of SEQ ID N0:140.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:139.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:139, but excluding the poly(A) tail at the
3' end of SEQ ID N0:139; and
(ab) the nucleotide sequence of the cDNA insert of clone
au36 42 deposited under accession number ATCC 207187;
(ii) hybridizing said probe{s) to human genomic DNA in
2 0 conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
2 5 (i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:139, but excluding the poly(A) tail at the
3' end of SEQ ID N0:139; and
3 0 (bb) the nucleotide sequence of the cDNA insert of clone
au36_42 deposited under accession number ATCC 207187;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
219
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:139, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:139 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:139 , but
excluding the poly(A) tail at the 3' end of SEQ IL) N0:139. Also preferably
the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:139 from nucleotide 1017 to
nucleotide 1274, and extending contiguously from a nucleotide sequence
corresponding
to the 5' end of said sequence of SEQ ID N0:139 from nucleotide 1017 to
nucleotide 1274,
to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ
ID N0:139
from nucleotide 1017 to nucleotide 1274.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:140;
(b) a fragment of the amino acid sequence of SEQ ID N0:140, the
fragment comprising eight contiguous amino acids of SEQ ID N0:140; and
(c) the amino acid sequence encoded by the cDNA insert of clone
2 0 au36_42 deposited under accession number ATCC 207187;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:140. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:140 having biological activity, the fragment
preferably
2 5 comprising eight (more preferably twenty, most preferably thirty)
contiguous amino acids
of SEQ ID N0:140, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:140 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 38 to amino acid 47 of SEQ ID N0:140.
In one embodiment, the present invention provides a composition comprising an
3 0 isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:141;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:141 from nucleotide 580 to nucleotide 774;
220
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone bo549 13 deposited under accession
number ATCC 207187;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone bo549_13 deposited under accession number ATCC 207187;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone bo549_13 deposited under accession number
ATCC 207187;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone bo549_13 deposited under accession number ATCC 207187;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:142;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:142 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:142;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
2 0 (k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
25% of the length of SEQ ID N0:141.
2 5 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:141 from nucleotide 580 to nucleotide 774; the nucleotide sequence of the
full-length
protein coding sequence of clone bo549 13 deposited under accession number
ATCC
207187; or the nucleotide sequence of a mature protein coding sequence of
clone bo549_13
deposited under accession number ATCC 207187. In other preferred embodiments,
the
3 0 polynucleotide encodes the full-length or a mature protein encoded by the
cDNA insert
of clone bo549 13 deposited under accession number ATCC 207187. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:142 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
221
CA 02339047 2001-02-12
- WO 00/09552 PCT/US99/18298
preferably thirty) contiguous amino acids of SEQ ID N0:142, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:142
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 27 to amino acid 36 of SEQ ID N0:142.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:141.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
{a) a process comprising the steps of:
(i) preparing.one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:141, but excluding the poly(A) tail at the
3' end of SEQ ID N0:141; and
(ab) the nucleotide sequence of the cDNA insert of clone
bo549_13 deposited under accession number ATCC 207187;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii} isolating the DNA polynucleotides detected with the
2 0 probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
2 5 the group consisting of:
(ba) SEQ ID N0:141, but excluding the poly(A) tail at the
3' end of SEQ ID N0:141; and
(bb) the nucleotide sequence of the cDNA insert of clone
bo549_13 deposited under accession number ATCC 207187;
3 0 (ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
222
CA 02339047 2001-02-12
WO 00/09552 PCTNS99/18298
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:141, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:141 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:141, but
excluding the poly(A) tail at the 3' end of SEQ ID N0:141. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:141 from nucleotide 580 to
nucleotide
774, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:141 from nucleotide 580 to nucleotide 774, to a
nucleotide
2 0 sequence corresponding to the 3' end of said sequence of SEQ ID N0:141
from nucleotide
580 to nucleotide 774.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:142;
(b) a fragment of the amino acid sequence of SEQ ID N0:142, the
fragment comprising eight contiguous amino acids of SEQ ID N0:142; and
(c) the amino acid sequence encoded by the cDNA insert of clone
bo549_13 deposited under accession number ATCC 207187;
2 0 the protein being substantially free from other mammalian proteins.
Preferably such
protein comprises the amino acid sequence of SEQ ID N0:142. In further
preferred
embodiments, the present, invention provides a protein comprising a fragment
of the
amino acid sequence of SEQ ID N0:142 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
2 5 of SEQ ID N0:142, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:142 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 27 to amino acid 36 of SEQ ID N0:142.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
3 0 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:143;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:143 from nucleotide 172 to nucleotide 969;
223
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:143 from nucleotide 385 to nucleotide 969;
(d) a polynucleotide comprising the nucleotide sequence of the full
length protein coding sequence of clone da529_3 deposited under accession
number ATCC 207187;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone da529_3 deposited under accession number ATCC 207187;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone da529_3 deposited under accession number
ATCC 207187;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone da529 3 deposited under accession number ATCC 207187;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:144;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:144 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:144;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
2 0 (k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
(m) a polynudeotide that hybridizes under stringent conditions to any
2 5 one of the polynucleotides specified in (a)-(i) and that has a length that
is at least
25% of the length of SEQ ID N0:143.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:143 from nucleotide 172 to nucleotide 969; the nucleotide sequence of SEQ
ID N0:143
from nucleotide 385 to nucleotide 969; the nucleotide sequence of the full-
length protein
3 0 coding sequence of clone da529_3 deposited under accession number ATCC
207187; or
the nucleotide sequence of a mature protein coding sequence of clone da529_3
deposited
under accession number ATCC 207187. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone da529_3 deposited under accession number ATCC 207187. In further
preferred
224
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:144 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:144, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:144
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 128 to amino acid 137 of SEQ ID N0:144.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:143.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:143, but excluding the poly(A) tail at the
3' end of SEQ ID N0:143; and
(ab) the nucleotide sequence of the cDNA insert of clone
da529_3 deposited under accession number ATCC 207187;
2 0 (ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
2 5 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:143, but excluding the poly(A) tail at the
3 0 3' end of SEQ ID N0:143; and
(bb) the nucleotide sequence of the cDNA insert of clone
da529 3 deposited under accession number ATCC 207187;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
225
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:143, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:143 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:143 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:143. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:143 from nucleotide 172 to
nucleotide
969, and extending contiguously from a.nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:143 from nucleotide 172 to nucleotide 969, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:143 from
nucleotide
172 to nucleotide 969. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:143 from nucleotide 385 to nucleotide 969, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:143 from
nucleotide 385 to nucleotide 969, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:143 from nucleotide 385 to nucleotide 969.
In other embodiments, the present invention provides a composition comprising
2 0 a protein, wherein said protein comprises an amino acid sequence selected
from the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:144;
(b) a fragment of the amino acid sequence of SEQ ID N0:144, the
fragment comprising eight contiguous amino acids of SEQ ID N0:144; and
2 5 (c) the amino acid sequence encoded by the cDNA insert of clone
da529 3 deposited under accession number ATCC 207187;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:144. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
3 0 amino acid sequence of SEQ ID N0:144 having biological activity, the
fragment preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:144, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:144 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 128 to amino acid 137 of SEQ ID N0:144.
226
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:145;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:145 from nucleotide 329 to nucleotide 667;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:145 from nucleotide 368 to nucleotide 667;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone dm365_3 deposited under accession
number ATCC 207187;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone dm365 3 deposited under accession number ATCC 207187;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone dm365_3 deposited under accession number
ATCC 207187;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone dm365_3 deposited under accession number ATCC 207187;
(h) a polynucleotide encoding a protein comprising the amino acid
2 0 sequence of SEQ ID N0:146;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:146 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:146;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
2 5 (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
3 0 (m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:145.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:145 from nucleotide 329 to nucleotide 667; the nucleotide sequence of SEQ
ID N0:145
227
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
from nucleotide 368 to nucleotide 667; the nucleotide sequence of the full-
length protein
coding sequence of clone dm365_3 deposited under accession number ATCC 207187;
or
the nucleotide sequence of a mature protein coding sequence of clone dm365 3
deposited
under accession number ATCC 207187. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone dm365_3 deposited under accession number ATCC 207187. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:146 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:146, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:146
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 51 to amino acid 60 of SEQ ID N0:146.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:145.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
2 0 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa} SEQ ID N0:145, but excluding the poly(A) tail at the
3' end of SEQ ID N0:145; and
(ab) the nucleotide sequence of the cDNA insert of clone
2 5 dm365 3 deposited under accession number ATCC 207187;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probes};
3 0 and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
228
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(ba) SEQ ID N0:145, but excluding the poly(A) tail at the
3' end of SEQ ID N0:145; and
(bb) the nucleotide sequence of the cDNA insert of clone
dm365 3 deposited under accession number ATCC 207187;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:145, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:145 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:145 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:145. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:145 from nucleotide 329 to
nucleotide
667, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:145 from nucleotide 329 to nucleotide 667, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID NO:145 from
nucleotide
329 to nucleotide 667. Also preferably the polynucleotide isolated according
to the above
2 0 process comprises a nucleotide sequence corresponding to the cDNA sequence
of SEQ ID
N0:145 from nucleotide 368 to nucleotide 667, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:145 from
nucleotide 368 to nucleotide 667, to a nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:145 from nucleotide 368 to nucleotide 667.
2 5 In other embodiments, the present invention provides a composition
comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:146;
(b) a fragment of the amino acid sequence of SEQ ID N0:146, the
3 0 fragment comprising eight contiguous amino acids of SEQ ID N0:146; and
(c) the amino acid sequence encoded by the cDNA insert of clone
dm365_3 deposited under accession number ATCC 207187;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:146. In further
preferred
229
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:146 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino ands
of SEQ ID N0:146, or a protein comprising a fragment of the amino acid
sequence of SEQ
5 ID N0:146 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 51 to amino acid 60 of SEQ ID N0:146.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:147;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:147 from nucleotide 103 to nucleotide 1368;
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone fal7l 1 deposited under accession
number ATCC 207187;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone fa171 1 deposited under accession number ATCC 207187;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone fa171 1 deposited under accession number
2 0 ATCC 207187;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone fa171 1 deposited under accession number ATCC 207187;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:148;
2 5 {h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:148 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:148;
(i) a polynucleotide which is an. allelic variant of a polynucleotide of
(a)-(f) above;
3 0 (j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
230
CA 02339047 2001-02-12
WO 00/09552 PCTNS99/18298
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a~(h) and that has a length that is
at least
25% of the length of SEQ ID N0:147.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
5 N0:147 from nucleotide 103 to nucleotide 1368; the nucleotide sequence of
the full-length
protein coding sequence of clone fa171_1 deposited under accession number ATCC
207187; or the nucleotide sequence of a mature protein coding sequence of
clone fa171_1
deposited under accession number ATCC 207287. In other preferred embodiments,
the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
10 of clone fa171 1 deposited under accession number ATCC 207187. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:148 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:148, or a
polynucleotide
15 encoding a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:148
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 206 to amino acid 215 of SEQ ID N0:148.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:147.
2 0 Further embodiments of the invention provide isolated polynucleotides
produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
2 5 consisting of:
(aa) SEQ ID N0:147, but excluding the poly(A) tail at the
3' end of SEQ ID N0:147; and
(ab) the nucleotide sequence of the cDNA insert of clone
fa172_1 deposited under accession number ATCC 207187;
3 0 (ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
231
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:147, but excluding the poly(A) tail at the
3' end of SEQ ID N0:147; and
(bb) the nucleotide sequence of the cDNA insert of clone
fa171_1 deposited under accession number ATCC 207187;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:147, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:147 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:147 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:147. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:147 from nucleotide 103 to
nucleotide
2 0 1368, and extending contiguously from a nucleotide sequence corresponding
to the 5' end
of said sequence of SEQ ID N0:147 from nucleotide 103 to nucleotide 1368, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:147 from
nucleotide
103 to nucleotide 1368.
In other embodiments, the present invention provides a composition comprising
2 5 a protein, wherein said protein comprises an amino acid sequence selected
from the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:148;
(b) a fragment of the amino acid sequence of SEQ ID N0:148, the
fragment comprising eight contiguous amino acids of SEQ ID N0:148; and
3 0 (c) the amino acid sequence encoded by the cDNA insert of clone
fa171_1 deposited under accession number ATCC 207187;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:148. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
232
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
amino acid sequence of SEQ ID N0:148 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
of SEQ ID N0:148, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:148 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 206 to amino acid 215 of SEQ ID N0:148.
In one embodiment, the present invention pxovides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:149;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:149 from nucleotide 190 to nucleotide 1407;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:149 from nucleotide 463 to nucleotide 1407;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone 1p572_2 deposited under accession
number ATCC 207187;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone 1p572 2 deposited under accession number ATCC 207187;
(f) a polynucleotide comprising the nucleotide sequence of a mature
2 0 protein coding sequence of clone 1p572_2 deposited under accession number
ATCC 207187;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone 1p572_2 deposited under accession number ATCC 207187;
(h) a polynucleotide encoding a protein comprising the amino acid
2 5 sequence of SEQ ID NO:150;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:150 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:150;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
3 0 (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i); and
233
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:149.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:149 from nucleotide 190 to nucleotide 1407; the nucleotide sequence of SEQ
ID
N0:149 from nucleotide 463 to nucleotide 1407; the nucleotide sequence of the
full-length
protein coding sequence of clone 1p572 2 deposited under accession number ATCC
207187; or the nucleotide sequence of a mature protein coding sequence of
clone 1p572 2
deposited under accession number ATCC 207187. In other preferred embodiments,
the
polynudeotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone 1p572_2 deposited under accession number ATCC 207187. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:150 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
preferably thirty) contiguous amino acids of SEQ ID N0:150, or a polynucleoHde
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:150
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 198 to amino acid 207 of SEQ ID N0:150.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID N0:149.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
2 5 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:149, but excluding the poly(A) tail at the
3' end of SEQ ID N0:149; and
(ab) the nucleotide sequence of the cDNA insert of clone
3 0 1p572_2 deposited under accession number ATCC 207187;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
234
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:149, but excluding the poly(A} tail at the
3' end of SEQ ID N0:149; and
(bb) the nucleotide sequence of the cDNA insert of clone
1p572 2 deposited under accession number ATCC 207187;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b}(iii}.
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:149, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:149 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:149 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:149. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
2 0 corresponding to the cDNA sequence of SEQ ID N0:149 from nucleotide 190 to
nucleotide
1407, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:149 from nucleotide 190 to nucleotide 1407, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:149 from
nucleotide
190 to nucleotide 1407. Also preferably the polynucleotide isolated according
to the above
2 5 process comprises a nucleotide sequence corresponding to the cDNA sequence
of SEQ ID
N0:149 from nucleotide 463 to nucleotide 1407, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:149 from
nucleotide 463 to nucleotide 1407, to a nucleotide sequence corresponding to
the 3' end
of said sequence of SEQ ID N0:149 from nucleotide 463 to nucleotide 1407.
3 0 In other embodiments, the present invention provides a composition
comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:150;
235
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(b) a fragment of the amino acid sequence of SEQ ID N0:150, the
fragment comprising eight contiguous amino acids of SEQ ID N0:150; and
(c) the amino acid sequence encoded by the cDNA insert of clone
1p572 2 deposited under accession number ATCC 207187;
5 the protein being substantially free from other mammalian proteins.
Preferably such
protein comprises the amino acid sequence of SEQ ID N0:150. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:150 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
10 of SEQ ID N0:150, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:150 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 198 to amino acid 207 of SEQ ID N0:150.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
15 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:151;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:151 from nucleotide 301 to nucleotide 1035;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
2 0 N0:151 from nucleotide 916 to nucleotide 1035;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone pe246_1 deposited under accession
number ATCC 207187;
(e) a polynucleotide encoding the full-length protein encoded by the
2 5 cDNA insert of clone pe246_1 deposited under accession number ATCC 207187;
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone pe246_1 deposited under accession number
ATCC 207187;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
3 0 insert of clone pe246_1 deposited under accession number ATCC 207187;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID NO:152;
236
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(i) a polynudeotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:152 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:152;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (ar(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i} and that has a length that is
at least
25% of the length of SEQ ID N0:151.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:151 from nucleotide 301 to nucleotide 1035; the nucleotide sequence of SEQ
ID
N0:151 from nucleotide 916 to nucleotide 1035; the nucleotide sequence of the
full-length
protein coding sequence of clone pe246_1 deposited under accession number ATCC
207187; or the nucleotide sequence of a mature protein coding sequence of
clone pe246_1
deposited under accession number ATCC 207187. In other preferred embodiments,
the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
2 0 of clone pe246_1 deposited under accession number ATCC 207187. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:152 having
biological
activity, the fragmert preferably comprising eight (more preferably twenty,
most
preferably thirty} contiguous amino acids of SEQ ID N0:152, or a
polynucleotide
2 5 encoding a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:152
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 117 to amino acid 126 of SEQ ID N0:152.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:151.
3 0 Further embodiments of the invention provide isolated polynucleotides
produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
237
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:151, but excluding the poly(A) tail at the
3' end of SEQ ID N0:151; and
(ab) the nucleotide sequence of the cDNA insert of clone
pe246_1 deposited under accession number ATCC 207187;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
I 5 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:151, but excluding the poly(A) tail at the
3' end of SEQ ID N0:151; and
(bb) the nucleotide sequence of the cDNA insert of clone
2 0 pe246_1 deposited under accession number ATCC 207187;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
2 5 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:151, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:151 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:151 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:151. Also preferably the
3 0 polynucleotide isolated according to the above process comprises a
nucleotide sequence
corresponding to the cDNA sequence of SEQ ID N0:151 from nucleotide 301 to
nucleotide
1035, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:151 from nucleotide 301 to nucleotide 1035, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:151 from
nucleotide
238
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
301 to nucleotide 1035. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:151 from nucleotide 916 to nucleotide 1035, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:151 from
5 nucleotide 916 to nucleotide 1035, to a nucleotide sequence corresponding to
the 3' end
of said sequence of SEQ ID N0:151 from nucleotide 916 to nucleotide 1035.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:152;
(b) a fragment of the amino acid sequence of SEQ ID N0:152, the
fragment comprising eight contiguous amino acids of SEQ ID N0:152; and
(c) the amino acid sequence encoded by the cDNA insert of clone
pe246_1 deposited under accession number ATCC 207187;
15 the protein being substantially free from other mammalian proteins.
Preferably such
protein comprises the amino acid sequence of SEQ ID N0:152. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:152 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
2 0 of SEQ ID N0:152, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:152 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 117 to amino acid 126 of SEQ ID N0:152.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
2 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:153;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:153 from nucleotide 94 to nucleotide 1281;
(c) a polynucleotide comprising the nucleotide sequence of the full
3 0 length protein coding sequence of clone qf122_3 deposited under accession
number ATCC 207187;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone qf122 3 deposited under accession number ATCC 207187;
239
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone qf122_3 deposited under accession number
ATCC 207187;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone qf122 3 deposited under accession number ATCC 207187;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID NO:154;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:154 having biological activity, the fragment
comprising eight contiguous.amino acids of SEQ ID N0:154;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
25% of the length of SEQ ID N0:153.
2 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:153 from nucleotide 94 to nucleotide 1281; the nucleotide sequence of the
full-length
protein coding sequence of clone qf122_3 deposited under accession number ATCC
207187; or the nucleotide sequence of a mature protein coding sequence of
clone qf122_3
deposited under accession number ATCC 207187. In other preferred embodiments,
the
2 5 polynucleotide encodes the full-length or a mature protein encoded by the
cDNA insert
of clone qf122_3 deposited under accession number ATCC 207187. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:154 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
3 0 preferably thirty) contiguous amino acids of SEQ ID N0:154, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:154
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 193 to amino acid 202 of SEQ ID N0:154.
240
CA 02339047 2001-02-12
WO 00/09552 PCTNS99/18298
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:153.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:153; and
(ab) the nucleotide sequence of the cDNA insert of clone
qf122 3 deposited under accession number ATCC 207187;
(ii) hybridizing said probes) to human genomic DNA in
conditions at Ieast as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
2 0 the group consisting of:
(ba) SEQ ID NO:I53; and
(bb) the nucleotide sequence of the cDNA insert of clone
qf122_3 deposited under accession number ATCC 207187;
(ii) hybridizing said prirner(s) to human genomic DNA in
2 5 conditions at least as stringent as 47C SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:153, and
3 0 extending contiguously from a nucleotide sequence corresponding to the 5'
end of SEQ
ID N0:153 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:153 . Also
preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:153 from
nucleotide 94 to nucleotide 1281, and extending contiguously from a nucleotide
sequence
241
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
corresponding to the 5' end of said sequence of SEQ ID N0:153 from nucleotide
94 to
nucleotide 1281, to a nucleotide sequence corresponding to the 3' end of said
sequence of
SEQ ID N0:153 from nucleotide 94 to nucleotide 1281.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:154;
(b) a fragment of the amino acid sequence of SEQ ID N0:154, the
fragment comprising eight contiguous amino acids of SEQ ID N0:154; and
(c) the amino acid sequence encoded by the cDNA insert of clone
qf122_3 deposited under accession number ATCC 207187;
the protein being substantially free from other mammalian proteins. Preferably
such
protein comprises the amino acid sequence of SEQ ID N0:154. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:154 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino ands
of SEQ ID N0:154, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:154 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 193 to amino acid 202 of SEQ ID N0:154.
2 0 In one embodiment, the present invention provides a composition comprising
an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:155;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
2 5 N0:155 from nucleotide 110 to nucleotide 742;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:155 from nucleotide 170 to nucleotide 742;
(d) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone qv538_1 deposited under accession
3 0 number ATCC 207187;
(e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone qv538_1 deposited under accession number ATCC 207187;
242
CA 02339047 2001-02-12
WO 00/09552 PCTNS99/18298
(f) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone qv538_1 deposited under accession number
ATCC 207187;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone qv538_1 deposited under accession number ATCC 207187;
(h) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:156;
(i) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:156 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:156;
(j} a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein
of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a}-(i); and
(m) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(i) and that has a length that is
at least
25% of the length of SEQ ID N0:155.
2 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:155 from nucleotide 110 to nucleotide 742; the nucleotide sequence of SEQ
ID N0:155
from nucleotide 170 to nucleotide 742; the nucleotide sequence of the full-
length protein
coding sequence of clone qv538_1 deposited under accession number ATCC 207187;
or
the nucleotide sequence of a mature protein coding sequence of clone qv538_1
deposited
2 5 under accession number ATCC 207187. In other preferred embodiments, the
polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert
of clone qv538_1 deposited under accession number ATCC 207187. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:156 having
biological
3 0 activity, the fragment preferably comprising eight (more preferably
twenty, most
preferably thirty) contiguous amino acids of SEQ ID N0:156, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:156
having biological activity, the fragment comprising the amino acid sequence
from amino
acid 100 to amino acid 109 of SEQ ID N0:156.
243
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:155.
Further embodiments of the invention provide isolated polynudeotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:155, but excluding the poly(A) tail at the
3' end of SEQ ID N0:155; and
(ab) the nucleotide sequence of the cDNA insert of clone
qv538_1 deposited under accession number ATCC 207187;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
2 0 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
(ba) SEQ ID N0:155, but excluding the poly(A) tail at the
3' end of SEQ ID N0:155; and
(bb) the nucleotide sequence of the cDNA insert of clone
2 5 qv538_1 deposited under accession number ATCC 207187;
(ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
3 0 Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:155, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:155 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:155 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:155. Also preferably the
244
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:155 from nucleotide 110 to
nucleotide
742, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:155 from nucleotide 110 to nucleotide 742, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:155 from
nucleotide
110 to nucleotide 742. Also preferably the polynucleotide isolated according
to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of
SEQ ID
N0:155 from nucleotide 170 to nucleotide 742, and extending contiguously from
a
nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:155 from
nucleotide 170 to nucleotide 742, to a.nucleotide sequence corresponding to
the 3' end of
said sequence of SEQ ID N0:155 from nucleotide 170 to nucleotide 742.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:156;
(b) a fragment of the amino acid sequence of SEQ ID N0:156, the
fragment comprising eight contiguous amino acids of SEQ ID N0:156; and
(c) the amino acid sequence encoded by the cDNA insert of clone
qv538_1 deposited under accession number ATCC 207187;
2 0 the protein being substantially free from other mammalian proteins.
Preferably such
protein comprises the amino acid sequence of SEQ ID N0:156. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:156 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
2 5 of SEQ ID NO:I56, or a protein comprising a fragment of the amino and
sequence of SEQ
ID N0:156 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 100 to amino acid 109 of SEQ ID N0:156.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
3 0 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:157;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:157 from nucleotide 41 to nucleotide 757;
245
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
(c) a polynucleotide comprising the nucleotide sequence of the full-
length protein coding sequence of clone ys20,_1 deposited under accession
number
ATCC 207187;
(d) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone ys20_1 deposited under accession number ATCC 207187;
(e) a polynucleotide comprising the nucleotide sequence of a mature
protein coding sequence of clone ys20_1 deposited under accession number ATCC
207187;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone ys20_1 deposited under accession number ATCC 207187;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID N0:158;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID N0:158 having biological activity, the fragment
comprising eight contiguous amino acids of SEQ ID N0:158;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above ;
2 0 (k} a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h); and
(1) a polynucleotide that hybridizes under stringent conditions to any
one of the polynucleotides specified in (a)-(h) and that has a length that is
at least
25% of the length of SEQ ID N0:157.
2 5 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:157 from nucleotide 41 to nucleotide 757; the nucleotide sequence of the
full-length
protein coding sequence of clone ys20_1 deposited under accession number ATCC
207187;
or the nucleotide sequence of a mature protein coding sequence of clone ys20_1
deposited
under accession number ATCC 207187. In other preferred embodiments, the
3 0 polynucleotide encodes the full-length or a mature protein encoded by the
cDNA insert
of clone ys20_1 deposited under accession number ATCC 207187. In further
preferred
embodiments, the present invention provides a polynucleotide encoding a
protein
comprising a fragment of the amino acid sequence of SEQ ID N0:158 having
biological
activity, the fragment preferably comprising eight (more preferably twenty,
most
246
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
preferably thirty) contiguous amino acids of SEQ ID N0:158, or a
polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:158
having biological activity, the fragment comprising the amino acid sequence
from amino
acid lI4 to amino acid 123 of SEQ ID N0:158.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:157.
Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize
in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
(aa) SEQ ID N0:157, but excluding the poly(A) tail at the
3' end of SEQ ID N0:157; and
(ab} the nucleotide sequence of the cDNA insert of clone
ys20_1 deposited under accession number ATCC 207187;
(ii) hybridizing said probes) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the
2 0 probe(s);
and
(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
2 5 the group consisting of:
(ba) SEQ ID N0:157, but excluding the poly(A) tail at the
3' end of SEQ ID N0:157; and
(bb) the nucleotide sequence of the cDNA insert of clone
ys20_1 deposited under accession number ATCC 207187;
3 0 (ii) hybridizing said primers) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide products of step (b)(iii).
247
CA 02339047 2001-02-12
WO 00/09552 PCT/US99/18298
Preferably the polynucleotide isolated according to the above process
comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:157, and
extending contiguously from a nucleotide sequence corresponding to the 5' end
of SEQ
ID N0:157 to a nucleotide sequence corresponding to the 3' end of SEQ ID
N0:157 , but
excluding the poly(A) tail at the 3' end of SEQ ID N0:157. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide
sequence
corresponding to the cDNA sequence of SEQ ID N0:157 from nucleotide 41 to
nucleotide
757, and extending contiguously from a nucleotide sequence corresponding to
the 5' end
of said sequence of SEQ ID N0:157 from nucleotide 41 to nucleotide 757, to a
nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID N0:157 from
nucleotide
41 to nucleotide 757.
In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from
the group
consisting of:
(a) the amino acid sequence of SEQ ID N0:158;
(b) a fragment of the amino acid sequence of SEQ ID N0:158, the
fragment comprising eight contiguous amino acids of SEQ ID N0:158; and
(c) the amino acid sequence encoded by the cDNA insert of clone
ys20_1 deposited under accession number ATCC 207187;
2 0 the protein being substantially free from other mammalian proteins.
Preferably such
protein comprises the amino acid sequence of SEQ ID N0:158. In further
preferred
embodiments, the present invention provides a protein comprising a fragment of
the
amino acid sequence of SEQ ID N0:158 having biological activity, the fragment
preferably
comprising eight (more preferably twenty, most preferably thirty) contiguous
amino acids
2 5 of SEQ ID N0:158, or a protein comprising a fragment of the amino acid
sequence of SEQ
ID N0:158 having biological activity, the fragment comprising the amino acid
sequence
from amino acid 114 to amino acid 123 of SEQ ID N0:158.
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
3 0 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:159;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:159 from nucleotide 28 to nucleotide 2253;
248
CA 02339047 2001-02-12
t
' a
DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTS PART1E DE CETTE DEMANDS OU CE BREVET
COMPREND PLUS D'UN TOME.
CECI EST LE TOME 'I DE
NOTE: ~ Pour les tomes additionels, veuilfez contacter le Bureau canadien des
brevets
JUMBO APPLICATIONS/PATENTS
THiS SECTION OF THE APPLICATtONIPATENT CONTAINS MORE
THAN ONE VOLUME ,
THlS IS VOLUME ~ , OF
NOTE: For additional volumes piease contact the Canadian Patent Office
